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ABSTRACT                
 
Branched Chain amino acids (BCAAs) play an essential role in cell metabolism 
supplying both carbon and nitrogen in pancreatic cancers, and their increased levels have 
been associated with increased risk of pancreatic ductal adenocarcinomas (PDACs). It 
remains unclear how stromal cells regulate BCAA metabolism in PDAC cells and how 
mutualistic determinants control BCAA metabolism in the tumor milieu. In chapter 1, we 
present an overview of PDAC biology, tumor microenvironment (TME), altered cancer 
metabolism and BCAA metabolism. In chapter 2, we uncover differential gene 
expression of enzymes involved in BCAA metabolism accompanied by distinct catabolic, 
oxidative, and protein turnover fluxes between cancer-associated fibroblasts (CAFs) and 
cancer cells with a marked branched-chain keto acids (BCKA)-addiction in PDAC cells. 
In chapter 3, we showed that cancer-induced stromal reprogramming fuels this BCKA-
addiction. We then show the functions of BCAT2 and DBT in the PDAC cells in chapters 
3 and 4. We identify BCAT1 as the BCKA regulator in CAFs in chapter 5. In chapter 6, 
we dictated the internalization of the extracellular matrix from the tumor 
microenvironment to supply amino acid precursors for BCKA secretion by CAFs.  We 
also showed that the TGF-β/SMAD5 axis directly targets BCAT1 in CAFs in chapter 7. 
In chapter 8, we validate the in vitro results in human patient-derived circulating tumor 
cells (CTCs) model. Furthermore, the same results were also validated in PDAC tissue 
slices, which recapitulate tumor heterogeneity and mimic the in vivo microenvironment 
in chapter 9. We conclude this manuscript with chapter 10 in which we propose future 
 xix 
studies and present directions towards pancreatic cancer research. In summary, our 
findings reveal therapeutically actionable targets in stromal and cancer cells to regulate 
the symbiotic BCAA coupling among the cellular constituents of the PDAC 
microenvironment. 
 1 
Chapter 1 Introduction 
 
1.1 Pancreatic ductal adenocarcinoma (PDAC) 
 
Pancreatic cancer has a high propensity for spreading to nearby organs, and it is 
seldom detected in its early stages [1]. The aggressive biological nature of pancreatic 
cancer makes it the most lethal digestive cancer and the fourth leading cause of cancer-
related deaths in the United States. Treatment strategies for pancreatic cancer have 
mainly focused on only the malignant cells in the tumor. However, in recent years, 
surrounding stroma in the tumor microenvironment is essential for tumorigenesis, as 
evidenced by several studies. The goal of my research is to understand the metabolic 
interaction between tumor stromal cells and cancer cells to target these interactions for 
therapeutic benefit. 
Pancreatic cancer has an unusually high propensity to spread to nearby organs and 
is seldom detected in its early stages. Due to its aggressive phenotype, pancreatic cancer 
is the most lethal digestive cancer and the fourth leading cause of cancer-related death in 
the United States. The median survival rate of pancreatic cancer patients with metastatic 
disease is 6-9 months, for them with the locally advanced is one year. For the resected 
disease, it is about two years [1]. It is estimated that in 2020, 57,600 adults (30,400 men 
and 27,200 women) in the United States will be diagnosed with pancreatic cancer. It is 
also estimated that 47,050 deaths (24,640 men and 22,410 women) will occur from 
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pancreatic cancer this year [1]. The estimated global mortality rate of pancreatic cancer at 
the beginning of the twenty-first century was a dismal 98%, and a recent study predicts 
that by the year 2030, the annual number of deaths will reach 88,000 in the USA. It is 
projected to become the second leading cause of cancer-related deaths in the United 
States by 2030 [2]. The only potentially curative therapy that currently exists is surgical 
resection followed by adjuvant treatment. However, only 20% of patients have resectable 
disease. [2]. Therefore, there is an urgency to investigate and develop novel strategies for 
pancreatic cancer treatment. 
1.1.1 Causes of pancreatic cancer 
Pancreatic cancer can originate from pancreatic acinar, ducts, and islets. 
Pancreatic tumors that arise from pancreatic ductal epithelium are the most common. 
Pancreatic ductal adenocarcinomas occur more frequently in the pancreatic head. The 
tumors located in the head of the pancreas are mostly hard and have no apparent 
boundaries with healthy pancreatic epithelial tissues, and can be widely infiltrated in the 
tissues around the pancreas. Pathological sections show a marked increase in fibrotic 
tissue, which is similar to the pathological features of chronic pancreatitis. Pancreatic 
cancer is a disease caused by multiple factors, such as smoking, chronic inflammation, 
and large amounts of secretion of certain inflammatory factors that can cause disease [3].  
Most pancreatic cancers have some gene alterations, such as amplifications, 
deletions, translocations, inversions, frameshifts, and substitutions. Disruptions of several 
genes in pancreatic cancer are almost universal and are present in 70%–98% of patients 
[4]. The mutation of genes can either enhance the function of the protein, sometimes 
making it even constitutively active or diminish the function completely. Subsequently, 
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the changes in protein functions can cause uncontrolled proliferation, migration, invasion, 
and adhesion of cells, protection from apoptosis and other types of cell death, DNA 
repairing, microsatellite instability, and other processes, which further lead to the 
development, growth, and spread of cancer. It has been proven that KRAS, TP53, and 
SMAD4 genes play an essential role in the development of pancreatic cancer [5]. 
1.1.2 Genetic mutations 
1.1.2.1 KRAS  
More than 90% of pancreatic cancer patients have KRAS gene mutations in their 
bodies, indicating that KRAS plays an essential role in the pathogenesis of pancreatic 
cancer [6]. The pathways involved in the KRAS gene are rough as follows: Under normal 
conditions, Ras binds to GDP, extracellular signals act on growth factor receptors to 
dissociate the two, and Ras binds to GTP encoded by KRAS. Ras-GTP active conjugate 
will gradually decrease with the hydrolysis of GTP. When the KRAS gene is activated 
and mutated, the Ras protein's GTPase activity is lost, and its signal continues to be 
amplified, thereby enabling several signaling pathways, including the phosphoinositide 
three kinase PI3K-AKT signaling pathway, Raf/MAPK, etc. [7]. 
1.1.2.2 SMAD4 
In the later stage of pancreatic cancer lesions, SMAD4 deletion may occur, and 
SMAD4 protein has been shown to play a critical role in the process of transmitting 
extracellular signals through the TGF-β signaling pathway. TGF-β is an important tumor 
suppressor gene in normal cells, which can regulate cell proliferation and differentiation. 
The signal pathways involved are as follows: type I or III serine/threonine kinase receptor 
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binds to TGF-β ligand and dimerizes the receptor, and the phosphorylated Smad2/Smad3 
protein binds to SMAD4 protein and transfers to the nucleus. Combined with 
transcription cofactors to regulate the cell cycle, differentiation, and growth [8]. The loss 
of SMAD4 in patients with pancreatic cancer lesions interrupts the above signaling 
pathways, making it lose its regulatory effect on cells. 
1.1.2.3 TP53  
Up to 85% of pancreatic cancer patients have inactivated TP53, and it also plays 
an essential role in regulating cell cycle and apoptosis [9]. The regulatory pathways 
involved in TP53 are as follows: DNA damage activates the TP53 gene to promote p21 
transcription, which is related to cyclin-CDK complex binds and stops the cell cycle in 
the G1 phase. It has been reported that germline mutations are also associated with 
familial pancreatic cancer, including the DNA mismatch repair gene MLH1 [10], the 
positive trypsinogen gene PRSS1 [11], and the target genes INK4A and LKB1 of sure 
tumor suppressors [12]. Recent evidence shows that the interaction of epithelial, stroma 
and extracellular matrix proteins plays an important role in the process of pancreatic 
cancer. It can be seen that PDAC development is a complex process, and the molecular 
pathway mechanism needs to be clarified. 
1.1.3 Signaling pathways 
1.1.3.1 TGF-β signaling pathway 
The human transforming growth factor TGF-β family includes TGF-β subtypes, 
kinetin, bone morphogenetic proteins (BMPs), growth, and differentiation factors (DGFs) 
total of 33 Members [13]. The role of TGF-β has two-phase specificity, which can inhibit 
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tumor growth in the stage of tumorigenesis and can promote tumor invasion and 
metastasis in the late stage of the tumor. The mechanism of action of TGF-β is to form 
heterotrimers by binding to cell membrane surface receptors, activate R-Smad protein to 
transmit signals into the cell, R-Smad binds to Co-Smad and transfers to the nucleus, and 
binds to target genes to regulate protein synthesis. The TGF-β family can regulate cell 
growth, survival, differentiation, and invasion, and plays an important role in embryo 
development and maintaining tissue homeostasis [14, 15]. TGF-β family members are 
involved in the occurrence and development of many diseases, including fibrosis, 
autoimmune diseases and cancer [16]. Epithelial-mesenchymal transition (EMT) refers to 
the ability of epithelial cells to transform into stromal cells and obtain migration 
morphologically. The tumor microenvironment, including tumor-associated 
macrophages, dendritic cells, and regulatory T cells, produces TGF-β1 that can 
effectively induce cell EMT [17]. Studies have also shown that overexpression of TGF-
β1 can cause chronic pancreatitis in mice [18], and TGF-β1-induced EMT is a bridge 
connecting inflammation and cancer [19]. Overexpression of TGF-β1 in the 
inflammatory microenvironment promotes the EMT process of chronic pancreatitis to 
pancreatic cancer by down-regulating miR-217, and miR-217 promotes this process by 
inhibiting the expression of SIRT1 [20]. During the development of EMT, the Wnt 
signaling pathway provides EMT ability to epithelial cells, and the TGF-β/BMP family 
provides a suitable micro-environment for EMT, and the two synergistically induce EMT 
[21]. In cancer, many stem cell pathways, such as Wnt, Ras, SHH (sonic hedgehog), and 
Notch (Notch homolog) signaling pathways are highly activated and provide tumor cells 
with EMT capabilities. Immune infiltrating cells secrete TGF-β1, IL8, IL6, MMPs and 
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TNF-α and other EMT promoting factors to induce EMT in the tumor microenvironment 
[20]. 
SMAD4 is the main effector of the TGF-β signaling pathway, in more than 50% 
of pancreatic cancer patients lose their activity [21]. The inactivation of SMAD4 alone 
cannot lead to the cancelation of the pancreas, and it is also optional for the development 
of normal pancreas [22]. Inactivation of the TGF-β signaling pathway leads to the up-
regulation of TGF-α expression, and SMAD4 inactivation coordinates the up-regulation 
of TGF-α expression to promote pancreatic fibrosis and promote pancreatic 
intraepithelial neoplasia, leading to the transformation of chronic pancreatitis into 
pancreatic cancer [23]. The hallmark of chronic pancreatitis is the fibrosis of pancreatic 
tissue, and the continuous activation of stellate cells is an important reason for promoting 
pancreatic fibrosis. 
1.1.3.2 JAK/STAT pathway  
The Janus kinase/signal transducers and activators of transcription (JAK/STAT) 
signaling pathway mediate multiple cytokine signal transduction pathways. It is widely 
involved in regulating cell proliferation and other biological processes such as 
differentiation, apoptosis and immune response. The activation of the JAK/STAT 
pathway is included in the occurrence and development of various diseases, including 
solid tumors, lymphomas, leukemias, chronic inflammation and other diseases [24]. The 
basic transmission process of the JAK/STAT signaling pathway is: cytokines and their 
receptors cause the dimerization of the receptor molecules, which makes the JAKs 
coupled to the receptors approach each other and are activated by interactive tyrosine 
phosphorylation. JAKs catalyzes the phosphorylation of the tyrosine of the receptor itself 
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and form the corresponding docking site of STATs, allowing STATs to bind to the 
receptor through the SH2 domain and achieve their phosphorylation activation under the 
action of JAKs. Then STATs form homo/heterodimerization, it enters the nucleus and 
combines with the promoter of the target gene to activate the transcription and expression 
of the corresponding gene. 
STAT3, as an important molecule in the inflammatory signaling pathway, also 
plays an important role in tumor development and invasion. The activation of the 
JAK/STAT pathway can inhibit apoptosis and promote tumor cell proliferation and 
invasion. Activated STAT3 can damage the extracellular matrix to different degrees and 
cause the degradation and destruction of the tissue basement membrane, providing a 
suitable environment for early metastasis of tumor cells. Also, STAT3 can promote the 
EMT process and promote the transformation of chronic inflammation into cancer. A 
recent study found that the Regenerating Family Member 3 Alpha (REG3A) high 
expression and SOCS3 methylation can up-regulate the JAK/STAT3 pathway and 
promote the malignant proliferation of human pancreatic cancer cells [25]. IL-6 can also 
activate the JAK/STAT pathway to promote the malignant transformation of chronic 
inflammation, leading to the occurrence of various malignant tumors [26]. Further 
research found that the mechanism of action of REG3A is similar to IL-6. In the 
inflammatory environment induced by IL-6, REG3A promotes the proliferation of 
pancreatic cancer cell lines by up-regulating the expression of JAK2/STAT3 pathway, 
while highly expressed STAT3 can positively Feedback upregulates the expression of 
REG3A, thereby forming a positive feedback loop to continuously promote the malignant 
proliferation of pancreatic cancer cells [27]. 
 8 
1.1.3.3 MAPK pathway  
The MAPK signaling pathway chain is composed of MAPK, MAPK kinase 
(MAPKK) and MAPKK kinase (MAPKKK), and is one of the important pathways in the 
signal transmission network of eukaryotes. It plays a key role in cytoplasmic functional 
activities and participates in the processes of cell proliferation, differentiation, migration 
and apoptosis. The MAPK signal transduction pathway uses a highly conserved tertiary 
kinase cascade to transmit signals: extracellular signals activate MAPKKK, which in turn 
activates MAPKK; then, MAPK is activated by phosphorylation of specific tyrosine and 
serine residues in the MAPK molecule. There are four subfamilies in the MAPK family, 
including extracellular signal-regulated kinase 1/2 (ERK1/2), c-Jun amino-terminal 
kinase (JNK), p38 mitogen-activated protein kinase (p38MAPK), and extracellular 
signals Regulate kinase 5 (ERK5). 
Early studies reported that ERK1/2 is the main regulatory pathway for the 
activation and proliferation of pancreatic stellate cells [28, 29]. Platelet-derived growth 
factor (PDGF) can stimulate the activation of pancreatic stellate cells, and its stimulation 
depends on the activation of the ERK1/2 pathway. ERK pathway inhibitor PD98059 
blocks the proliferation of pancreatic stellate cells after acting on pancreatic stellate cells 
and can inhibit the migration of pancreatic stellate cells by up to 50% [29]. Also, the 
inhibition of pancreatic stellate cells by hydrogen sulfide (H2S) donor NaHS is achieved 
through the ERK1/2 pathway [30]. Angiotensin II can induce the proliferation of 
pancreatic stellate cells, and it can activate JNK and ERK1/2 while promoting the 
proliferation of pancreatic stellate cells, suggesting that angiotensin II may achieve the 
proliferative effect on pancreatic stellate cells through JNK and ERK [31]. JNK inhibitor 
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SP600125 can inhibit the activation of JNK and AP-1 while inhibiting PDGF-induced 
pancreatic stellate cell activation, indicating that the activation of the JNK pathway can 
promote the activation of pancreatic stellate cells [32]. In a mouse model of chronic 
pancreatitis, BMP inhibits the activation of pancreatic stellate cells by inhibiting the 
TGF-β/Smad2 and p38MAPK pathways, and plays a role in reversing pancreatic tissue 
fibrosis [33]. Studies have reported that high glucose uptake can significantly activate the 
proliferation of rat pancreatic stellate cells, and the p38MAPK blocker SB203580 can 
reduce the expression of α-SMA, indicating that high glucose environment-induced 
pancreatic stellate cells proliferation is mediated through the p38MAPK pathway [34]. 
1.1.3.4 NF-κB pathway  
Nuclear transcription factor kappa B (NF-κB) is an important type of 
transcriptional activation factor that exists in various eukaryotic cells and is widely 
involved in a series of biological processes, including immune response, cell proliferation 
and apoptosis. It is closely related to the occurrence and development of various tumors. 
The NF-κB family includes the five members of the oncogenes C-Rel, NF-κB1 
(p50/p105), NF-κB2 (p52/p100), Re1A (p65) and RelB. Under normal circumstances, 
most of the NF-κB dimer in the cell is inactive in the cell by binding to one of the three 
NF-κB inhibitory proteins (IκBα, IκBβ, IκBε) in the cytoplasm. Recent studies have 
shown that chronic inflammation, NF-κB stimulation, is related to the development of 
cancer [35]. NF-κB shows abnormal activation in both chronic pancreas and pancreatic 
cancer, suggesting its important role in the development of chronic pancreatitis to 
pancreatic cancer [36]. The autocrine of pro-inflammatory factors such as IL-1α can 
induce the activation of NF-κB, and the continuously activated NF-κB promotes the 
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development of pancreatic cancer [37]. Activated NF-κB and downstream target genes 
such as pro-inflammatory factors TNF-α and IL-1 are key factors for the transformation 
of inflammation into tumorigenesis. Studies have reported that the mechanism of aspirin 
in preventing pancreatic cancer is to block the activation of NF-κB in the inflammatory 
response to inhibit the occurrence of pancreatic cancer [38]. IKK2 is an inhibitor of κB 
kinase 2, a member of the NF-κB pathway. IKK2 coordinates the Notch pathway to 
upregulate Notch target genes HES1 and HEY1, inhibits the expression of anti-
inflammatory factors, and promotes the development of pancreatic cancer [39]. Besides, 
NF-κB can also promote EMT by inhibiting the expression of E-cadherin, and NF-κB is 
also necessary for TGF-β1-induced EMT [40, 41]. 
1.1.3.5 TLRs pathway  
Toll-like receptors (TLRs) are a highly conserved family of receptors, including at 
least 12 members. TLRs can specifically recognize pathogen-associated molecular 
patterns (PAMPs), which can not only activate innate immunity but also play an 
important role in regulating acquired immunity. It is a bridge connecting innate immunity 
and acquired immunity. Many immune effector cells, including monocytes/macrophages, 
neutrophils, and dendritic cells, express TLRs. TLRs recognize and bind PAMPs to 
activate downstream signaling molecules, inducing chemokines, interleukins, and other 
costimulatory molecules. Current research indicates that TLRs mediate at least two signal 
cascade amplification pathways, one is the myeloid differentiation factor 88 (MyD88) 
dependent pathway, and the other is the MyD88 independent pathway [42]. 
On the one hand, TLRs play an important role in immunity, and excessive 
activation of TLRs is also crucial in promoting tumor formation and migration. Studies 
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have shown that TLR4 and TLR7 are highly expressed in human and mouse pancreatic 
cancer cells [43, 44]. The continuous activation of TLR in acute and chronic pancreatitis 
models not only aggravates inflammation of the pancreas but also accelerates tumor 
formation in the pancreas [44]. LPS can induce the activation of NF-κB through the 
TLR4/MyD88 pathway, thereby producing a series of biological effects such as 
promoting cell proliferation, migration and invasion [45]. TLR7 is not expressed in 
normal human and mouse pancreatic tissues. Still, in the KRAS mutant pancreatic cancer 
mouse model and human pancreatic cancer samples, whether it is in epithelial cells or 
macrophages, dendritic cells, T/ B cells have extremely high expression levels. In 
pancreatic cancer with obvious inflammation, the activation of TLR7 accelerates the 
formation and deterioration of pancreatic tumors [46]. 
1.1.3.6 The non-coding RNA pathways 
The non-coding RNA pathways have also been shown to involve in the malignant 
transformation of chronic pancreatitis. MicroRNA (miRNA) and long-chain non-coding 
RNA (lncRNA) are non-coding RNAs with post-transcriptional regulatory functions in 
eukaryotic organisms, which play an important role in various biological pathways. It has 
been reported in that in pancreatic cancer, miR-1290, miR-200a and miR-200b showed 
high expression and predicted poor prognosis, and could be used as a diagnostic indicator 
for pancreatic cancer in the future [47, 48].  
 
1.2 Tumor microenvironment (TME) 
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The tumor microenvironment was proposed by Ioannides in 1993 [49]. It 
specifically refers to the local environment in which tumors develop and develop. It 
mainly consists of tumor cells, stromal cells, immune cells and their secreted cytokines, 
and the surrounding extracellular matrix. A unique environment is conducive to tumor 
survival, proliferation, invasion and metastasis [49]. The characteristics of the pancreatic 
cancer tumor microenvironment include abundant matrix, hypoxia, insufficient blood 
supply, and high immunosuppression. It is difficult for traditional radiotherapy and 
chemotherapy to play a therapeutic role. Therefore, finding new therapeutic targets 
through pancreatic cancer tumor microenvironment is a promising research direction.  
1.2.1 Stromal cells and extracellular matrix 
The stromal cells of pancreatic cancer are mainly pancreatic stellate cells and 
cancer-associated fibroblasts. The extracellular matrix mainly includes collagen, 
fibronectin and hyaluronic acid. Stromal cells and extracellular matrix play a vital role in 
the proliferation, invasion and metastasis of pancreatic cancer [50]. The matrix barrier 
formed by their interaction is an important reason for the resistance of pancreatic cancer 
to radiotherapy and chemotherapy. 
1.2.1.1 Pancreatic stellate cells (PSCs) 
Pancreatic stellate cells are one of the primary cells in the microenvironment of 
pancreatic cancer. Under physiological conditions, pancreatic stellate cells are at the 
resting stage and are mainly involved in maintaining the normal structure of pancreatic 
tissues [51]. Pancreatic tumor cells can transform resting pancreatic stellate cells into 
activated myofibroblast-like cells [52]. Transformed pancreatic stellate cells can rapidly 
proliferating and secrete large amounts of extracellular matrix and cytokines, forming a 
 13 
microenvironment that is conducive to tumor growth. PSCs have been shown to promote 
the growth and proliferation of pancreatic cancer. Pancreatic stellate cells and pancreatic 
tumor cells promote each other through "positive feedback." Pancreatic tumor cells 
secrete platelet-derived growth factor, TGF⁃β, fibroblast growth factor, etc. to promote 
the activation of pancreatic stellate cells and recruit them around the tumor cells. 
Activated pancreatic stellate cells rapidly proliferate and secrete TGF⁃β, fibroblast 
growth factor, connective tissue growth factor, etc. in a paracrine manner, which in turn 
promotes the growth and proliferation of pancreatic tumor cells [53]. PSCs can also 
promote the invasion and metastasis of pancreatic cancer. The results of studies on 
pancreatic ductal cancer organoids showed metalloproteinase two secreted by pancreatic 
stellate cells could induce the destruction of the basement membrane structure and 
promote local tumor invasion [54]. Through inhibition of metalloproteinase, two can 
weaken the destruction of pancreatic stellate cells to the basement membrane, retaining 
the organoid duct structure [54]. 
PSCs can also promote chemotherapy resistance. On the one hand, pancreatic 
stellate cells secrete a large amount of extracellular matrix and cytokines to form a 
microenvironment of dense fiber, hypoxia, and insufficient blood supply. Among them, 
occlusion of non-functional blood vessels and an impenetrable fiber barrier make it 
difficult for chemotherapy drugs to enter the tumor tissue through the blood [55]. On the 
other hand, pancreatic stellate cells downregulate the nucleoside transporter that mediates 
the uptake of gemcitabine in tumor tissues by secreting cysteine-rich angiogenin 
inducers, leading to pancreatic cancer resistance to gemcitabine [56]. In recent studies, 
PSCs also showed immunosuppression properties. Nuclear factor κB in pancreatic 
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stellate cells can increase the expression of chemokine ligand 12, thereby reducing the 
cytotoxic T cell infiltration killing effect [55]. Pancreatic stellate cells regulate the 
secretion of various cytokines in T cells and induce the apoptosis of CD4+ and CD8+ T 
cells by overexpressing galectin-1, assisting tumor immune escape [57]. 
1.2.1.2 Cancer associated fibroblasts (CAFs) 
Cancer associated fibroblasts are fibroblasts of mesenchymal origin and an 
important part of tumor stromal cells. There are a large number of cancer associated 
fibroblasts in the pancreatic tumor microenvironment, which mainly promote the 
invasion, metastasis and chemotherapy resistance of pancreatic cancer by secreting 
growth factors, chemokines and extracellular matrix.  Cancer associated fibroblasts have 
been shown to promote tumor stromal barrier and angiogenesis by secreting a large 
amount of extracellular matrix and tumor-associated angiogenesis factors, thereby 
accelerating tumor progression and reducing chemotherapy drug penetration [58]. Cancer 
associated fibroblasts promote tumor proliferation, invasion and metastasis by secreting 
IL⁃6, IL⁃8, chemokine two and chemokine ligand 12 etc. Results show that the use of a 
new vinblastine derivative, Conpholine, can inhibit the activity of cancer associated 
fibroblasts and reduce the synthesis of cytokines, thereby reducing pancreatic cancer 
tissue fibrosis, inhibiting tumor proliferation, metastasis, and increasing the permeability 
of chemotherapy drugs [59]. Cancer associated fibroblasts can also mediate the formation 
of chemotherapy resistance through a variety of signaling pathways and exosome 
pathways. The use of specific inhibitors can improve the efficacy of chemotherapy drugs 
[60]. 
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Some research results show that inhibiting or depleting tumor-related fibroblasts 
in mouse model experiments can delay the progression of pancreatic cancer. Still, the 
same results have not been obtained in clinical trials [61]. There are also research results 
showing that a dense matrix barrier may delay tumor invasion and metastasis, and simply 
eliminating the matrix may lead to tumor progression. Application of curcumin can make 
cancer associated fibroblasts lose the characteristics of mesenchymal cells and transform 
into nearly normal fibroblasts, thereby inhibiting the tumor-promoting effect of tumor-
associated fibroblasts [62]. Therefore, reversing the abnormal cell structure may be a 
feasible strategy for tumor targeted therapy. 
1.2.1.3 Hyaluronic acid 
Hyaluronic acid is highly expressed in various tumors and is closely related to 
tumor progression. On the one hand, hyaluronic acid is deposited in large amounts 
around pancreatic cancer tissue. Its high hydrophilicity leads to the collapse of blood 
vessels and low perfusion, forming a physical barrier that hinders the delivery of 
chemotherapy drugs, stimulating the migration ability of pancreatic cancer cells and 
cancer associated fibroblasts, and participate in the invasion and metastasis of pancreatic 
cancer [63]. Recent results show that the degradation of hyaluronic acid by pegylated 
hyaluronidase can gradually restore the interstitial pressure and microvascular 
abnormalities [64]. The combined use of pegylated hyaluronidase and hyaluronic acid 
synthesis inhibitor can improve anti-tumor drug penetration, thereby delaying tumor 
progression and prolonging patient survival time [65]. Another recent study showed that 
the use of hyaluronic acid synthesis inhibitor 4⁃methylumbelliferone in a mouse 
xenograft model could reduce the hyaluronic acid in the tumor and promote the 
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infiltration of the γδT cells into the tumor tissue, thereby inhibiting tumor growth [66]. 
This means that the hyaluronic acid synthesis inhibitor may become an effective 
immunosensitizer. Stromal cells and extracellular matrix play an extremely important 
role in the proliferation, invasion and metastasis of pancreatic cancer. Targeted therapy 
for stromal cells and extracellular matrix is an important direction of pancreatic cancer 
research. Some research results show that simple elimination of stromal cells and 
extracellular matrix may lead to further progress of pancreatic cancer, suggesting that 
stromal cells and extracellular matrix may play a role in inhibiting the progress of 
pancreatic cancer [67]. 
1.2.2 Immune cells 
The immune system plays an important role in removing malignant cells. 
Pancreatic cancer can imbalance the number and function of immune cells with anti-
tumor effects through a variety of ways, thereby creating a highly immunosuppressed 
microenvironment to help tumor cells escape immune surveillance. 
1.2.2.1 Tumor-associated macrophages (TAMs) 
Normal macrophages can differentiate into two phenotypes, M1 and M2, under 
different conditions. M1 type macrophages can promote local inflammation of tumors 
and participate in immune surveillance; M2 type macrophages can secrete IL⁃10, TGF⁃β 
and other cytokines to promote tumor angiogenesis, participate in tissue remodeling, 
suppress the immune response and induce chemotherapy resistance, thereby accelerating 
the proliferation, invasion and metastasis of pancreatic cancer [68]. Pancreatic cancer can 
actively recruit monocytes by secreting macrophage colony-stimulating factor, TGF⁃β, 
IL⁃6, IL⁃10, etc. and promote their transformation into M2 macrophages [69]. The results 
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of a co-injection experiment in mice showed that M2-type macrophages could induce 
tumor cell epithelial-mesenchymal transition, promote tumor growth and peritoneal 
metastasis and confer stronger chemotherapy resistance on tumor cells [70]. In pancreatic 
cancer, specific inhibition of macrophage colony-stimulating factor and chemokine 
ligand two can reduce tumor-associated macrophages, inhibit tumor growth and increase 
the killing ability of effector T cells and improve the efficacy of gemcitabine [71]. 
Furthermore, IL⁃27 can transform M2 type macrophages into M1 type and regain their 
anti-tumor potency [72]. 
1.2.2.2 Regulatory T cells (Tregs) 
Regulatory T cells are a multifunctional subset of T cells that mainly induce 
immune tolerance and exert immunomodulatory effects in normal organisms. They 
mostly play an immunosuppressive role in tumor patients and promote tumors by 
suppressing the killing ability of effector T cells, immune evasion and transfer. TGF⁃β in 
the tumor microenvironment can induce the generation of regulatory T cells, and the 
application of TGF⁃β neutralizing antibodies can inhibit the maturation of regulatory T 
cells [73]. Pancreatic cancer cells can also recruit regulatory T cells to the tumor by 
secreting chemokine ligand 5, vascular endothelial growth factor (VEGF), the application 
of corresponding inhibitors can reduce the infiltration of regulatory T cells in the tumor 
[74]. Regulatory T cells can secrete TGF⁃β to directly inhibit the anti-tumor effect of 
CD8+ T cells and natural killer cells. They can also induce apoptosis of CD8+ T cells and 
natural killer cells by secreting granzyme B and perforin [75]. Regulatory T cells can also 
interact with antigen-presenting cells to inhibit their CD80 and CD86 expression, leading 
to dysfunction of cytotoxic T cells and dendritic cells [76]. Cytotoxic T-lymphocyte-
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associated protein 4(CTLA4) on the surface of regulatory T cells plays an important role 
in the process of immunosuppressive regulation. Neutralizing antibodies can induce the 
apoptosis of regulatory T cells and reduce the inhibitory signal. A small dose CTLA4 
monoclonal antibody can effectively reduce tumor volume, but systemic use of large 
doses will increase the infiltration of secondary lymph node regulatory T cells [77]. 
Gemcitabine can significantly reduce regulatory T cells in peripheral blood, and 
monoclonal antibodies, vaccines, and various combination treatments against regulatory 
T cells have also achieved positive results in animal experiments. 
1.2.2.3 Myeloid-derived suppressor cells (MDSCs) 
Myeloid-derived suppressor cells are a group of immature heterogeneous cells 
derived from bone marrow. Myeloid-derived suppressor cells in pancreatic cancer can 
mediate immunosuppression through a variety of pathways to assist immune escape. 
Myeloid-derived suppressor cells can produce arginase and nitric oxide synthase. 
Arginase can decompose arginine necessary for T cell proliferation, thereby reducing T 
cell production. Nitric oxide synthase can inhibit T cell signaling pathways and induce T 
cell apoptosis, thus inhibiting its cytotoxicity [78]. Myeloid-derived suppressor cells can 
also release reactive oxygen species, causing oxidative stress in surrounding cells, 
thereby promoting tumorigenesis and development. The use of antioxidants to treat 
pancreatic cancer can improve the prognosis of patients [79]. IL⁃10, IFN-γ, and TGF⁃β in 
the tumor microenvironment can activate myeloid-derived suppressor cells. The activated 
myeloid-derived suppressor cells can induce the proliferation of regulatory T cells and 
further mediate immunosuppression [80]. Myeloid-derived suppressor cells have high 
expression of Programmed death-ligand 1 (PD-L1). The myeloid-derived PD-L1 highly 
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expressed on cells can specifically bind to Programmed cell death protein 1(PD-1) to 
inhibit the activation of T cells and reduce the tumor-killing ability of T cells [81]. 
Targeting depletion of Myeloid-derived suppressor cells in pancreatic cancer can reshape 
the tumor matrix, increase the number of CD8+ T cells in the tumor tissue and induce 
tumor cell apoptosis, which may be a way to enhance classic cytotoxicity and adoptive 
immunity based immunotherapy [82]. Tumor-associated macrophages, regulatory T cells, 
and myeloid-derived suppressor cells, etc., create a highly immunosuppressive 
microenvironment through multiple pathways, which is an important reason why 
pancreatic cancer is insensitive to radiotherapy and chemotherapy. The above immune 
cells can not only suppress the immune response in their own way, but also induce 
immunosuppression through a common pathway. 
1.2.3 Summary 
The interaction of various cells and non-cellular components in pancreatic cancer to 
create a microenvironment rich in the extracellular matrix, hypoxia, inadequate blood 
supply, and high immunosuppression is an important reason for pancreatic cancer to be 
insensitive to radiotherapy and chemotherapy. At present, many potential targets based 
on stromal cells or extracellular matrix in the tumor microenvironment have been found. 
A large number of experimental studies have obtained good results in animal models, but 
some research results suggest that tumor growth was not being restrained. Due to the 
complexity and specificity of the microenvironment of pancreatic cancer, compared with 
single-target therapy, immunotherapy, radiotherapy and chemotherapy combined with 
multi-target therapy, may be a more effective strategy. However, to design an efficient 
and safe joint scheme, we must further understand the mechanism of the tumor 
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microenvironment, and more research is needed to find the synergy and adverse reactions 
between different therapies and different drugs. 
1.3 Circulating tumor cells (CTCs) 
 
Circulating tumor cells (CTCs) are tumor cells that shed from the primary tumor 
tissue into the blood circulation [83]. After the CTCs enter the blood circulation, most of 
them undergo anoikis, blood flow shear stress, immune recognition and killing. The 
number of CTCs that can eventually survive in peripheral blood is very small, usually 
1~10²/mL (the number of white blood cells is 105~106/mL, and the number of red blood 
cells is 109~1010/mL). CTCs and the clusters formed by multiple CTCs play a key role in 
tumor metastasis [84]. The surface antigens, genotypes and pathological characterization 
of CTCs during the transmission process are the main points of the current research on 
the mechanism of cancer metastasis. CTCs based liquid biopsy technology is simple and 
minimally invasive and can better represent tumor heterogeneity. It has been regarded as 
a new type of tumor biomarker. CTCs counts, count changes, subgroup characteristics, 
etc. have been related to patient prognosis and have established more and more links with 
personalized treatment. Using the functional diagnosis results of CTCs to develop a 
personalized cancer treatment plan is an important and reliable way to achieve precise 
drug use for cancer.  
1.3.1 Isolation of CTCs  
The isolation methods of CTCs can be divided into two categories: biological 
method and physical method, according to the isolation principle [85]. Biological 
methods use surface antigens of CTCs that are different from other blood cells (white 
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blood cells, red blood cells, platelets), and physical methods are based on differences in 
density, size, and deformability of CTCs and other blood cells. After the red blood cells 
in the patient's blood sample are lysed, surface-fixed EpCAM antibodies are used to 
recognize and capture the CTCs expressing the EpCAM antigen directly, and the 
obtained CTCs can be subjected to downstream analysis. This isolation method belongs 
to positive enrichment in biological methods. The CELLSEARCH system is the 
representative of this isolation technology and is currently the only CTCs isolation 
system approved by the FDA for the prognosis of metastatic breast cancer, colon cancer, 
and prostate cancer [86-88]. Magnetic beads with leukocyte-specific antibodies are used 
to eliminate leukocytes to obtain an unlabeled CTCs suspension. This method is also 
known as negative enrichment in biological methods [89, 90]. In the physical method, the 
OncoQuick system does not rely on antigen recognition but is separated by the density of 
CTCs and other blood cells [91]. Therefore, both EpCAM positive and negative CTCs 
can be obtained. The technical principle of the MetaCell system is to use CTCs with a 
diameter greater than other blood cells, and the blood sample is filtered through a 
polycarbonate membrane with a pore size of 8um to separate CTCs [92]. Hou et al. 
designed spiral micro-pipes based on the principles of hydrodynamics and isolated CTCs 
and leukocytes by coupling inertial micro-flows with Dean circulation [93]. The same 
group also further designed a microfluidic device that can separate a single CTC base on 
this so that the obtained CTCs can be directly used for downstream molecular biological 
applications [94]. 
At present, there are also reports on the application of nanotechnology in the 
isolation of CTCs. Halo et al. attached single-stranded DNA complementary to specific 
 22 
genes (such as TWIST1 or 2) mRNA in CTCs to the surface of gold nanoparticles [95]. 
When nanoparticles enter CTCs, the two-release fluorescence when they are combined, 
and CTCs can be detected semi-quantitatively according to the fluorescence intensity. It 
should be noted that the detection rate and purity of CTCs in different principles and 
different isolation systems will vary greatly. For example, when the antigen-based 
CELLSEARCH system and the size-based FMSA system were used to detect 
perioperative CTCs, the detection rate of the FMSA system was as high as 93.4%, and 
the average number of CTCs was 22.56/7.5mL The CellSEARCH system is only 26.1% 
and 0.87/7.5mL [96]. Biological methods based on antigen recognition have the 
advantage of high purity, but will miss CTCs that do not express the corresponding 
antigen, and may affect downstream functional detection due to the role of antigen 
antibodies; physical isolation methods based on density and size are not subject to CTCs 
surface antigens. The detection rate is high, but the purity may be lower due to the 
possibility of mixing with other blood cells. CTCs isolation technology has developed 
rapidly, and many more sophisticated systems already have faster sample processing 
speed, higher detection rates, and detection purity. What is urgently needed is the 
corresponding technical specifications and operating standards to standardize and 
standardize clinical application research and experimental research. 
1.3.2 Molecular biological characteristics of CTCs 
With the continuous improvement of CTCs isolation technology, the emergence 
of biological achievements such as genomics, transcriptomics, and proteomics has 
provided the possibility to reveal the molecular biological characteristics of CTCs and 
their role in the development of tumor metastasis. Epithelial-to-mesenchymal transition 
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(EMT) refers to the biological process of transforming epithelial cells into mesenchymal 
phenotype cells through a specific procedure [97]. In this process, tumor cells lose their 
polarity, adhesion and other epithelial phenotypes and transform into mesenchymal 
phenotypes with high movement and invasion ability, thereby greatly improving the 
ability of tumor cells to invade and metastasize [98]. Existing studies have shown that in 
the epithelial cell-derived tumor cells, the expression of E- cadherin protein is inhibited 
by the transcription factors of SNAI1, SNAI2, ZEB1, ZEB2, MMP9, TWIST1, TWIST2, 
EMT then occurs, tumor cells lost polarity, and cell adhesion sheds from tumor tissue and 
enters the circulatory system [99]. Most of the CTCs that enter the circulatory system 
undergo apoptosis or enter a dormant state under the effect of immune editing. Only 
about 0.1% of CTCs are still alive after 24 hours, of which less than 1/10 is still 
tumorigenic [100]. EMT is a complex process regulated by multiple factors and signaling 
pathways, and its specific mechanism still needs to be further clarified. IL-6 has long 
been considered to have the function of promoting EMT of colorectal malignancies. IL-6 
regulates the EMT process through Fos-related antigen 1 (FRA1) and signal transducer 
and activator of transcription 3 (STAT3) [101]. After knocking down the expression of 
STAT 3 or IL-6 by siRNA, EMT, cell migration, invasion and other phenomena are 
hindered. The transcription factor, nuclear factor kappa-light-chain-enhancer of activated 
B cells (NF- κB), regulates a wide range of biological processes, including inflammation, 
cell expansion, and apoptosis. Maier et al. found that when NF- κB is inhibited, 
transforming growth factor β (TGF-β)-induced EMT cannot occur, and after activation of 
NF- κB, cells exhibit vimentin and ZEB1 related EMT features such as up-regulation and 
down-regulation of E-cadherin [102]. Gu et al. found that IL-17 in lung cancer cells have 
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to up-regulate ZEB1 via NF- κB pathway, further inducing EMT [103]. Based on the 
structural analysis of the regulatory signal network of EMT, Chanrion et al. proposed and 
verified that the loss of p53 and Notch activation synergistically induce EMT [104]. Yang 
et al. found that fucosyltransferase can activate P13K/Akt and NF- κB pathways to 
further activate SNAI1 and MMP-9 to induce EMT [105]. Salnikov et al. proved that a 
hypoxic environment would positively regulate EMT-related genes, resulting in 
decreased expression of E-cadherin and increased expression of vimentin [106]. Zheng et 
al. used genetically engineered mice knocked out of Snai1 or Twist, proving that the 
inhibition of EMT does not change the occurrence, spread and metastasis of pancreatic 
ductal adenocarcinoma, but enhanced expression of nucleoside transporters [107]. 
Suppression of EMT increases the sensitivity and overall survival rate to the 
chemotherapy drug gemcitabine [107]. 
1.3.3 Survival mechanism of CTCs 
Entering the blood system, CTCs will be inactivated by blood shear stress and 
immune cell killing. During the transmission process, CTCs adopt multiple mechanisms 
to protect themselves, including using platelets as a protective barrier and avoiding 
immune recognition. Tumor cells polymerize with platelets in the blood and resist the 
shear stress of blood flow. Zheng et al. found that platelets and tumor cells express the 
main receptor of fibrinogen and β-integrin [108]. Fibrinogen can bridge the two types of 
cells, strengthen the combination of the two, and promote the protection of CTCs. 
Heparin and chemical derivatives can inhibit the binding of fibrinogen and β-integrin and 
have the potential to develop into anti-cancer metastasis drugs. In terms of 
immunorecognition, CD47 is a widely expressed transmembrane protein, which can bind 
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to the single regulatory protein α expressed by macrophages and dendritic cells to inhibit 
its phagocytosis. Willingham et al. systematically analyzed CD47 expression of 
malignant tumor cells from various parts of the human body (including ovary, breast, 
colon, bladder, prostate, etc.), CD47 expression of tumor cells was found to be about 3.3 
times that of corresponding normal cells on average [109]. The same study found that 
CD47 mRNA levels were negatively correlated with the patient's progression-free 
survival (PFS), and anti-CD47 antibodies restored phagocytosis, further proving that high 
expression of CD47 can reduce the immune system's killing of CTCs. 
Monocyte chemoattractant protein-1 (MCP-1) is a chemokine that can attract 
immune cells such as natural killer cells (NK) and memory T lymphocytes and is related 
to tumor growth and diffusion. Mardani et al. analyzed and compared the MCP-1 
concentration in the serum samples of healthy volunteers and patients with 
benign/malignant salivary gland tumors, and found that the MCP-1 concentration in the 
blood samples of patients with high progression was low, and believed that low 
concentration MCP-1 provided favorable conditions for the tumor diffusion [110]. NK 
cells are a type of cells that directly kill tumor cells through perforated proteins and 
granzymes or indirectly eliminate tumors by regulating factors such as interferon γ (IFN- 
γ), tumor necrosis factor-alpha (TNF-α) and other factors, and their activation depends on 
a variety of protein receptors. Rocca et al. found that the expression of CD16. NKG2D, 
DNAM-1, CD161, NKp46, NKp30 and other activated receptors on the surface of NK 
cells in peripheral blood were negatively regulated. In contrast, inhibitory receptors such 
as CD85j and NKG2A were positively regulated; these regulations reduce the 
cytotoxicity of NK cells and the amount of IFN- γ secretion [111]. It is speculated that 
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during the spread of cancer, the decrease in NK cell activity leads to enhanced survival of 
tumor cells in the circulatory system. The overexpression of protease-activated receptors-
1 (PAR-1) on the surface of breast cancer, prostate cancer, melanoma cells is also related 
to its enhanced metastatic ability. Villares et al. found that PAR-1 negatively regulates 
the level of Maspin, and the latter can increase the apoptosis of tumor cells and reduce 
tumor angiogenesis [112]. After fully understanding the molecular-level mechanism of 
CTCs to avoid immune system attacks, it is possible to use human autoimmunity to 
intervene in the occurrence and development of tumor metastasis. 
1.3.4 Heterogeneity   
Tumor tissue has heterogeneity (such as different mutation sites and different cell 
phenotypes). CTCs not only have the same heterogeneity but also may become an 
effective tool for studying tumor heterogeneity. Li et al.  stained CTCs of gastric cancer 
patients with keratin 8, 18, 19, and EpCAM as epithelial (E) markers, and vimentin and 
TWIST as mesenchymal (M) markers. Then categorize patients into five categories (E, 
E>M, E=M, E<M, M), it was found that most (31/35) samples contained two or more 
CTC states, that is, between epithelial cells and mesenchymal cells [113]. Another study 
compared the nucleus size of 304 prostate cancer CTCs and their host cancer metastasis 
and found that CTCs can be divided into large nuclei (>14.99 pm), small nuclei 
(8.54~14.99um), and extremely small according to the size of the nuclei. Nuclei (<8.54 
um), the number of small and very small CTCs is significantly related to cancer 
metastasis, and the number of very small CTCs is significantly related to visceral 
metastasis [114]. Due to factors such as EMT and environmental induction, CTCs may 
acquire mutations that are different from tumors in situ, making them different from 
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tumors in situ and richer in heterogeneity. CD24 is a ubiquitous marker on the surface of 
breast epithelial cells. Rostoker et al. isolated CD24+ and CD24- cells from breast cancer 
cell lines proving that CD24+ cells are easier to aggregate into microspheres, and CD24+ 
tumors grow faster and are easier to metastasize [115]. They also found that about 70% of 
the tumors that grew from CD24+ cells were CD24. Pavese et al. used CTCs cell lines 
produced by orthotopically transplanted prostate cancer mice to conduct cell invasion, 
migration, colony formation, xenotransplantation and other experiments, and compared 
the doubling time, cell morphology, and migration of CTCs compared with orthotopic 
tumor cells. There was no obvious change in the ability and the size of the induced tumor, 
while the invasion ability increased by 50%, and the number of metastatic tumor cells 
increased [116]. Further studies have shown that the MMP-2 and EMT-related proteins of 
CTCs have increased in quality and show a slightly different drug sensitivity (increased 
resistance to mitoxantrone) from tumor cells in situ. Pailler et al. detected Proto-
Oncogene 1 (ROS1) rearranged CTCs in patients with non-small cell lung cancer and 
found that the average and standard deviation of ROS1 copy number was significantly 
higher than that of tumor tissue cells, proves CTC has higher heterogeneity [117].  On the 
one hand, CTCs usually exhibit richer heterogeneity than clinically acquired local tumor 
tissues, and can provide strong support and guidance when formulating medication 
regimens based on the patient's genotype and phenotype; on the other hand, CTCs may be 
more Tumor tissue cells accumulate additional gene mutations, and they need to be 
cautious when using their molecular biological properties as a window to observe tumor 
tissue. 
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1.3.5 Application of CTCs in diagnosis and staging 
Difficulties in early diagnosis and lack of effective individualized treatment are 
important reasons for the poor prognosis of pancreatic cancer. About 80% of pancreatic 
cancer patients have had peripheral tumor invasion or distant metastasis at the time of 
diagnosis and cannot be treated with surgery [118]. CA19-9 is the most important clinical 
serum biomarker for pancreatic cancer. Still, the sensitivity and specificity are only 80% 
and 82%. In contrast, some patients with pancreatic cancer do not have elevated CA19-9 
levels, and some patients with benign diseases (such as pancreatitis, biliary obstruction) 
will have false positives elevated CA19-9 levels [119]. Therefore, it is necessary to find 
new and effective biomarkers, which can be used not only for the early diagnosis of 
pancreatic cancer but also to monitor the efficacy and guide clinical treatment. As an 
important part of liquid biopsy, CTCs are the hot spots of clinical research. The venous 
blood of the pancreas first flows back to the liver through the portal vein system and then 
reaches the systemic circulation. The peripheral blood CTCs are significantly less than 
those of breast cancer, prostate cancer and other tumors. Pancreatic cancer is rich in the 
stroma, and the proportion of tumor cells is limited, so the CTCs in peripheral blood are 
also less than those of colorectal cancer and gastric cancer that also return through the 
portal vein [120]. Some studies failed to draw meaningful conclusions due to the low 
detection rate of pancreatic cancer CTCs and the low CTCs count per unit of blood 
sample [121]. 
Kulemann et al. found that 75.0% of early pancreatic cancer patients (AJCC stage 
≤ IIB) were positive for CTCs, and 71.4% of advanced patients (AJCC stage ≥ III) were 
positive for CTCs [122]. Therefore, CTCs not only appear in patients with metastasis or 
 29 
advanced stage but can appear in different stages of pancreatic cancer. Zhang et al. used 
Pan-CK, CD45, DAPI, and CEP8 (chromosome centromere probe 8) as markers to detect 
CTCs from 22 cases of pancreatic cancer, 3 cases of solid pseudopapillary tumors, and 6 
cases of benign pancreatic tumors and 30 healthy volunteers [123]. They found when 
Pan-CK+, CD45+, DAPI+ and CEP ≥ 2 were used as the criteria for pancreatic cancer 
CTCs, and the CTCs count ≥ 2/3.75mL had a sensitivity and specificity of 68.18% and 
94.87% for the diagnosis of pancreatic cancer, respectively [123]. Zhou et al. detected the 
expression of C-MET, h-TERT, CK20 and CEA genes in pancreatic cancer CTCs at 
80%, 100%, 84% and 80%, respectively, and 0, 0, 6.7% and 0 in normal somatic cells 
[124]. If the above four gene expressions are used as the standard for pancreatic cancer 
CTCs at the same time, the sensitivity and specificity of diagnosis can reach 100%. 
Ankeny et al. detected the CTCs from 72 patients with pancreatic cancer and 28 patients 
with other pancreatic diseases. They showed that the positive rate of CTCs in stage Ⅰ to Ⅱ 
patients was 54.84% (17/31), and the positive rate of stage Ⅲ was 78.57% (11/14), the 
positive rate of stage Ⅳ was 96.30% (26/27), while only 1 of 28 patients with other 
pancreatic diseases detected one CTCs [125]. They show that CTCs ≥3/4mL can be used 
as the criterion for stage Ⅳ pancreatic cancer diagnosis. CTCs are expected to become 
biological markers for the diagnosis and staging of pancreatic cancer. 
1.4 Cancer metabolism  
1.4.1 The glycolysis and TCA cycle 
In the 1920s, Warburg et al. observed that tumor tissue consumes glucose faster 
than surrounding healthy tissue, and cancer cells can rely on rapid glycolysis and 
mitochondrial respiration at the same time [126, 127]. Since this discovery, glycolysis 
 30 
and other metabolic pathways related to tumor metabolism have been extensively 
explored. The glycolytic metabolic pathway begins with the uptake of extracellular 
glucose from the environment surrounding the cell and subsequent intracellular 
processing of glucose in the cytosol to yield pyruvate along with numerous other 
products eventually. Glycolytic metabolism is a relatively inefficient pathway for the 
generation of cellular ATP, netting only two molecules of ATP per unit of glucose. 
Energy metabolism is the process of energy generation, release, conversion and 
utilization of energy in the process of organism metabolism. Normal cells are mainly 
powered by aerobic oxidative phosphorylation of glucose, and glycolysis is the main 
method in an anoxic environment. The energy metabolism characteristics of tumor cells 
are different. Even in the case of sufficient oxygen supply, tumor cells still actively take 
up glucose and perform glycolysis, while producing a large amount of lactate. This is the 
pioneer theory of the tumor energy metabolism-Warburg Effect [126]. Although 
glycolysis has low productivity, it is necessary for rapidly proliferating tumor cells. It not 
only provides ATP for tumor cells quickly but also provides a variety of biological 
macromolecules for the construction of new cells, thereby giving them growth advantage. 
The special energy metabolism pattern of tumor cells has become a new tumor sign 
phenomenon [128]. In recent years, research on tumor energy metabolism has become a 
hot research direction of scientists and even pharmaceutical companies. With the 
deepening of its research, targeted energy therapy of tumors will also usher in new 
opportunities. Since the tumor is a heterogeneous disease, the heterogeneity of cells and 
structure gives it a complex energy metabolism phenotype.  
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Although tumor cells have different energy metabolism methods, in general, the 
glycolysis phenotype is still dominant and dependent on glutamine consumption. The 
study found that even if the tumor tissue is rich in oxygen, its glycolysis is still at a 
productivity advantage, but oxidative phosphorylation is relatively inhibited [129]. This 
reprogramming of energy metabolism may be related to the following factors. 
1.4.1.1 Hypoxia 
With the increase in the number and volume of tumor cells, the original blood 
vessels have been difficult to meet the supply of nutrients and oxygen, and the number of 
new blood vessels is insufficient, the framework is disturbed, the self-regulation ability is 
poor, and there is a lack of vasomotor structure and physiological drug receptor. This also 
further affects the transportation of oxygen and nutrients. Besides, there are blood 
rheology changes in tumors. These factors will lead to the formation of a hypoxic 
environment with chronic diffusion disorders in tumors [130]. 
There are two reasons for hypoxia to cause the glycolysis energy metabolism 
phenotype of tumor cells. First, hypoxia stimulates the expression of hypoxia inducible 
factor-1 (HIF-1), which can upregulate the expression of glucose transporter 1/3 
(GLUT1/3) to ensure a large amount of glucose uptake [131]. Meanwhile, HIF-1 up-
regulates the expression of most glycolysis related enzymes, such as hexokinase-1/2 
(HK1/2), phosphoglycerate kinase 1(PGK1), lactate dehydrogenase A (LDHA), 6-
phosphofructo-2 -kinase/fructose-2,6-bisphosphatase-3/4 (PFKFB3/4), pyruvate kinase 
M2 (PKM2), etc., and this makes the glycolysis pathway more prereferral [132, 133]. 
Second, hypoxia and HIF-1 inhibit mitochondrial biosynthesis and cause mitochondrial 
autophagy, thereby reducing the copy number of mitochondria. They can also reduce the 
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expression of pyruvate dehydrogenase kinase 1 (PDK1) and acetyl-CoA production, or 
inhibit mitochondrial electron transport chain components iron-sulfur cluster assembly 
enzyme (ISCU) and cytochrome c oxidase assembly factor heme A:farnesyltransferase 
(COX10) expression, which in turn inhibits the mitochondrial oxidative phosphorylation 
function [134, 135]. Therefore, tumor cells need to supply energy by glycolysis. 
1.4.1.2 Activation of oncogenes and inactivation of tumor suppressor genes 
HIF-1 can bind to the promoter region of the Myc gene and stimulate Myc gene 
expression [136]. Also, the c-Myc gene can be activated by gene amplification and 
chromosomal translocation. High Myc expression is very common in tumors. Myc is a 
transcription factor with a wide range of biological functions, including cellular energy 
metabolism. Myc can stimulate the expression of many genes, including GLUT and 
glycolysis related genes, so that the metabolism of tumor cells moves towards the 
Warburg effect. Abnormal activation of the Myc gene also leads to abnormally increased 
synthesis of LDHA [137]. LDHA catalyzes the formation of pyruvate to form lactate, and 
the resulting lactate is discharged out of the cell, which is closely related to the 
acidification of the tumor microenvironment. This acidified environment is not good for 
normal tissues, but it is good for tumor tissues, which can stimulate the growth of tumor 
cells [138]. Recently, it has been suggested that lactate excreted by hypoxic tumor cells 
can be taken up by adjacent subpopulation tumor cells as an energy source, thereby 
forming a metabolic symbiont of lactate excretion and lactate utilization cells. This 
phenomenon is not unique to tumors, and it reflects that tumors use other physiological 
mechanisms for their rapid growth [139]. Therefore, blocking the activity of LDHA may 
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effectively cut off the energy source of cancer cells, thereby causing them to die without 
affecting normal cells with aerobic metabolism. 
1.4.1.3 PKM2 
Recently, researchers have discovered that pyruvate kinase M2 (PKM2) is a very 
important metabolic molecule behind the glycolysis process [140]. There are two isomers 
of M-type pyruvate kinase, PKM1 and PKM2. PKM2 is usually expressed in embryonic 
tissue, while PKM1 is expressed in adult tissue. When the cells become cancerous, 
PKM2 resumes expression, while PKM1 expression is suppressed. Analysis of various 
tumor cell lines confirmed that PKM2 is the only form of pyruvate kinase found in 
cancerous tissues. When PKM1 is used to replace PKM2 in tumor cells, it leads to a 
decrease in lactate production and an increase in oxygen consumption, which is exactly 
the opposite of the Warburg effect. Only cells expressing PKM2 can form tumors in 
mice, indicating that PMK2 can promote unique metabolic phenotypes in tumor cells 
[140]. The expression of PKM2 in tumor cells is also related to Myc protein. Myc protein 
can induce the expression of PKM2, which is consistent with Myc's energy metabolism 
of tumor cells towards the Warburg effect [141]. Recent studies have shown that PKM2 
can be used as a partner factor for HIF1 transcription and enhance HIF1 transcription, 
from which we can see that the Warburg effect of tumor cells is the result of the 
synergistic effect of different factors. PKM catalyzes the conversion of 
phosphoenolpyruvate to pyruvate and simultaneously produces an ATP molecule. This 
reaction is the penultimate reaction of glycolysis. The current view is that PKM2 does not 
promote glycolysis, but inhibits glycolysis. As a result, the intermediate product of 
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glycolysis turns to biomacromolecule synthesis and maintains the redox balance of tumor 
cells to support the growth of tumor cells [142]. 
1.4.1.4 PI3K-Akt signal activation stimulates glycolysis 
The PI3K-Akt signaling pathway widely exists in cells and exerts a wide range of 
biological functions by regulating the cell cycle, protein synthesis, and cell energy 
metabolism. PI3K-Akt signal is positively regulated by the oncogene KRAS and 
negatively regulated by the tumor suppressor gene PTEN, and mutations or inactivation 
of the KRAS gene and PTEN gene are common in tumors, so many tumors have PI3K-
Akt signaling activation [143]. Akt enhances the Warburg effect of tumor cells by 
increasing the activity of GLUT, HK, PGK and PFK1 and other factors [142]. HK is the 
first rate-limiting enzyme for glycolysis, catalyzing the phosphorylation of glucose to 
glucose 6-phosphate. After isomerization of 6-phosphate glucose, fructose 6-phosphate is 
formed, and then fructose 6-phosphate is catalyzed by PFK1 to 1,6-phosphate fructose, 
and then enters glycolysis. Both HK and PFK1 are key enzymes for glucose to enter 
glycolysis. Akt can also enhance protein and lipid synthesis by activating the mammalian 
target of rapamycin (mTOR) signal [144]. At the molecular level, the above metabolic 
changes also activate HIF, tilting cellular energy metabolism towards glycolysis. 
1.4.1.5 TP53 regulates cellular energy metabolism 
Although about 56% to 63% of the ATP energy of most tumor cells comes from 
anaerobic glycolysis, the remaining about 44% to 37% of the ATP energy still needs to 
be provided by aerobic oxidation. The tumor suppressor gene TP53 plays an important 
role in regulating the balance between mitochondrial aerobic oxidation and glycolysis 
[145]. TP53 is a transcription factor with a wide range of biological functions, including 
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cellular energy metabolism. Recent studies showed that TP53-induced genes, such as 
TP53 Induced Glycolysis Regulatory Phosphatase (TIGAR) and Synthesis Of 
Cytochrome C Oxidase 2 (SCO2) are involved in cell energy metabolism [146]. TIGAR 
reduces the level of fructose-2,6-bisphosphate in cells, thereby inhibiting glycolysis 
levels, and SCO2's role is to participate in the assembly of cytochrome c oxidase (located 
in Electron transport chain complex IV), which is related to the mitochondrial electron 
transport chain [146]. Abnormal expression of SCO2 can increase the mitochondrial 
reactive oxygen species (ROS) and affect the mitochondrial oxidative phosphorylation 
function. Therefore, the inactivation of TP53 in tumor cells is the main force for tumor 
cells to obtain glycolysis phenotype. 
1.4.1.6 Impaired mitochondrial oxidative phosphorylation 
Warburg believed that tumor cells mainly adopt aerobic glycolysis for energy 
supply because mitochondria are irreversibly damaged. Studies have also found that 
tumor cell mitochondrial oxidative phosphorylation function may be damaged, which is 
related to hypoxia, mitochondrial DNA mutations, and electron transport chain 
dysfunction [147]. Abnormal expression of energy metabolism enzymes, such as 
mitochondrial Tu Translation Elongation Factor (TUFM) is involved in the malignant 
biological behavior of colon cancer [148], cytochrome B (Cytb) mutation is associated 
with bladder cancer [149], mutations of isocitrate dehydrogenase IDH1 and IDH2 are 
associated with glioma and acute myeloid leukemia [150], and mutations in fumarate 
hydratase (FH), succinate dehydrogenase (SDH) and other genes are involved in the 
formation of kidney cancer and paraganglioma [151]. The abnormality of these key 
molecules involved in the process of mitochondrial oxidative phosphorylation not only 
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inhibits the production of mitochondrial energy but at the same time, the functional 
mutations obtained by themselves increase the heterogeneity of tumor cells. Besides, 
some cancer cells produce a "truncated tricarboxylic acid cycle" due to damage to the 
respiratory chain [152]. Because the damaged mitochondria are attacked by reactive 
oxygen species (ROS), ROS inhibits the activity of aconitase and increases the 
concentration of citrate in the mitochondria. After the citrate enters the cytoplasm, it 
cooperates with acetyl-CoA to complete the TCA cycle. The NADH produced by this 
process inhibits the complete tricarboxylic acid cycle. It does not produce energy but 
provides raw materials for biological macromolecules for rapidly growing tumor cells. 
Therefore, under the above circumstances, assuming that the total cellular ATP is 
unchanged if the oxidative phosphorylation function is weakened, the role of glycolysis 
must be enhanced to maintain the cell energy balance. 
1.4.1.7 Other aspects 
In addition to the above reasons, other factors can also cause tumor cell glycolysis 
phenotype. Chronic inflammation is a major cause of tumorigenesis. Some inflammatory 
factors can promote glycolysis of breast cancer cells, and miR-155 can be involved as a 
transit molecule between inflammation and glycolysis [153]. In addition to inflammatory 
pathways, microRNAs lin28/let-7 regulatory axis post-transcriptionally regulates the 
metabolic enzyme PDK1, thereby reprogramming tumor metabolism to promote 
glycolysis [154]. There are also lncRNAs, such as UCA1 promotes the glycolysis ability 
of bladder cancer cells by increasing HK-2 expression [155]. The researchers also found 
that defects in fatty acid metabolism can aggravate the aerobic glycolysis process of 
colorectal cancer and promote malignant features of the tumor, which is related to the 
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deletion of the Abhydrolase Domain Containing 5 (ABHD5) associated with lipid 
droplets [156]. Activation of certain signaling pathways such as Wnt signaling can drive 
the glycolytic phenotype of colon cancer cells and promote their proliferation, which 
depends on the activation of PDK1, a downstream target of Wnt [157]. 
1.4.1.8 ATP supply for growth and proliferation 
Tumor cells can overcome the constant uptake of nutrients caused by the 
stimulation of normal cell growth signals, and by ingesting glucose and glutamine in 
large amounts, they can obtain the ability to continue to grow, divide and multiply. Fast-
growing tumor cells can still produce a high proportion of ATP/ADP using glycolysis 
because lack of ATP is not conducive to cell survival, and it has a complete energy-
sensing signal pathway [158]. AMP-activated protein kinase (AMPK) acts as an energy 
sensor. When AMP/ATP increases, AMPK activates, which can increase ATP by 
increasing glucose transport and fatty acid oxidation and appropriately inhibit the 
consumption of ATP by anabolic metabolism [159]. In addition to providing sufficient 
ATP for cell growth and proliferation, enhanced glycolysis metabolism can also inhibit 
cell death, because, on the one hand, it reduces the production of reactive oxygen species, 
thereby weakening the damage of oxygen free radicals to the cell; on the other hand, it 
reduces caspase-dependent and non-dependent apoptosis, such as overexpression of 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) can increase glycolysis and ATP 
levels, blocking non-caspase-dependent apoptosis [160]. After inhibiting cancer cell 
PDK1 with small molecules of sodium dichloroacetate (DCA), forcibly increasing 
oxidative phosphorylation and inhibiting glycolysis, it can make cancer cell membrane 
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hyperpolarization and potassium ion voltage-gated channels open, triggered 
mitochondrial activation-induced caspase-dependent apoptosis [161]. 
1.4.1.9 Provide macromolecular materials to form new cells 
In addition to the need for ATP, rapidly proliferating tumor cells also need 
biological macromolecular materials to form new cells. The unique energy metabolism of 
tumor cells can provide a large number of metabolic intermediates to facilitate the 
synthesis of fatty acids, membrane phospholipids, nucleic acids, and proteins [162]. For 
example, tumor cells increase the production of acetyl-CoA through reductive glutamine 
metabolism and up-regulate the expression of fatty acid synthases (FASN) by HIF-1, 
which is conducive to the large-scale synthesis of fatty acids. On the one hand, fatty acids 
synthesize phospholipids to facilitate cell membrane construction. On the one hand, the 
synthesis of triglycerides facilitates energy storage and signal transmission, which are 
closely related to tumor formation and progression [163, 164]. Many tumor cells 
specifically express pyruvate kinase PKM2, which can promote the conversion of sugar 
to membrane phospholipids, giving cancer cells a selective growth advantage [140]. A 
large number of pyruvate products produced by glycolysis can stimulate the synthesis of 
lipids, while glucose 6-phosphate can synthesize ribose and NADPH through the pentose 
phosphate pathway; glutamine metabolite glutamate can also be metabolized by the TCA 
cycle [164]. Converted to lactic acid, together with lactic acid produced by glycolysis, 
NADPH is produced for phospholipid biosynthesis, and oxaloacetate is used as an 
intermediate product of the TCA cycle [165]. 
Based on previous knowledge, it can be seen that the metabolic phenotype of 
tumor cells provides potential theoretical value for the diagnosis and treatment of clinical 
 39 
tumors, such as the application of metabolic imaging technology. An in-depth 
interpretation of the internal molecular mechanism of different energy metabolism 
phenotypes of tumor cells will help to reveal the causal relationship between tumor cell 
metabolism changes and biological behaviors and provide new opportunities for targeted 
energy therapy of tumors, such as "starved" tumor cells. After the glycolysis phenotype 
of tumor cells is promoted, they will be completely wiped out. 
1.4.2 Amino acid metabolism 
The proliferation of cancer cells needs to obtain the corresponding energy and material 
basis to meet the biosynthesis needs of replication while maintaining the redox steady 
state. A large number of studies have shown that the metabolism of tumor cells is 
abnormally active, and the nutrients and energy necessary to maintain their rapid 
proliferation can be obtained in various ways [162]. The metabolism of cancer cells is 
also different from that of normal cells, and its metabolic changes are also considered to 
be the hallmarks of cancer [142, 166]. In recent years, several studies have shown that the 
metabolic level of various amino acids in tumor cells has changed to adapt to the increase 
in energy requirements and changes in the environment [128]. Multiple signaling 
pathways and transcription factors often drive the changes in tumor amino acid 
metabolism. A large number of basic and clinical trials have shown that targeting tumor-
dependent amino acid metabolism and developing new drugs can effectively inhibit 
tumor growth [167].  
1.4.2.1 Arginine metabolism  
Arginine (Arg) is synthesized from citrulline through a two-step catalytic 
synthesis of Argininosuccinate Synthase 1 (ASS1) and Argininosuccinate lyase (ASL), 
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and then Arginase 1 (Arg1) breaks down arginine into ornithine and urea. Arg and 
Ornithine carbamoyltransferase (OTC) are used to convert ornithine to citrulline for 
recycling in mitochondria. The abnormality of ASS1, ASL or OTC will affect the storage 
of arginine in the cell. ASS1 deficiency is common in tumors, causing tumor cells to have 
to obtain arginine in serum [168]. Therefore, the rapid depletion of arginine in serum can 
be used as a new strategy for cancer treatment [169]. Arginine deiminase (ADI) and Arg1 
can deplete arginine in serum by converting arginine to citrulline and ornithine, then 
inducing of cell cycle arrest, apoptosis, autophagy and causing inhibition of angiogenesis 
[170, 171]. 
1.4.2.2 Asparagine and aspartate metabolism 
Mammalian cells produce asparagine from aspartate and glutamine via asparagine 
synthetase (ASNS). However, some cancer cells lack ASNS expression and need to rely 
on asparagine in serum to meet their needs. ASNS catalyzes the synthesis of the non-
essential amino acid asparagine from aspartate and glutamine. ASNS expression is highly 
regulated at the transcriptional level and is also subject to the amino acid response. 
Lacking ASNS protein expression is a hallmark of acute lymphoblastic leukemia (ALL), 
so this is auxotrophic for asparagine. Using bacterial L-asparaginase (L-ASPase) for ALL 
treatment is the first example of anti-cancer treatment for tumor metabolism. L-ASPase is 
widely present in the serum of microorganisms, plants and some serrated animals. It is an 
enzyme inhibitor produced by microbial fermentation. L-ASPase catalyzes the 
deamidation of asparagine, which rapidly consumes asparagine in serum, leading to the 
inhibition of tumor cell protein synthesis and growth inhibition [172]. Many clinical trials 
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are currently evaluating the efficacy of L-ASPase in treating a series of malignant 
hematological tumors. 
Other hematological and solid cancers also have elevated ASNS levels, so they 
should also respond to asparagine deprivation. In the past few years, some reports have 
shown that in certain cancer types, ASNS is overexpressed, thereby promoting cell 
proliferation, chemoresistance, and metastatic behavior [173, 174].  Limiting asparagine 
by knocking out asparagine synthase, treating it with L-asparaginase, or restricting 
asparagine in the diet can reduce metastasis without affecting the growth of the primary 
tumor. Moreover, asparagine availability also promotes the epithelial-to-mesenchymal 
transition [174]. Activated transcription factor 4 (ATF4) is the main transcriptional 
regulator of the integrated stress response (ISR), which transforms cells to survive the 
nutrient transformation.  Zinc Finger and BTB domain-containing protein 1 (ZBTB1) has 
been shown to regulate ASNS directly through binding [175]. The loss of ZBTB1 
sensitizes T-cell leukemia cells that are resistant to treatment to L-asparaginase, which is 
a chemotherapy that reduces the serum asparagine content [175].  
1.4.2.3 Glutamine metabolism  
Normal cells can produce glutamine by self-synthesis, but tumor cells rely on 
self-synthesized glutamine to not meet their rapid proliferation needs and need to ingest 
glutamine from extracellular or enhance glutamine metabolism pathways through the 
membrane transporter. Tumor cells rely on SLC (solute carrier) superfamily transporters 
on the cell membrane to take up glutamine from the extracellular environment. As a key 
transporter for the transfer of glutamine into cells, SLC1A5, SLC7A5, SLC7A11 and 
SLC6A14 play an important role in tumor cells [176]. It has been reported that the 
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expression of the transporter SLC6A4 is upregulated in colon cancer, cervical cancer, 
breast cancer and pancreatic cancer, and it is expressed at low levels in normal cells. 
Blocking the SLC6A14 protein will affect the intracellular biosynthesis of tumor cells, 
but has little effect on normal cells [177]. Nicklin et al. found that inhibition or deletion 
of SLC1A5 would lead to a decrease in glutamine content in tumor cells, mTOR 
signaling pathway could not be activated, and eventually, tumor growth was inhibited 
[178]. 
In mitochondria, glutamine is catalyzed by glutaminase (GLS) to glutamate. 
There are two subtypes of glutaminase in the human body: renal glutaminase (GLS1) and 
liver glutaminase (GLS2). In the tumor cells of lymphoma, glioma, breast cancer, 
pancreatic cancer, non-small cell lung cancer and kidney cancer, the use of small-
molecule inhibitors or genetic knockdown suppresses the widely expressed GLS1 and 
produces antitumor activity [179]. In B lymphoma cells and prostate cancer cells, the 
highly expressed oncogenic transcription factor c-Myc can inhibit miRNA-23a/b, up-
regulate the expression of GLS1, enhance glutamine metabolism, and promote the 
proliferation of tumor cells [180]. Wang et al. found that the up-regulation of GLS1 in 
breast cancer depends on the role of Rho family proteins and the NF-κB signaling 
pathway and proved that the reduction of GLS1 expression could effectively inhibit the 
proliferation of tumor cells [181]. c-Myc can induce GLS1 without inducing GLS2 
expression, while the tumor suppressor p53 induces GLS2 without inducing GLS1 
expression. GLS2 expression is reduced or even deleted in hepatocellular carcinoma. 
GLS2 overexpression can significantly reduce the formation of tumor cell colonies, 
indicating the potential role of GLS2 in inhibiting the growth of tumor cells [182]. After 
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Glutamine is catalyzed into glutamate by GLS, glutamate is oxidized and deaminated by 
glutamate dehydrogenase (GLUD1, GLUD2) and transaminase (GOT1, GOT2) into α-
KG and ammonia in the mitochondria, and enters the TCA cycle. GLUD can regulate the 
production of α-KG in tumor cells, and its expression is up-regulated in lung cancer and 
breast cancer cells. The knockdown of  GLUD1 can inhibit tumorigenesis in lung cancer 
xenograft models [183]. 
Whereas most cells use glutamate dehydrogenase (GLUD1) to convert glutamine-
derived glutamate into α-KG in the mitochondria to fuel the TCA cycle, KRAS derived 
PDAC relies on a distinct pathway in which glutamine derived aspartate is transported 
into the cytoplasm where it can be converted into oxaloacetate (OAA) by aspartate 
transaminase (GOT1) [165]. Furthermore, OAA is converted into malate and then 
pyruvate, then increases the NADPH/NADP+ ratio, which is used to maintain the cellular 
redox state [165]. Tumor vascular tissue usually leads to areas of nutritional deficiencies 
and hypoxia. Even we understand the response of solid tumors to hypoxia, but little is 
known about how nutritional deficiency locally affects tumor growth and treatment 
response. Due to decreased levels of low glutamine in the core region of the tumor, 
histone hypermethylation is caused, which is a key cofactor containing the Jumonji 
domain-containing (JmjC) histone demethylases (JHDMs) [184].  Low glutamine-
induced histone hypermethylation leads to de-differentiation and drug resistance, which 
is mainly mediated by methylation on H3K27[184].  Increased consumption of glutamine 
will lead to the consumption of nutrients in the tumor, which may cause metabolic stress, 
thereby affecting tumor progression. Glutamine deficiency regulates EMT by 
upregulating the main EMT regulator, Zinc finger protein SNAI2 (SNAI2) [185].  This 
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process depends on the MEK/ERK signaling pathway and ATF4 [185]. SNAI2 in PDAC 
cells are necessary for glutamine deprivation-induced EMT, cell movement, and 
nutritional stress survival.  
At present, many inhibitors against GLS have anti-tumor activity. Glutamine 
analogs, 6-Diazo-5-oxo-L-norleucine (DON), can successfully inhibit glutamine 
metabolic enzymes by combining with the enzyme active site, which has antitumor 
activity. Still, its clinical application is limited due to non-selectivity and toxicity [167]. 
Bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide (BPTES) is a selective 
allosteric modulator of GLS1, inhibits the proliferation of glutamine-dependent cancer 
cells in vitro, and slows the growth of transplanted animal tumors and the oncogenic 
factor c-Myc Growth of mouse tumors [181, 186]. CB-839, which is currently 
undergoing clinical trials, has a similar allosteric binding mechanism and particular 
characteristics to BPTES, but exhibits stronger inhibitory activity and unique kinetic 
properties. CB-839 has shown antiproliferative activity in triple-negative breast cancer 
(TNBC) cell lines and shows significant antitumor activity in two xenograft tumors 
[179]. The main component of green tea catechins, epigallocatechin gallate (EGCG), is 
an inhibitor of GDH, which can inhibit the growth of glutamine-dependent cancer cells 
[187]. Pan-transaminase inhibitor, Aminooxyacetate (AOA), mainly inhibits 
glutamylation in breast cancer cell lines that highly express c-Myc by activating the 
endoplasmic reticulum stress pathway, leading to cancer cell death [188].  
1.4.2.4 Serine and glycine metabolism  
Changes in the de novo serine synthesis pathway (SSP) are common in cancer 
cells. Start with 3-phosphoglycerate (3-PG), the intermediate metabolite of glycolysis, 
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produce serine after involving 3- Phosphoglycerate dehydrogenase (PHGDH), 
Phosphoserine aminotransferase 1 (PSAT1) and three enzymatic reactions regulated by 
Phosphoserine phosphatase (PSPH). The increased expression of enzymes in SSP is one 
of the factors that cancer cells can survive in a serine starvation environment. Increased 
PHGDH expression can promote melanoma and breast cancer growth in mice [189]. The 
expression of PHGDH in triple-negative breast cancer and melanoma cells is 
significantly increased, and inhibition of PHGDH expression can lead to a significant 
decrease in the proliferation rate of tumor cells [190]. PHGDH and PSAT1 are activated 
in non-small cell lung cancer and participate in tumorigenesis and development [191]. 
Besides, PSAT1 and PSPH are also highly expressed in highly metastatic breast cancer 
cell lines [192]. Inhibition of PHGDH can attenuate brain metastasis and improved 
survival in mice with multiple cancer types [193]. 
Serine is a non-essential amino acid that inhibits the de novo synthesis of serine 
and may cause tumor cell tolerance [194]. Exogenous serine is converted into glycine by 
serine hydroxymethyltransferase (SHMT1 or SHMT2), providing a carbon unit to 
participate in the one-carbon cycle for nucleotide biosynthesis. Increased levels of 
SHMT1 and SHMT2 have been observed in transgenic mice susceptible to the oncogenic 
factor Myc-driven B-cell lymphoma [195]. SHMT2 is one of the most commonly 
expressed "metabolic genes" in human tumors [196]. Knocking out of SHMT2 seriously 
damages the proliferation of cancer cells. Moreover, glycine decarboxylase (GLDC) in 
the glycine cleavage system (GCS) is one of the most up-regulated genes in tumor-
initiating cells isolated from non-small cell tumors, inhibition of GLDC can improve the 
survival rate of patients with non-small cell lung cancer [197]. 
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1.4.2.5 Tryptophan metabolism  
In mammalian cells, L-tryptophan (Trp) catabolizes mainly through the 
kynurenine pathway and converts to L-kynurenine (Kyn). Three different dioxygenases 
control the catabolism of Trp by the kynurenine pathway: tryptophan 2,3-dioxygenase 
(TDO), indoleamine 2, 3-dioxygenase 1 (IDO1) and indoleamine 2, 3-dioxygenase 2 
(IDO2). The cleaved product N-formyl kynurenine is enzymatically reacted or 
spontaneously hydrolyzed to Kyn. IDO is the rate-limiting enzymes in the kynurenine 
pathway and is highly expressed in a variety of human tumors [198]. IDO can suppress 
innate and adaptive immune cell responses by depleting tryptophan, which is essential for 
T cell proliferation in the tumor microenvironment, and causing the accumulation of 
tryptophan metabolite kyn and its derivatives, resulting in the rapid proliferation of tumor 
cells [199]. IDO (IDO1 and IDO2) are overexpressed in a variety of cancers, and most 
studies have been focused on the research of IDO1. Preclinical studies have shown that 
targeting IDO1 in rodent models can trigger an anti-tumor immune response and inhibit 
tumor growth [198]. IDO2 is a paralog of IDO1, and they have similar structures. 
However, IDO1 and IDO2 exhibit different substrate specificities and tissue distribution. 
The expression of IDO2 in various cancers has been confirmed [200]. Also, IDO2 is 
necessary to induce several key inflammatory cytokines, and targeting IDO1 and IDO2 
can enhance immune effects [201]. TDO, a homotetrameric protein, together with IDO1 
and IDO2 catalyze the first rate-limiting reaction of the kynurenine pathway, but TDO 
has a higher affinity for L-tryptophan than IDO1. TDO is usually expressed in the liver, 
and most of it is highly expressed in human tumors [202]. Preclinical studies have shown 
 47 
that TDO inhibitors can promote the immune rejection of host cells against tumor cells 
and can be used as a safe and effective cancer treatment [203]. 
1.5 BCAA metabolism 
 
BCAAs are essential amino acids include leucine, isoleucine, and valine, which not 
only act as building blocks for tissue proteins (accounting for 35% of the essential amino 
acids in muscle) but also contribute carbon and nitrogen through catabolism. Unlike other 
amino acids, BCAA levels are not regulated by the liver. BCAA is relatively high in 
dietary protein, accounting for 15-20% of protein intake [204]. Under physiological 
conditions, BCAA is in a steady-state, and it plays a variety of important physiological 
functions in the body, which are important nutritional signals that affect metabolism. 
1.5.1 The biological role of BCAA 
1.5.1.1 Influencing the structure and function of the protein 
BCAA plays an important role in protein structure (especially globular proteins) 
and functions, especially the interaction between membrane protein transmembrane 
regions and phospholipid bilayer. Mutation of BCAA sites in proteins caused by gene 
mutations will cause certain diseases. For example, the replacement of isoleucine with 
valine in thyroxine carrier protein will lead to cardiomyopathy characterized by amyloid 
deposition [205]. In Peroxisome proliferator-activated receptor alpha (PPAR-α)  protein, 
leucine replacing valine will cause changes in blood lipids [206]. BCAA can also 
promote protein synthesis through the mammalian target of rapamycin (mTOR) signaling 
pathway, and leptin can enhance this effect [207]. 
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1.5.1.2 Regulate the energy metabolism of the body and tissue cells 
About 20% of the ingested BCAA is oxidized and decomposed by the TCA cycle 
and the biological oxidation system to produce adenosine triphosphate (ATP) for energy 
supply [208]. BCAA can also perform gluconeogenesis through the alanine-glucose cycle 
and the glutamine pathway to maintain blood glucose levels. Besides, BCAA catabolism 
plays an important role in regulating cardiac glucose metabolism. BCAA can directly 
inhibit pyruvate dehydrogenase complex (PDH) activity leads to a significant decrease in 
glucose uptake, oxidation, glycogen content, and protein glycosylation in hearts [209]. 
1.5.1.3 Regulating cell growth and metabolism as a signaling molecule 
A large number of studies have shown that BCAA, especially leucine, can 
activate protein synthesis, glucose utilization, lipid metabolism, cell growth of the liver, 
skeletal muscle and other tissues by activating a series of signaling molecules such as 
mTOR activation, insulin sensitivity, autophagy, and neurotransmitter synthesis are 
regulated [207, 210, 211]. Recent studies have shown that BCAA metabolic derivative 3-
hydroxyisobutyric acid can also promote skeletal muscle vasculature signal transduction 
or directly promote the synthesis of branched-chain fatty acids in adipocytes [212, 213]. 
Extensive biological functions BCAA can be converted into neurotransmitters, hormones 
and other important physiologically active substances in addition to the above functions. 
Besides, recent studies have found that an unbalanced intake of BCAA in food will 
promote the decomposition of lipids. BCAA can promote glucose utilization by up-
regulating glucose transporters in the intestinal and muscle tissues [214].  BCAA can 
promote intestinal development, intestinal amino acid transport and mucin production, 
which are beneficial to breast health, breast milk quality and embryo growth, respectively 
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[215-217]. BCAA can also participate in the upregulation of innate and adaptive immune 
responses [218]. 
1.5.2 Regulation of body BCAA level 
Increased plasma BCAA levels depend not only on their intake but also on their 
balance between catabolism and protein synthesis and degradation in the body. 
1.5.2.1 BCAA catabolic regulation  
BCAA mainly depends on food intake, so its content mainly depends on catabolic 
regulation [219]. BCAA is the only amino acid that can be metabolized outside the liver. 
Catabolic metabolism is mainly carried out in the liver, skeletal muscle, heart muscle and 
other tissues. The first step in the catabolism of BCAA is the reversible production of the 
corresponding branched-chain α-keto acid, α-ketoisovalerate (KIV), α-keto-β-
methylbutyrate (KMV), and α-ketoisocaproate (KIC) (Figure 1.1), by the catalysis of 
branched-chain aminotransferase (BCAT) and the synergy of α-ketoglutarate and 
glutamine. The second step of BCAA catabolism is a rate-limiting step: BCKA was 
catalyzed by the mitochondrial branched-chain alpha ketoacid dehydrogenase (BCKDH) 
complex to produce branched-chain acyl-CoA intermediates. The liver is the main 
oxidative decarboxylation site of BCKA, and 80% of the body's BCKA is decomposed in 
the liver [220]. The above two steps are the basic steps of BCAA metabolism. After 
oxidative decarboxylation, BCKA is transformed into the corresponding branched acyl-
CoA through its respective metabolic pathway and finally enters the TCA cycle for 




Figure 1.1 Schematic of BCAA metabolism.    
The catabolism regulation of BCAA in the body mainly depends on the activity of 
the rate-limiting enzyme BCKDH complex. BCKDH kinase (BCKDK) and BCKDH 
phosphatase (PPM1K, PP2Cm) can regulate the activity of BCKDH complex and affect 
BCAA metabolism. The BCKDH complex is located on the mitochondrial inner 
membrane matrix side and contains three subunits: alpha-ketoacid dehydrogenase (E1 
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component), dihydrolipoyltransacylase (E2 component), and dihydrolipoamide 
dehydrogenase (E3 component). The activity of the BCKDH complex is mainly regulated 
by the phosphorylation level of the E1α subunit serine at position 293. Under the action 
of BCKDK, the phosphorylation of the E1α subunit of the BCKDH complex is 
inactivated, while under the action of PP2Cm, its dephosphorylation is activated (Table 
1.1). Studies have shown that when the activity of the BCKDH complex in the liver 
decreases, it not only causes BCKA to accumulate in the body but also causes an increase 
in the content of BCAA in the circulating blood [221]. 
 
 Table 1.1 BCAA metabolism related enzymes
 Enzyme 
Name 
Full name Location 
BCAT1 Branched-chain amino acid 
transaminase 1 
cytosolic  
BCAT2 Branched-chain amino acid 
transaminase 2 
mitochondrial 
BCKDHA Branched-chain keto acid 
dehydrogenase E1, alpha polypeptide 
mitochondrial 
BCKDHB Branched-chain keto acid 
dehydrogenase E1 subunit beta 
mitochondrial 
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DBT dihydrolipoamide branched chain 
transacylase E2 
mitochondrial 
DLD dihydrolipoamide dehydrogenase mitochondrial 
BCKDK Branched-chain keto acid 
dehydrogenase kinase 
mitochondrial 
PP2Cm protein phosphatase 2cm mitochondrial 
 
Nutritional status and hormone signals can also change the gene expression of 
BCAA-related regulatory enzymes: in the rat liver, a low-protein diet can increase BDK 
mRNA expression, while removing BCAA in the culture medium can increase the 
BCKDK expression level of cultured hepatocytes and make BCKDH complex activity 
reduced [222]. BCKDK activity is also regulated by allosteric modulation of BCKA, 
thiamine pyrophosphate and other factors. BCKA can allosterically inhibit BCKDK and 
weaken the interaction between BCKDK and BCKDH complex [223]. Mitochondrial 
matrix resident type 2C phosphatase (PP2Cm) is the only endogenous BCKDH 
phosphatase found so far. PP2Cm is a soluble protein located in the mitochondrial matrix. 
Its distribution is tissue-specific. It is highly expressed in the brain, heart, liver, kidney, 
and diaphragm, but low in skeletal muscle [223]. Studies have shown that starvation or 
low BCAA status can inhibit PP2Cm transcription, and PP2Cm can compete with 
BCKDK to bind and interact with the BCKDH complex E2 subunit. This competitive 
effect is regulated by BCKA levels, which cause low levels of BCKA to make BDK 
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dominant and high levels of BCKA dominate the role of PP2Cm [223]. The study found 
that PP2Cm knockout mice had BCAA catabolism disorders, which showed a significant 
increase in plasma BCAA concentration [222]. 
1.5.2.2 Protein synthesis and degradation balance 
  Protein synthesis and degradation rate can also affect plasma BCAA levels. 
Studies have confirmed that insulin, insulin-like growth factor and BCAA can damage 
the autophagy process and the ubiquitin-proteasome pathway mediated by mTORC1 and 
PI3K/AKT pathways, thereby inhibiting the rate of protein degradation in muscle and 
liver [224]. Amino acids can stimulate protein synthesis in human leg muscles, while 
insulin can reduce protein synthesis in human leg muscles [225]. 
1.5.3 BCAA and diseases 
BCAA maintains a steady-state under physiological conditions and exerts a 
variety of important physiological functions. When its catabolism is abnormal, resulting 
in the accumulation of BCAA and decomposition products, it may produce a series of 
harmful effects. Genetic defects of BCAA catabolism-related genes can cause a series of 
inborn metabolic diseases, such as Maple syrup urine disease (MSUD) [226]. In recent 
years, a large number of studies have shown that abnormal catabolism of BCAA is 
associated with many diseases such as Huntington's disease, pancreatic cancer, 
cardiovascular disease, diabetes, obesity. 
1.5.3.1 BCAA and MSUD 
MSUD is a rare autosomal recessive genetic disease with an incidence rate of 
about 1/85,000 [227]. It was first reported by Menkes et al. in 1954 that it got its name 
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because of the peculiar smell of caramel (maple sugar) in the urine of children [228]. The 
disease is due to the congenital disability of branched-chain alpha ketoacid 
dehydrogenase (BCKDH) complex, which causes the catabolism of branched-chain 
amino acids (leucine, isoleucine, valine) to be blocked, and the corresponding keto acids 
cannot be oxidatively decarboxylated and retained. In the body, it produces nervous 
system damage and maple odor urine. According to the different activity of BCKD 
complex, MSUD is divided into 5 types: classic type (< 2%), intermediate type (3% ~ 
8%), intermittent type (8% ~ 15%), effective type of vitamin B1 and E3 subunit-deficient 
type [229]. The key to the treatment of MSUD during the acute phase is to promote 
protein synthesis, inhibit protein breakdown, and avoid damage to the nervous system 
caused by the accumulation of branched-chain amino acids. The branched-chain amino 
acid with a large degree of damage to the nervous system is leucine, and the blood 
leucine concentration is usually higher than isoleucine and valine. Therefore, the rapid 
reduction of leucine with neurotoxicity in plasma is the focus of treatment. 
1.5.3.2 BCAA and diabetes  
As early as 1942, studies reported that plasma BCAA levels in diabetic patients 
increased significantly, and plasma BCAA levels in obese patients also increased 
significantly. However, this phenomenon has not received due attention. Until 2009, 
Newgard et al. [25] reported that BCAA is involved in the development of insulin 
resistance in obese patients. McCormack et al. [26] found that serum BCAA levels (not 
BCAA dietary intake) are associated with obesity and insulin resistance. A large number 
of studies have shown that plasma BCAA levels in patients with diabetes are significantly 
increased, and BCAA can increase the risk of type 2 diabetes (T2DM) by five times. The 
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Framingham Heart Study evenly matched 378 respondents based on body mass, lipid 
metabolism indicators, and other clinical variables. The results showed that the high 
BCAA group was more prone to diabetes, and subsequent Malmo studies also confirmed 
this conclusion [27]. Recently, a large human genome-wide association study showed 
that the mechanism of impaired BCAA metabolism is involved in the pathophysiological 
process of T2DM. These results suggest that there may be a causal relationship between 
BCAA and insulin resistance. 
Studies have confirmed that the activity of the BCKD complex in diabetic patients 
and animal liver is reduced, and it leads to the accumulation of plasma BCAA and 
BCKA. BCAA accumulation can inhibit the transport and utilization of pyruvate and 
fatty acids [16], inhibit the use of insulin-stimulated sugars [28], promote glycogen 
synthesis and lead to hyperglycemia [29]. BCAA inhibits phosphatidylinositol-3-kinase 
and insulin signaling by activating mTOR/p70S6 kinase (which phosphorylates insulin 
receptor substrate 1), which may be one of the mechanisms that promote T2DM after 
elevated BCAA levels [30]. However, some studies have shown that BCAA activation of 
mTORC1 is not enough to cause insulin resistance; while long-term supplementation of 
BCAA activates mTOR, insulin resistance has not been found. Most research results 
support the positive correlation between the accumulation of BCAA and its metabolites 
and the increased risk of insulin resistance. Therefore, the content of BCAA in circulating 
blood has potential clinical application value as a biomarker to predict the level of insulin 
resistance in diabetes. 
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1.5.3.3 BCAA and heart disease  
BCAA and its metabolites play an important role in the regulation of cardiac 
substrate metabolism. Elevated BCAA levels can affect the development of 
cardiovascular and metabolic diseases. Li et al. found that chronic accumulation of 
BCAA can inhibit glucose metabolism and sensitize the heart to ischemic injury [209]. 
This further indicates that high BCAA levels can increase ischemia-reperfusion injury 
(I/RI) caused by myocardial infarction. High levels of BCAA can selectively inhibit PDH 
activity, thereby interfering with the usage of pyruvate by mitochondria. This is because 
the chronic accumulation of BCAA causes the downregulation of the hexosamine 
biosynthesis pathway (HBP), which decreases protein O-linked N-acetylglucosamine (O-
GlcNAc) modification and inactivates PDH, resulting in a marked reduction in 
myocardial glucose oxidation and an increase in fatty acid oxidation.  
The heart has high energy consumption and is sensitive to the nutritional 
environment. Therefore, abnormal metabolism of nutrients will seriously affect the heart 
function and the progress of related diseases. Sun et al. showed that BCAA metabolism 
changes the most significant in the cardiac metabolism of mice with heart failure induced 
by stress overload [230]. They found that the expression of a variety of important BCAA 
catabolism related genes (BCAT2, BCKDHA, BCKDHB, DBT, PP2Cm) was reduced, 
and the expression of BCKDK did not change significantly, which made the role of 
BCKDK dominant, leading to a significant increase in BCAA catabolism in the heart. 
Abnormal catabolism of BCAA can promote myocardial contractile disorders 
independently of other pathological factors, and impaired catabolism of BCAA and its 
increased BCKA will impair mitochondrial function and induce myocardial oxidative 
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stress, significantly promoting the progression of heart failure [230]. Kruppel Like Factor 
15(KLF15) is an important transcriptional regulator of nutrient metabolism, and its 
various target genes are involved in the regulation of glucose and lipid metabolism. The 
same study also found that KLF15 plays an important role in regulating BCAA 
catabolism. The decrease in KLF15 expression in pathologically stressed myocardium 
may be one of the mechanisms of BCAA catabolism abnormalities induced by pressure 
overload in heart disease [230]. Another study showed that BCKA could down-regulate 
the mTORC2-Akt signaling pathway and increase myocardial apoptosis induced by 
pressure overload in a concentration-dependent manner [231]. 
Furthermore, myocardial BCAA metabolism is significantly impaired after MI in 
mice, resulting in a significant increase in myocardial BCAA levels. Activating the 
myocardial mTOR signaling pathway aggravates cardiac dysfunction and myocardial 
remodeling, and promotes the progression of heart failure after MI [231]. These all 
indicate that the reduction of BCAA metabolism related gene expression and the 
accumulation of BCAA and BCKA metabolites caused by BCAA catabolism disorder are 
one of the signs of heart disease.  
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Pancreatic tumors have a rich stromal diversity containing fibroblasts, stellate cells 
and infiltrating immune cells, which cumulatively account for up to 90% of the total 
tumor volume. Fibroblasts are the most common cells in the normal pancreatic stroma. 
Fibroblasts were first defined as cells in the connective tissue that synthesized collagen 
150 years ago [232]. Fibroblasts in normal tissues are generally present as single cells in 
the interstitial space or occasionally near a capillary, without any association with a 
basement membrane, but are embedded within fibrillar ECM of the interstitium [232]. 
These cells exhibit classic spindle-shaped morphology with a potential for planar 
polarity. Fibroblasts in normal tissue are generally considered indolent with negligible 
metabolic and transcriptional activity. Resting fibroblasts may share many features with 
mesenchymal stem cells. In response to the presence of tumor cells, quiescent fibroblasts 
and stellate cells become activated cancer-associated fibroblasts (CAFs) that express 
alpha-smooth muscle actin (αSMA). CAFs develop from bone marrow-derived 
mesenchymal stem cells, pancreatic stellate cells (PSCs), and quiescent resident 
fibroblasts through distinct pathways of activation. However, a recent study showed that 
tumors form their CAFs predominantly from precursors present in the local tumor 
microenvironment, and the contribution from bone marrow is rare [233]. It is known that 
CAFs contribute to tumor proliferation, invasion, and metastasis, and they are a physical 
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barrier for drugs that help enable chemoresistance [232]. However, there is a lack of 
knowledge regarding the metabolic interactions between CAFs and cancer cells.  
2.2 Expression of BCAA metabolism related enzymes in cell lines 
 
Metabolic activity of the BCAAs, leucine, valine, and isoleucine, is both cell- and 
tissue-dependent and takes place in several steps beginning with BCAA deamination. 
BCAA transaminase (BCAT), the enzyme that initiates this process, has two isoforms 
(BCAT1 in the cytosol and BCAT2 in the mitochondria), which result in corresponding 
branched-chain ketoacids (BCKAs), α-ketoisovalerate (KIV), α-keto-β-methylbutyrate 
(KMV), and α-ketoisocaproate (KIC). The second step in BCAA metabolism involves 
irreversible BCKA oxidation catalyzed by the mitochondrial inner membrane complex, 
branch-chain α-ketoacid dehydrogenase (BCKDH) complex. The BCKDH complex 
consists of three catalytic components, alpha-ketoacid dehydrogenase (E1 component), 
dihydrolipoyltransacylase (E2 component), and dihydrolipoamide dehydrogenase (E3 
component). E1 has two isoforms encoded by BCKDHA and BCKDHB, the DBT gene 
encodes E2, and the DLD gene encodes E3. BCKDH complex E1 and E3 units are linked 
via E2. Oxidation of BCKAs results in IB-CoA, 2MB-CoA and IV-CoA, which are 
further converted into succinyl-CoA and acetyl-CoA that act as anaplerotic or ketogenic 
sources for the TCA cycle.  
To determine the differences in BCAT catabolism between stromal and PDAC 
cells, we analyzed protein and gene expression of BCAT1 and BCAT2 (Figure 2.1a-b). 
Interestingly, we found that CAFs had significantly higher BCAT1 expression when 
compared to PDAC cell lines. In contrast, BCAT2 expression was higher in PDAC cells 
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relative to CAFs. Besides, PDAC cells displayed a higher expression of the BCKDH 
complex enzymes BCKDHA, BCKDHB, and DBT than CAFs (Figure 2.1c). Differential 
DBT expression was also corroborated by immunoblotting (Figure 2.1a). These results 
suggest differential BCAA deamination and oxidation potential in stromal and cancer cell 
lines.  
 
Figure 2.1 Expression of BCAA metabolism related enzymes in CAFs and cancer 
cell lines.  a. Immunoblots of BCAT1, BCAT2 and DBT expression in CAFs and 
pancreatic cancer cell lines. HSP90 and Vinculin used as loading control. n = 4 
biologically independent samples. Experiments were repeated independently three times 
with similar results. b. Relative BCAT1 and BCAT2 mRNA expression in CAFs and 
pancreatic cancer cell lines. Expression normalized to gene expression in CAF1. n = 4 
biologically independent samples. c. Relative BCKDHA, BCKDHB, and DBT mRNA 
expression were determined by qRT–PCR in CAFs and pancreatic cancer cell lines. 
Expression normalized to gene expression in CAF1. n = 4 biologically independent 
samples.  
2.3 Expression of BCAA metabolism related enzymes in PDAC tissues 
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To corroborate our observations regarding BCAT1/2 expression in cancer and CAF 
cell-lines, we analyzed human PDAC tissue through staining. IHC staining of PDAC 
tumor similarly revealed that the stromal component had significantly higher expression 
of BCAT1 compared to its epithelial counterpart (Figure 2.2). We further compared 
BCAT1 and α-SMA expression in PDAC patient paired tumor and adjacent normal 
regions (Figure 2.3) and found that both BCAT1 and α-SMA were highly expressed in 
CAFs compared to fibroblasts in the normal stroma, thereby suggesting that enhanced 
BCAT1 expression in tumor stroma is associated with distinct desmoplasia differing from 
normal tissue (Figure 2.3).  
 
Figure 2.2 BCAT1 expression in human PDAC tissues   Representative IHC staining 
image comparing BCAT1 expression between stromal and tumor compartments. 





Figure 2.3 BCAT1 expression in paired healthy and PDAC tissue.   Representative IF 
images were showing protein expression of stromal αSMA, BCAT1 and Vimentin from 
paired healthy and PDAC tissue. Experiments were repeated independently two times 
with similar results. 
 
2.4 PDAC cells are more BCAA dependent 
 
Since differential gene and protein expression does not always translate to 
metabolic phenotype, we measured BCAA catabolic flux using 13C-labeled BCAAs in 
PDAC cells and CAFs (Figure 2.4a). We observed that CAFs had three-fold higher 
BCAA catabolic flux compared to PDAC cell-lines. To evaluate the essentiality of 
BCAAs for CAFs’ and cancer cells’ growth, we cultured them under BCAA deprived 
conditions. Expectedly, CAFs were observably resilient to BCAA deprivation vis a vis 
proliferation, whereas cancer cells were BCAA-dependent (Figure 2.4b-c). The finding 
that cancer cells not only have reduced BCAA catabolic flux compared to CAFs but are 
BCAA-addicted for growth suggests that BCAA intermediates like BCKAs play a 






Figure 2.4 Growth rates of pancreatic cancer cells or CAFs under BCAA 
deprivation.  a. The stable-isotope tracing experiment reveals that CAFs deaminate 
BCAAs into BCKAs at a rate three-fold faster than PDAC cells. n = 3 biologically 
independent samples.  b. Relative proliferation rates of Mia Paca-2, Panc-1 and Patu 
8988t pancreatic cancer cells or CAFs under BCAA deprivation. n = 4 biologically 
independent samples. c. Absolute cell numbers of PDAC CAFs were determined in the 
presence or absence of BCAA. n = 3 biologically independent samples.  d. Absolute cell 
numbers of PDAC cells were determined in the presence or absence of BCAA. n = 3 
biologically independent samples.   
2.5 Discussion 
 
Previously, most BCAA catabolism studies were focused only on the cancer cells in 
diseases like glioma, lung cancer or pancreatic cancer, and they completely ignored the 
role of the stroma. In this chapter, we examined the BCAA related enzyme expression in 
the PDAC tumor microenvironment. We also analyzed the difference of BCAA 
catabolism flux that is distributed within the PDAC tumor microenvironment.  First, 
CAFs had high BCAT1 expression, while PDAC cell lines lack expression of BCAT1. In 
contrast, BCAT2 expression was higher in PDAC cells relative to CAFs. IHC staining of 
human PDAC tissue found that the stromal component had significantly higher 
expression of BCAT1 compared to its epithelial counterpart. Similar expressions were 
also confirmed in normal pancreas tissue. 
Moreover, the BCAA catabolic flux using 13C-labeled BCAAs revealed that CAFs 
had three-fold higher BCAA catabolic flux compared to PDAC cell-lines. Moreover, 
compared to PDAC cells, CAFs were observably resilient to BCAA deprivation. These 
findings suggest that PDAC cells have reduced BCAA catabolic flux compared to CAFs, 
and stromal BCAT1 may also play an important role in the PDAC tumor environment. 
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Our previous work that genetic mutations can also influence how BCAA 
metabolism impacts PDAC progression [234]. Malic enzyme 2(ME2) is near the 
SMAD4, which is commonly deleted PDAC, in the human genome, so ME2 is usually a 
passenger deletion in PDAC. When ME2 is deleted, malic enzyme 2(ME3) became 
essential. Moreover, ME3 regulates BCAT2 through AMP-activated protein kinase 
(AMPK)-sterol regulatory element-binding protein 1 (SREBP1) pathways [234]. 
Knockdown of BCAT2 in ME2-deficient PDAC cell lines inhibited colony formation, 
which could be rescued by nucleotide supplementation, suggesting BCAAs to play an 
important role in PDAC. Li et al. showed that BCAT2 is elevated during PDAC 
progression. Pancreatic tissue-specific knockout of BCAT2 impedes the progression of 
pancreatic intraepithelial neoplasia (PanIN) in mice. Functionally, BCAT2 enhances 
BCAA uptake to sustain BCAA catabolism and mitochondrial respiration. 
Mechanistically, KRAS stabilizes BCAT2 through spleen tyrosine kinase (SYK) and E3 
ligase tripartite-motif-containing protein 21 (TRIM21), so BCAT2-mediated BCAA 
catabolism is critical for the development of PDAC harboring KRAS mutations [235].  
Lei et al. show that BCAT2 is acetylated, which is acetylated at lysine 44 (K44) [236]. 
BCAT2 acetylation leads to its degradation through the ubiquitin-proteasome pathway, 
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and they also identified cAMP-responsive element-binding (CREB)-binding protein 
(CBP) and SIRT4 as the acetyltransferase and deacetylase for BCAT2, respectively 
[236]. All these data suggest that BCAT2 has an important role in PDAC. 
MicroRNAs have also been shown to regulate BCAT2. MiR-182 can reduce the 
expression of Bcat2, Foxo3 and Adcy6 to regulate the hypertrophic response in placental 
growth factor-induced mice [237]. The knocking down of BCAT2 promotes Akt 
(Ser473)/p70-S6K (Thr389) phosphorylation and cardiomyocyte hypertrophy [237, 238]. 
In muscle cells, Dhanani et al. showed that leucine is required for myotube formation, 
which can also be replaced by KIC and BCAT2 is induced in the differentiation [239]. 
The inhibition of BCAT2 also abolished myoblast differentiation [239]. Moreover, both 
of KLF15 and PGC-1α can regulate BCAA metabolism by targeting BCAT2 skeletal 
muscle [240, 241]. 
 
3.2 CAF support PDAC cell growth under BCAA deprivation 
 
To address whether upregulated BCAA deamination in pancreatic CAFs fuels the 
BCAA addiction of cancer cells, we measured the proliferation rate of GFP-labeled 
PDAC cell lines, Mia PaCa-2, Panc-1 and PaTu 8988t, directly coculture with patient-
derived CAFs or normal fibroblasts (NOFs). Notably, we observed that CAFs completely 
rescued the loss of proliferation of cancer cells under BCAA-deprivation, while NOFs 
did not affect (Figure 3.1a-c). Similar results were also seen by AsPC-1 and BxPC3 
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PDAC cell lines (Figure 3.1d). These data suggest that CAFs may either be secreting 
BCAAs or their catabolic product, BCKAs.  
 
 
Figure 3.1 CAFs support PDAC growth under BCAA deprivation.  a. Fluorescence 
microscopy images comparing the growth of GFP-labeled Mia Paca-2 and Panc-1 cells in 
contact co-cultures with CAFs or NOFs under BCAA deprivation. Experiments were 
repeated independently three times with similar results. b. Fluorescence microscopy 
images merged with brightfield images comparing the growth of GFP-labeled Mia Paca-2 
and Panc-1 cells in contact co-cultures with CAFs or NOFs under BCAA deprivation. c. 
Relative proliferation rates of Mia Paca-2, Patu 8988t and Panc-1 pancreatic cancer cells 
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under BCAA deprivation. n = 3 biologically independent samples.   d. Relative growth 
rates of AsPc1 and BxPC-3 cells co-cultured with CAFs or NOFs under BCAA 
deprivation. n = 3 biologically independent samples.     
 
3.3 CAF secrete BCKA to support PDAC cells 
 
First, we check the CAF’s rescue effect at different co-culture ratio, since the ratio 
influences the effect, it supposes to come from soluble factor secreted by CAFs (Figure 
3.2a). We measured BCKA secretion by CAFs to be around 200 pmol/µg protein, which 
increased under BCAA-deprivation to around 300 pmol/µg protein (Figure 3.2b). 
Interestingly, we found that under BCAA-deprivation, BCKAs rescued the proliferation 
at concentrations as low as 5-50uM, whereas 100µM BCAA was needed to obtain a 
similar effect (Figure 3.2d). This suggests that BCKA is a more effective nutrient at 
lower concentrations compared to BCAAs (Figure 3.2c). 
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Figure 3.2 CAFs support PDAC growth through BCKA.  a. Relative growth rates of 
Mia Paca-2 cells co-cultured with CAFs or NOFs at different seeding ratios under BCAA 
deprivation. n = 3 biologically independent samples.  b. BCKA secretion by CAFs 
estimated by measuring the extracellular concentration of BCKAs, KIC and KMV, at 6, 
12, 24, and 48 hours by LC-MS. n = 3 biologically independent samples. c. Model for the 
rescue of proliferation in BCAT2 KD cancer cells by BCKAs released from CAFs under 
BCAA deprivation. d. Relative growth rates of Mia Paca-2 cells in various concentrations 
of BCAAs or BCKAs. n = 6 biologically independent samples.     
 
3.4 BCKA contribute to TCA cycle and protein synthesis 
 
Once the CAF-secreted BCKAs are consumed by cancer cells, they may be used 
directly for BCKA oxidation through the BCKDH complex to maintain oxidative TCA 
cycle metabolite levels. BCKAs can also act as substrates for de novo synthesis of 
BCAAs through reanimation by the reversible enzyme BCAT2 (Figure 3.3). Although 
not explicitly shown before, this newly synthesized BCAAs could maintain de novo 
protein synthesis in cancer. To confirm the fate of BCKAs, we cultured cancer cells with 
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13C labeled BCKAs. They estimated their contribution towards the TCA cycle as an 
anaplerotic substrate and for de novo BCAA and subsequent de novo protein synthesis 
(Figure 3.3). We observed that BCKAs are indeed oxidized and incorporated into the 
TCA cycle via acetyl-CoA and succinyl-CoA, as evident from the 13C labeled TCA 
intermediates citrate, malate, and aspartate (Figure 3.3). 
Interestingly, BCKAs were also utilized for de novo protein synthesis and were 
found to contribute more than 60% of the intracellular BCAA pools under BCAA-
deprived conditions (Figure 3.3). Further, 15N labeled glutamine and serine were found to 
contribute the required nitrogen for BCAA synthesis commensurately. The amino acid 
composition of intracellular protein was determined using acid hydrolysis and GC-MS 
analysis. The constituent BCAAs in the protein achieved 40% enrichment from 13C 
labeled BCKAs and 50% enrichment from 15N labeled glutamine and serine, definitively 
proving that BCKA-derived BCAAs contributed significantly to de novo protein 
synthesis (Figure 3.3). 
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Figure 3.3 BCKA metabolism in PDAC cells.  The fate of 13C-BCKAs in PDAC cells 
elucidated by measuring mole percent enrichment (MPE) of TCA cycle intermediates 
that represent BCKA oxidation and of intracellular BCAAs and BCAAs from acid-
hydrolyzed proteins that represent de novo protein synthesis. n = 7 biologically 
independent samples for intracellular metabolites and n = 4 biologically independent 
samples for protein hydrolyzed metabolites. 
3.5 BCKA contribute to protein synthesis through BCAT2 
 
To substantiate the functional role of BCAT2 in the BCAA metabolism of PDAC 
cells, we silenced BCAT2 using both CRISPR and short hairpin (sh) RNA in PDAC cells 
(Mia Paca-2, Panc-1 and Patu 8988t). We found that BCAT2 knockdown (KD) 
significantly reduced the growth rate of PDAC cells implying that BCAT2 plays an 
important role in these cells (Figure 3.4ab). The knockdown of BCAT2 resulted in a 
decrease of the 13C enrichment of BCAAs obtained after protein hydrolysis, thereby 
confirming the BCKA-mediated, anabolic, regulatory role of BCAT2 in PDAC (Figure 
 73 
3.4c). Having delineated that BCKAs can contribute towards de novo protein synthesis, 
we next assessed whether CAFs could promote protein synthesis in cancer cells. We used 
the SUnSET assay to measure de novo protein synthesis and found that CAFs, indeed 
increased protein synthesis in cancer cells (Figure 3.4d). Consistent with significant 
enrichment of labeled BCKA-derived BCAAs in hydrolyzed protein, BCKA 
supplementation restored the loss of newly synthesized protein levels under BCAA 
deprivation (Figure 3.4e). To establish the essentiality of BCAT2 in PDAC, we 
cocultured BCAT2 knockdown PDAC cells with patient-derived CAFs (Figure 3.4f).  
Intriguingly, knocking down BCAT2 in cancer cells had no effect on CAF-mediated 
rescue of cancer cell growth under BCAA deprivation conditions.  
 
Figure 3.4 BCAT2 regulates protein synthesis in PDAC cells.  a. Relative proliferation 
rates of Mia Paca-2, Panc-1 and Patu 8988t pancreatic cancer cells with BCAT2 
knockdown by shRNA. n = 4 biologically independent samples.    b. Relative 
proliferation rates of Panc-1 and Patu 8988t pancreatic cancer cells with BCAT2 
knockdown by CRISPR. n = 4 biologically independent samples.  c. Mole percent 
enrichment (MPE) of BCAAs in hydrolyzed protein obtained from BCAT2 knockdown 
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Mia Paca-2 cells cultured with 13C-BCKA. n = 4 biologically independent samples. d. 
FACS analysis of GFP-labeled Mia Paca-2 cells detected with Alexa 647–labeled 
antibodies to puromycin (puro-A647). n = 3 biologically independent samples.    e. 
Representative images of SUnSET assay of Mia Paca-2 cells cultured in the indicated 
medium for 48 hr. Whole-cell lysates were subjected to western blotting with puromycin 
antibody. Experiments were repeated independently three times with similar results. f. 
CAF cocultures rescue the loss of growth in BCAT2-knockdown PDAC cells. n = 6 
biologically independent samples. 
3.6 CAF support PDAC cells through BCKA independent of autophagy 
 
We further excluded the possibility that BCAAs are directly catabolized from 
autophagy-induced protein degradation[242] by knocking down autophagy-related 5/7 
(ATG5/7) in CAFs and coculturing them with PDAC cells under BCAA deprivation. We 
found that ATG5/7 knockdown did not suppress CAF-mediated rescue of cancer cell-
growth under BCAA-deprivation (Figure 3.5a). Moreover, autophagy inhibitors, 
chloroquine, Bafilomycin A1 and LY294002 did not inhibit the rescue effect of CAFs on 
cancer cell growth under BCAA-deprivation conditions (Figure 3.5b). These results 
provide strong evidence of the regulation of BCAA metabolism by BCAT2 in PDAC 
cells. 
 
Figure 3.5 CAF support PDAC cells under BCAA deprivation independent of 
autophagy.  a. Relative growth rates of Mia Paca-2 and Panc-1 cells co-cultured with 
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ATG-5/7 knockdown CAFs. n = 3 biologically independent samples.   b. Relative growth 
rates of Mia Paca-2 and Patu 8988t cells cocultured with CAFs treated with autophagy 
inhibitors (chloroquine, Bafilomycin A1 and LY294002) under BCAA deprivation. n = 3 




The role of BCAA catabolism in cancer was largely overlooked until 2013 when 
Tonjes et al. reported overexpression of BCAT1 in gliomas, which excrete glutamate and 
promote glioma cell proliferation [243]. BCAT1 expression in glioma is specific to those 
gliomas with wild-type isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2). Also, 
BCAT1 is required for chronic myeloid leukemia (CML) growth. It was shown that 
BCAT1 is upregulated during the progression of CML and promotes BCAA production 
in leukemia cells by the amination of branched-chain keto acids [244]. BCAAs are also 
important nitrogen sources since the transamination of BCAAs leads to the regeneration 
of glutamate, which can be used for biosynthesis of other nonessential amino acids. 
Previous studies have demonstrated that elevated plasma levels of BCAAs are associated 
with a greater than 2–fold increased risk of pancreatic cancer [245]. Previously we 
demonstrated that knockdown of BCAT2 in Malic Enzyme 2 (ME2)-deficient pancreatic 
cell lines inhibited cell proliferation, which could be rescued by nucleotide 
supplementation, suggesting that BCAA is an important nitrogen source in pancreatic 
cancer [234].  Pancreatic tissue-specific knockout of BCAT2 impedes the progression of 
PanIN in mice, and BCAT2 enhances BCAA uptake to sustain BCAA catabolism and 
mitochondrial respiration [235]. Also, BCAT2 can be acetylated, which is acetylated at 
 76 
lysine 44 (K44), and its acetylation leads to degradation through the ubiquitin-proteasome 
pathway [236].   
In this chapter, we showed that CAFs are secreting BCAA catabolic products, 
BCKAs. Moreover, CAF-secreted BCKAs are consumed by PDAC cells. They can be 
used directly for BCKA oxidation through the BCKDH complex to maintain oxidative 
TCA cycle metabolite levels. BCKAs can also act as substrates for de novo synthesis of 
BCAAs through reanimation by the reversible enzyme BCAT2. We also found that 
BCAT2 knockdown significantly reduced the growth rate of PDAC cells implying that 
BCAT2 plays an important role in these cells. We also showed that CAFs increased 
protein synthesis in cancer cells. However, when we cocultured BCAT2 knockdown 
PDAC cells with CAFs, knocking down BCAT2 in cancer cells had no effect on CAF-
mediated rescue of cancer cell growth under BCAA deprivation conditions. This would 









Since the catabolism of BCAA starts with branched-chain aminotransferases giving 
rise to corresponding BCKA.  The second step is catalyzed by the mitochondrial inner 
membrane complex called branch-chain α-ketoacid dehydrogenase (BCKDH) complex.  
The BCKDH complex consists of three catalytic components, alpha-ketoacid 
dehydrogenase (also referred to as the E1 component), dihydrolipoyl transacylase (E2 
component), and dihydrolipoamide dehydrogenase (E3 component). The branched-chain 
keto acid dehydrogenase E1 has two isoforms, alpha polypeptide and subunit beta, which 
are encoded by BCKDHA and BCKDHB, respectively.  Dihydrolipoamide 
dehydrogenase (E3 component) is encoded by the DLD gene, which also acts as the 
common part for pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase. 
Compared to BCAT1/2, BCKDH was not well studied yet. Most of the research related to 
BCKDH is coming from MUSD; these studies identified different mutations of 
BCKDHA, BCKDHB, and DBT can cause MUSD [246]. Lee et al. found knocking 
down of BCKDHA inhibited PDAC cell proliferation but not pancreatic duct epithelial 
cell proliferation [247]. Similar to adipocyte, BCKDHA knockdown also inhibited fatty-
acid synthesis in PDAC cells, indicating that PDAC cells also utilize BCAAs for fatty 
acid biosynthesis [247, 248]. Xue et al. found that BCKDK is widely expressed in 
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colorectal cancer patients and related to survival times [249]. Nevertheless, BCKDK 
promotes colorectal cancer by enhancing the MAPK signaling pathway through direct 
MEK phosphorylation rather than by branched-chain amino acid catabolism [249]. White 
et al. found inhibition of BCKDK or overexpression of the PPM1K can regulate BCKDH 
complex activity, lower circulating BCAA, reduce hepatic steatosis, and identified ATP-
citrate lyase (ACL) as an alternate substrate of BCKDK and PPM1K [250]. Hepatic 
overexpression of BCKDK increased ACL phosphorylation and activated de novo 
lipogenesis. Furthermore, mechanically ChREBP-β regulates BCKDK and PPM1K 
transcription levels to control lipid metabolism [250].  
The DBT gene encodes Dihydrolipoyl transacylase (E2), it is also the center of 
the BCKDH complex E1 and E3 are all linked to it [251]. Targeting the DBT gene will 
directly target the whole BCKDH complex instead of the target of genes, BCKDHA and 
BCKDHB. Furthermore, its encoded component is the core of the BCKDH complex, 
which all makes DBT a good target in BCAA catabolism.    
4.2 PDAC cells are DBT dependent 
 
Because BCAT2 knockdown did not result in a loss of cancer cell growth in 
cocultures with CAFs under BCAA-deprivation, we hypothesized that irreversible BCKA 
oxidative decarboxylation by the BCKDH complex might be facilitating biosynthesis. To 
regulate BCKDH complex activity, we targeted the core, the E2 component encoded by 
DBT. Knocking down DBT using shRNA-DBT profoundly reduced proliferation and 
colony formation (Figure 4.1a-c). In agreement with the essentiality of the BCKDH 
complex, the addition of BCKAs under BCAA deprivation rescued the loss of 
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proliferation in PDAC cells (Figure 4.1d), but not in CAFs (Figure 4.1e).To confirm that 
BCKA-mediated growth-rate rescue is conferred via the BCKDH complex and not due to 
BCAT2, we cultured DBT knockdown cells under BCAA deprivation. As expected, 
BCKA-mediated rescue of cancer cell growth was attenuated (Figure 4.1f).  
 
Figure 4.1 PDAC cells are DBT dependent.  a. Absolute cell numbers of PDAC cells 
expressing control shRNA or two independent shRNAs to DBT. n = 3 biologically 
independent samples.  b. Relative proliferation rates of Mia Paca-2, Panc-1 and Patu 
8988t cells expressing control shRNA or two independent shRNAs to DBT. n = 8 
biologically independent samples. c. Colony-formation assay of DBT knockdown PDAC 
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cell lines. n = 3 biologically independent samples.   d. BCKAs can rescue BCAA 
deprivation in the cancer monoculture. n = 4 biologically independent samples.  e. BCKA 
does not influence CAF proliferation. n = 4 biologically independent samples.  f. Relative 
proliferation rates of DBT knockdown cells in BCAA depleted media under BCKA 
replete conditions. n = 8 biologically independent samples.   
Next, we cocultured DBT-knockdown PDAC cells with CAFs under BCAA 
deprivation to substantiate the BCKDH-dependent role of CAF-secreted BCKA in 
maintaining PDAC cells’ growth (Figure 4.2a-b). Notably, knockdown of DBT in PDAC 
cells abrogated the rescue effect from CAFs, thereby validating the role of the BCKDH 
complex. 
 
Figure 4.2 CAF's rescue effect is regulated by DBT. a. Relative proliferation rates of 
DBT knockdown cells co-cultured with CAFs. n = 3 biologically independent samples. b. 
Schematic for the loss of rescue in DBT knockdown cancer cells by BCKA released from 
CAFs under BCAA deprivation. 
4.3 BCKA support NADH through DBT 
 
Given that complete oxidation of one molecule of KIV, KMV, or KIC can provide 
6, 5, or 10 NADH molecules, respectively, BCKA-driven NADH could provide a 
substantial measure of BCKA oxidative capacity in cells. To further validate the effect of 
BCKA oxidation on mitochondrial activity, we used a fluorescent, genetically encoded 
NADH sensor to measure mitochondrial NADH/NAD+ in MiAPaCa-2 cells cultured in 
the absence or presence of either BCAA or BCKA (Figure 4.3). Interestingly, BCKAs 
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increased the mitochondrial NADH/NAD+ ratio and corroborated our findings that 
BCKA oxidation enhances energy metabolism. BCKAs have two fates in the cells; they 
can either be reanimated into BCAAs via BCAT2 or be oxidized through the BCKDH 
complex. To investigate both possible fates, we measured NADH in DBT, BCAT2 
knockdown PDAC cells and PDAC cells under varying α-KG/Glutamate ratios. 
 
Figure 4.3 BCKA rescue NADH supply under BCAA deprivation. a. Colocalization 
of Mitotracker and RexMito fluorescence in Mia Paca-2 cells. Mitotracker (red), 
RexMito (green), and DAPI (blue).  Experiments were repeated independently three 
times with similar results. b. NADH/NAD+ ratio measured using confocal fluorescence 
imaging of Mia Paca-2 cells in BCAA depleted media under BCKA replete conditions. 
Experiments were repeated independently three times with similar results.   c. 
NADH/NAD+ ratio measured using confocal fluorescence imaging of Mia Paca-2 cells in 
BCAA depleted media under BCKA replete conditions. n = 5 biologically independent 
samples.    
The knockdown of DBT reduced the NADH/NAD+ ratio in PDAC cells, 
confirming the involvement of DBT and BCKA oxidation in increasing this ratio (Figure 
4.4). We further increased the ratio of α-KG/glutamate by supplementing αKG in the 
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media to regulate the flux of the BCAT2 pathway to reduce the reanimation of BCKAs 
and favor oxidation. The increased α-KG/glutamate ratio nudges BCKAs towards 
oxidation, which is confirmed with the observation of an increased NADH/NAD ratio 
and increased growth of PDAC cells (Figure 4.5). Since the effect of modulating NADH 
should directly affect mitochondrial oxygen consumption rate (OCR), we measured OCR 
under different substrates and varying α-KG/glutamate ratios. As seen in Figure 4.5e, 
increasing the α-KG/glutamate ratio (by supplementing α-KG) increased the OCR 
significantly, whereas the converse was true when this ratio was decreased (by 
supplementing glutamate). 
 
Figure 4.4 Inhibition of DBT reduces NADH. a. NADH/NAD+ ratio measured using 
confocal fluorescence imaging of Mia Paca-2 transfected with siControl or siDBT.  b. 
NADH/NAD+ ratio measured using confocal fluorescence imaging of Mia Paca-2 cells 
transfected with siControl or siDBT. n = 5 biologically independent samples. c. DBT 
inhibition impedes oxidation of BCKAs via BCKDH complex, and thus pushes the 




Figure 4.5 α-KG/Glutamate ratio regulates BCKA oxidation. a. NADH/NAD+ ratio 
measured using confocal fluorescence imaging of Mia Paca-2 cells in complete media 
with 4mM α-KG added BCKAs.   b. NADH/NAD+ ratio measured using confocal 
fluorescence imaging of Mia Paca-2 cells in complete media with 4mM a-KG added 
BCKAs n = 4 biologically independent samples.  c. BCKAs have two fates, but the 
reanimation of BCKAs is dependent on nitrogen availability via glutamate. We regulate 
the α-KG/glutamate ratio by supplementing α-KG to impede the reanimation of BCKAs 
via BCAT2, thereby pushing BCKAs towards oxidation via BCKDH. d. EdU uptake was 
measured in Mia Paca-2 cells in the presence of a-KG or/and BCKA after one day. n = 3 
biologically independent samples.   e. Substrate-specific oxygen consumption rate (OCR) 
in permeabilized pancreatic cancer cells measured using Seahorse Analyzer. n = 6 
biologically independent samples.  
Finally, we used BCAT2 knockdown cells and found that adding BCKAs in 
BCAT2 knockdown cells (Fig. 3M, Extended Fig. 3J-K) increased NADH, thus 
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substantiating that two outcomes, delamination and oxidation of BCKA, control its fate. 
Cumulatively, these experiments show that both fates of BCKAs are relevant in the 
context of PDAC cells. Thus BCKAs contribute to both the proliferation and bioenergetic 
metabolism of PDAC cells. 
 
Figure 4.6 BCAT2 regulates downstream BCKA oxidation. a. NADH/NAD+ ratio 
measured using confocal fluorescence imaging of Mia Paca-2 cells transfected with 
siControl or siBCAT2 in complete media or BCAA depleted media under BCKA replete 
conditions. b. BCAT2 inhibition has the same effect as α-KG supplementation and 
pushes the accumulated BCKAs towards oxidation via BCKDH. c. NADH/NAD+ ratio 
measured using confocal fluorescence imaging of Mia Paca-2 cells transfected with 
siControl or siBCAT2 in complete media or BCAA depleted media under BCKA replete 
conditions. n = 6 biologically independent samples.   
4.4 DBT regulate BCKA specific OCR 
 
To identify the dominant substrates contributing to cellular oxidative capacity, we 
measured OCR. Remarkably, BCKA-driven OCR in PDAC cells is significantly higher 
than that of alternative substrates (Figure 4.7a). To dissect the role of BCAT2 and DBT 
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in the oxidative capacity of PDAC cells, we measured the OCR of DBT- and BCAT2-
knockdown PDAC cells and found that their OCR was significantly reduced (Figure 
4.7b-c). 
 
Figure 4.7 BCKA OCR is higher than BCAA in PDAC cells. a. Substrate-specific 
OCR in permeabilized cells. n = 4 biologically independent samples.  b. OCR 
measurements in DBT knockdown cells. n = 6 biologically independent samples. c. OCR 
measurements in BCAT2 knockdown cells. n = 6 biologically independent samples.  
To associate substrate specificity with BCAT2 and the BCKDH complex, we 
performed substrate-specific OCR in BCAT2- and DBT-knockdown cells. Interestingly, 
in BCAT2-knockdown cells, there was no change in BCKA-driven OCR, whereas 
BCAA-driven OCR was significantly reduced (Figure 4.8ab). Strikingly, in DBT-
 86 
knockdown cells, both BCAA- and BCKA-driven OCR are significantly reduced (Figure 
4.8cd).  Further, BCKA-driven OCR is higher than BCAA-driven OCR, thereby 
suggesting that BCKAs are a better fuel source for PDAC cells (Figure 4.8cd). These 
results strongly suggest that PDAC cells are heavily dependent on BCKAs, and DBT is a 
potential target for exploiting this dependency. 
 
 
Figure 4.8 BCKA specific OCR is regulated by DBT. a. Substrate-specific OCR 
measurements of BCAT2 knockdown Mia Paca-2 cells. n = 4 biologically independent 
samples.   b. Substrate-specific OCR measurements of BCAT2 knockdown Panc-1 cells. 
n = 4 biologically independent samples.  c. Substrate-specific OCR measurement of DBT 
knockdown Mia Paca-2 cells. n = 4 biologically independent samples.     d. Substrate-
specific OCR measurement of DBT knockdown Panc-1 cells. n = 4 biologically 
independent samples.   
4.5 Discussion 
 
The second step of BCAA metabolism is catalyzed by the mitochondrial inner 
membrane complex called branch-chain α-ketoacid dehydrogenase complex (BCKDH 
complex).  The BCKDH complex consists of three catalytic components, alpha-ketoacid 
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dehydrogenase (also referred to as the E1 component), dihydrolipoyl transacylase (E2 
component), and dihydrolipoamide dehydrogenase (E3 component). The branched-chain 
keto acid dehydrogenase E1 has two isoforms, alpha polypeptide and subunit beta, which 
are encoded by BCKDHA and BCKDHB, respectively.  Dihydrolipoamide 
dehydrogenase (E3 component) is encoded by the DLD gene, which is also a subunit of 
pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase complexes. The DBT 
gene encodes Dihydrolipoyl transacylase (E2), BCKDC E1 and E3 are linked via E2. 
After the second step, BCKAs are catalyzed into IB-CoA, 2MB-CoA and IV-CoA, which 
are then converted into succinyl-CoA and Acetyl-CoA to contribute to the TCA cycle. 
Since BCAT2 knockdown did not result in a loss of cancer cell growth in cocultures 
with CAFs under BCAA-deprivation, we use DBT knockdown PDAC cells to 
characterize the functions of the BCKDH complex in this chapter. Knocking down DBT 
reduced proliferation and colony formation. In agreement with the essentiality of the 
BCKDH complex, the addition of BCKAs under BCAA deprivation rescued the loss of 
proliferation in PDAC cells is conferred via the BCKDH complex. Furthermore, DBT-
knockdown PDAC cells with CAFs under BCAA deprivation proved the BCKDH-
dependent role of CAF-secreted BCKA in maintaining PDAC cells’ growth. 
Also, we showed that BCKAs increased the mitochondrial NADH/NAD+ ratio and 
corroborated our findings that BCKA oxidation enhances energy metabolism. BCKA's 
contribution to oxidization through the BCKDH complex is regulated by DBT, BCAT2 
and α-KG/Glutamate ratios in PDAC cells. To identify the dominant substrates 
contributing to cellular oxidative capacity, we measured OCR differences in BCAT2 and 
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DBT knockdown cells. We showed that that PDAC cells are heavily dependent on 








The BCAT1 gene, also known as the ECA39 or PNAS121, is located in the 12p12-
11 segment. The mRNA is 8191 bp in length, contains 11 exons, and encodes 641 amino 
acids. It was first found in teratocarcinoma cell lines in 1990 [252]. In normal organisms, 
BCAT1 is located in the cytoplasm, which is mainly expressed in brain tissue, spinal 
cord, peripheral neurons and other tissues [253]. The corresponding isozyme BCAT2 is 
often found in mitochondria and is expressed in all tissues of the body [254]. The first 
step of BCAA catabolism is to transfer the α-amino group to α-ketoglutarate through 
BCAT1 in the cytoplasm or BCAT2 isozyme in mitochondria, the product is glutamate, 
and corresponding branched-chain keto acids. The resulting branched-chain keto acids 
can be further metabolized into acetyl-CoA and succinyl-CoA, enter the tricarboxylic 
acid cycle, generate precursors needed for the synthesis of other biological 
macromolecules and provide energy for the synthesis of mitochondrial ATP [204]. In 
1996, BCAT1 was first identified as the direct target of c-MYC regulation, which is 
highly conservative during evolution and involved in the regulation of the yeast cell cycle 
[255, 256].  
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5.1.1 Glioma  
Glioma is derived from the glial cells and neuronal cells of the nervous system, 
also known as neuroepithelial tumors. It is the most common malignant tumor in the 
brain, accounting for 35.26%-60.96% of the primary intracranial tumors [257]. The 
transamination of BCAA via BCAT1 provides an important nitrogen source for the body 
to synthesize non-essential amino acids, and down-regulation of BCAA catabolism often 
leads to neurological dysfunction [243]. This shows that BCAA plays an important role 
in maintaining normal neurological function. Tönjes et al. found that BCAT1 is highly 
expressed in gliomas carrying wild-type IDH (IDHwt), but not significantly increased in 
mutant IDH (IDHmut) gliomas and normal brain tissues [243]. It found that compared to 
IDHmut glioma, an important difference between IDHwt glioma is the overexpression of 
BCAT1. Therefore, it is different from the commonly used IDH1-R132H staining is 
similar, and BCAT1 staining can also be used for differential diagnosis of related brain 
gliomas; in glioma cell lines, the expression level of BCAT1 depends not only on the 
concentration of its substrate α-ketoglutarate, but also overexpression of IDHmut can 
inhibit the expression of BCAT1; at the same time, in vitro experiments found that 
inhibiting the expression of BCAT1 in glioma cells directly leads to a reduction in 
glutamate production, and the cell proliferation and invasion ability also decreases; not 
only that, It is also found in the mouse model of glioma transplantation that the growth of 
the transplanted tumor is also significantly restricted under the condition of inhibiting the 
expression of BCAT1 [243]. Zhang et al. show that hypoxia upregulates the BCAA 
transporter LAT1 and BCAT1, but not BCAT2 in glioblastoma [258]. HIF-1α regulates 
BCAT1 expression by directly binding to the hypoxia response element at the first intron 
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of the BCAT1 in glioblastoma [258]. Knockout of HIF-1α reduces flux labeling from 
BCAAs in glioblastoma under hypoxia, and inhibition of BCAT1 inhibits glioblastoma 
cell growth under hypoxia [258]. BCAT1 expression can be used as a new diagnosis and 
treatment target for glioma. 
5.1.2 Liver cancer  
Hepatocellular carcinoma (HCC) has gradually increased in incidence in recent 
years and is the third leading cause of tumor death in the world [259]. Wang et al. 
discussed the expression of BCAT1 protein in hepatocellular carcinoma and its 
correlation with the prognosis of hepatocellular carcinoma [260]. Moreover, a later study 
found that BCAT1 was highly expressed in liver cancer [261]. They found that BCAT1 
expression in liver cancer cell lines and c -Myc expression is positively correlated, and 
knocking down c-Myc can also down-regulate the expression of BCAT1 [261]. 
Combined with in vivo experiments, after interfering with the expression of BCAT1, the 
ability of hepatocellular carcinoma cell migration and invasion also decreases. 
Conversely, loss of BCAA deamination enhances mTORC1 activity and promotes 
tumor development in the liver[262]. Another study also found that BCAT1 expression 
enhances the resistance of hepatocellular carcinoma to cisplatin drugs by inducing 
autophagy [263]. These findings suggest that BCAT1 is a potential biomarker for the 
diagnosis and treatment of hepatocellular carcinoma.  
5.1.3 Ovarian cancer  
Ovarian malignant tumors are one of the three most common malignant tumors in 
female genitals [264]. Wang et al. pointed out that the BCAT1 gene is overexpressed in 
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low-grade malignant tumors and high-grade serous epithelial ovarian tumors, and 
suggested that BCAT1 expression is closely related to BCAT1 due to significant 
hypomethylation [265]. It was found that the knocking down of BCAT1 in epithelial 
ovarian cancer cells attenuates cell proliferation, metastasis and invasion, and inhibits the 
cell cycle and inhibiting BCAT1 leads to a decrease in lipid synthesis and protein 
synthesis [265]. Further metabolomics analysis shows that more amino acids and sheath 
substances are consumed, suggesting that BCAT1 plays an important role in the 
metabolism of ovarian cancer [265]. 
5.1.4 Leukemia 
Acute myeloid leukemia (AML) is the most common adult acute leukemia, and its 
morbidity and mortality are both high. Raffel et al. find the BCAA enriched and BCAT1 
overexpressed in leukemia stem cells. BCAT1 is also necessary for α-ketoglutarate (α-
KG) homeostasis and links BCAA deamination to epigenomic regulation via α-KG 
dependent dioxygenases in AML stem cells[266]. Knockdown of BCAT1 in AML cells 
caused accumulation of α-KG, which leads to Egl-9 family hypoxia-inducible factor 1 
(EGLN1) -mediated HIF1α protein degradation. By contrast, overexpression of BCAT1 
in AML cells decreased intracellular αKG levels and caused DNA hypermethylation 
through altered ten-eleven translocation (TET)activity.  Gu et al.  show that EZH2 and 
NRASG12D mutations cooperatively induce the progression of myeloid leukemias in 
mice [267]. BCAT1 is repressed by EZH2 in normal cells and aberrantly activated in 
EZH2-deficient myeloid leukemias. BCAT1 reactivation sustains intracellular BCAA 
pools, resulting in enhanced mTOR signaling in EZH2-deficient leukemia cells, and 
inhibition of BCAT1 selectively inhibits EZH2-deficient leukemia-initiating cells [267].  
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Hattori et al. showed that BCAT1 is upregulated in chronic myeloid leukemia (CML) and 
promotes BCAA production in CML cells by aminating the branched-chain keto acids. 
The inhibition of BCAT1 induces cellular differentiation and impairs the propagation of 
blast crisis CML [244]. They also identified Musashi2 (MSI2), an RNA binding protein 
that is required for CML, as a regulator of BCAT1. These studies also suggest that 
BCAT1 has an important role in leukemia. 
5.1.5 Colorectal cancer  
Colorectal cancer is a common malignant tumor of the digestive system; the overall 
morbidity and mortality of colorectal cancer are stable. Still, its proportion of global 
malignant tumor morbidity and mortality has increased [268]. BCAT1 is significantly 
higher expressed in colorectal cancer with distant metastasis compared to colorectal 
cancer without distant metastasis, and BCAT1 expression can reliably predict whether 
colorectal cancer is distant metastasis [269]. Mitchell et al. found that when screening 
biomarkers diagnosed by colorectal cancer, BCAT1 Methylation is more common in 
colorectal tissue [270]. Other studies also pointed out that methylated BCAT1 and IKZF1 
are significantly increased in colorectal cancer, which is circulating in the blood [271, 
272]. So BCAT1 can also be used as a potential biomarker for the diagnosis of colorectal 
cancer [271, 272].  
 
5.2 CAF secreting BCKAs medicated by BCAT1 
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The mechanistic underpinnings of stromal BCKA secretion are necessary to 
elucidate its dynamics and targetable vulnerabilities. Because the synthesis of stromal 
BCKA is dependent on the transamination by BCAT1 or BCAT2.  We first check the 
PDAC cell growth in shBCAT1/2 CAFs, knockdown of BCAT1 by shRNA-BCAT1 in 
CAFs and consequent reduced BCKA secretion significantly reduced the growth rate of 
PDAC cells (Figure 5.1ab). Importantly, knockdown of BCAT2 by shRNA-BCAT2 in 
CAFs did not affect the growth rate of PDAC cells (Figure 5.1a). 
We then inhibited BCAT1 activity using Gabapentin, a BCAT1 inhibitor and 
measured BCKA secretion in CAFs[273]. Gabapentin concentration was selected after 
assessing its inhibition efficacy on BCAT1 activity (Figure 5.1c). Indeed, Gabapentin 
significantly reduced BCKA production and subsequent secretion by 40-50%, as 
observed by the extracellular BCKA concentrations using LC-MS analysis (Figure 
5.1d).To conclusively associate BCAT1 with CAF-mediated rescue of cancer cells under 
BCAA-deprived conditions, we added Gabapentin to cocultures (Figure 5.1e). Notably, 
inhibition of stromal BCAT1 abrogated the CAFs’ ability to rescue PDAC cell growth, 
whereas the addition of BCKA markedly restored the PDAC cell growth. These results 
suggest that BCKA synthesis in CAFs can be severely impacted upon loss of BCAT1 
expression or activity.   
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Figure 5.1 CAF secreting BCKAs medicated by BCAT1.  a. Effect of BCAT1 
knockdown in CAFs on the CAF-mediated rescue of cell growth rate under BCAA 
deprivation. n = 3 biologically independent samples. b. The effect of knockdown of 
BCAT1 in CAFs on CAF growth rates. n = 4 biologically independent samples.  c. BCAT 
activity is CAFs treated with Gabapentin measured by spectrophotometric assay. n = 6 
biologically independent samples.   d. BCKA secretion by CAFs treated with 10mM 
Gabapentin. n = 3 biologically independent samples.   e. Effect of 10mM Gabapentin on 
CAF-mediated rescue of MiaPaca-2 growth rate under BCAA deprived conditions. n = 6 
biologically independent samples.  
 
5.3 Inhibition of stromal BCAT1 down-regulate cancer protein synthesis and 
NADH 
 
We further investigated if Gabapentin-mediated BCAT1 inhibition in CAFs could 
influence de novo protein synthesis in PDAC cells in coculture. We found that BCAT1 
suppression in CAFs not only markedly reduced de novo protein synthesis (Figure 5.2a), 




Figure 5.2 Inhibition of stromal BCAT1 down-regulate cancer protein synthesis and 
NADH.   a. FACS analysis of GFP-labeled Mia Paca-2 cells detected with puromycin 
antibodies in the co-culture system with 10mM gabapentin. n = 6 biologically 
independent samples. b. Effect of 10mM gabapentin on the NADH/NAD+ ratio of cancer 




In recent studies, the high catabolic activity of BCAT1 was shown to promote cell 
proliferation in wild type isocitrate dehydrogenase 1 (IDH1) gliomas [243]. BCAT1 is 
also necessary for α-ketoglutarate (α-KG) homeostasis and links BCAA deamination to 
epigenetic regulation via α-KG dependent dioxygenases in acute myeloid leukemia stem 
cells [266]. Conversely, loss of BCAA deamination enhances mTORC1 activity and 
promotes tumor development in the liver [262, 274]. BCAT1 is upregulated during the 
progression of chronic myeloid leukemia and promotes BCAA production by aminating 
the BCKAs [244]. Finally, high glucose uptake suppresses BCAA deamination in 
cardiomyocytes [275].  
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In this chapter, we identified BCAT1 as the regulator of BCKA secretion in CAFs. 
We first performed the PDAC cell growth assay in shBCAT1/2 CAFs. After confirmation 
of BCAT1 in CAFs, we then used BCAT1 inhibitor, Gabapentin. Indeed, Gabapentin 
significantly reduced BCKA production. Furthermore, we also used Gabapentin to CAF 
cocultures; it showed that Gabapentin inhibits the CAFs’ ability to rescue PDAC cell 
growth. These results suggest that BCAT1 regulates BCKA synthesis in CAFs in CAFs. 
Gabapentin could inhibit de novo protein synthesis and the mitochondrial NADH/NAD+ 
ratio in PDAC cells in coculture. With the continuous development of BCAT1 related 
research, more and more are found that malignant tumors, BCAT1 is highly expressed, 
and it is suggested that it plays an important role in promoting tumor cell proliferation, 
invasion and metastasis. It may be a potential clinical aid for related tumors to diagnostic 
biomarkers or therapeutic targets. 
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Chapter 6 Internalization of The Extracellular Matrix to Supply Amino Acid 




One of the hallmarks of PDAC histology is desmoplasia, where the fibrosis 
reaction is caused by excessive fibroblasts and ECM deposition of most tumor masses 
[52, 276, 277]. ECM is made of structural protein, an adaptor protein, dense network 
structure of proteins and enzymes found in all tissues, providing biochemical and 
structural support for tissue homeostasis [278]. In PDAC, the deposition of ECM has 
increased significantly with progression. Collagen is the main structural protein in the 
ECM. Type I and IV collagens are the main structural proteins constituting PDAC ECM 
[279]. 
6.1.1 Collagen Type I (Col I) 
Col Ⅰ is a heterogeneous triplet that constitutes the extracellular matrix. The main 
component is fibrous collagen, and Col Ⅰ has a wide range of biological activities. In 
addition to regulating cell protein synthesis and secretion, it can also regulate the 
production of some proteolytic enzymes [280]. Moreover, through the induction of tumor 
cells, a variety of hydrolytic enzymes are produced. Moreover, under the regulation of 
various cytokines, it affects the growth, differentiation, migration or gene expression of 
cells through the interaction with the cells, thus in the tumor and It plays an extremely 
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important role in the process of inflammation occurrence, development and wound 
healing. 
The role of Col Ⅰ in the process of tumor evolution has been gradually understood 
and increasingly valued in recent years. It is related to a variety of tumors. Kiefer et al. 
[1] found that α2β1 and α3β1 integrins can mediate the adhesion of Col Ⅰ to cells, and 
then stimulates the proliferation and growth of cells through the transduction of signaling 
pathways [281]. Furthermore, incubating bladder cancer cells on Col Ⅰ coating, the 
expression of genes related to metabolism, transcription and translation has been 
changed, which has increased the proliferation of cells and contributed to the bone 
metastasis of bladder cancer [282]. In normal tissues, Col Ⅰ is mainly produced by 
fibroblasts in the interstitium. The content of Col Ⅰ in the main depends on two aspects: 
one is the synthesis and deposition of collagen, and the other is the role of collagen 
dissolution factors. The two together determine the content of Col Ⅰ in tumor tissues. In 
tumor tissues, tumor cells and fibroblasts are involved in the process of Col Ⅰ synthesis 
and deposition, and there is an interaction between the two. Dahlman et al. found that 
tumor cells can stimulate the transcription of Col Ⅰ mRNA of fibroblasts through direct 
interactions between cancer cells and fibroblasts or stimulation of cytokines such as 
PDGF and TGFGβ [283]. Sengupta et al. found that when the methylation level of α2(Ⅰ) 
transcription initiation site increased, the steady-state level of Col Ⅰ mRNA decreased, 
and the production of collagen decreased [284]. This shows that the collagen synthesis 
process is extremely complicated. It is regulated by various factors and needs further 
discussion. 
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Similarly, the dissolution factor of Col Ⅰ is a factor that cannot be ignored and is 
closely related to tumor invasion and metastasis. In tumor tissues, the dissolution of Col Ⅰ 
is mainly related to hydrolytic enzymes that are mainly related to MMP1, MT-MMP1, 
and other enzymes [285]. Although tumor cells can secrete these enzymes to degrade Col 
Ⅰ, Col Ⅰ has a certain regulatory effect on the production of these enzymes. Studies have 
found that Col Ⅰ can regulate the production and secretion of MMP-2 and can also 
regulate the secretion ability of fibroblast MMP-2 and cathepsin B precursors [286]. 
Therefore, Col Ⅰ can reduce the barrier effect on tumor invasion through the action of 
lytic factors, and can also induce tumor cells to produce multiple hydrolases. 
The abnormal expression of Col Ⅰ is related to the occurrence and evolution of 
multiple types of tumors. The degradation and synthesis of Col Ⅰ in tumor tissue is a 
dynamic process, and the enhancement of collagen synthesis and deposition may be 
involved in preventing the growth of tumors. In contrast, the dissolution of collagen may 
cause tumor invasion and expansion. At the same time, in highly malignant tumors, the 
abnormality of collagen may promote the evolution of the tumor. It can be seen that the 
role of Col Ⅰ in the process of malignant transformation of cancer cells cannot be ignored. 
6.1.2 Collagen Type IV (Col IV) 
Col Ⅳ is the main component of the dense layer of the basement membrane and 
also belongs to the fibrous collagen. The basement membrane has a three-dimensional 
network structure, which is maintained by covalent bonds and is connected with other 
components, such as laminin, fibronectin, etc. [287]. The extracellular matrix structure 
constitutes the cell's microenvironment. Current research has found that Col Ⅳ can 
provide sites for cell adhesion. These sites are specifically recognized by receptors on the 
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cell surface and participate in the regulation of cell function. Therefore, they are involved 
in tumors and inflammation. The development process also has important significance. 
During the invasion and metastasis of many tumors, the expression of Col Ⅳ is generally 
reduced or absent. Col Ⅳ expression was negatively correlated with cervical lymph node 
metastasis in larynx cancer [288]. Erkan et al. found that as the degree of tumor invasion 
increased, the rate of expression loss of Col Ⅳ is also gradually worsened, and is closely 
related to the lymph node metastasis of the tumor [289]. Ozer et al. reported that the 
expression of Col Ⅳ and laminin in urinary tract tumors is closely related to the survival 
time of patients [290]. In recent years, studies have also found that Col Ⅳ expression is 
related to tumor differentiation, invasion and metastatic ability. At the same time, it has a 
certain value for judging tumor invasion, metastasis and prognosis. 
6.2 Uptake of collagen under BCAA deprivation 
 
Activated CAFs in PDAC is known to secrete a vast array of ECM proteins, such 
as collagen, enzymes, and glycoproteins [291-293]. Therefore, we surmised that under 
the nutrient-scarce conditions of the pancreatic TME, the ECM proteins in the milieu 
could be a source of amino acids for CAFs. However, there continues to be sparse data 
regarding the role, if any, of ECM protein uptake by stromal fibroblasts in cancer. To 
illustrate that CAFs utilize ECM proteins, which in turn influence CAF-mediated rescue 
of PDAC cells under BCAA deprivation conditions, we added collagen I or collagen IV 
to coculture. As seen in Figure 6.1a, both collagen I and IV enhanced PDAC cell growth 
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rate in coculture under BCAA-deprivation but did not affect monoculture. Further, 
Gabapentin attenuated ECM protein-mediated rescue of cancer cell growth by CAFs.  
To characterize internalization, confirm uptake and cleavage of ECM proteins by 
CAFs, we used fluorogenic DQ collagen (self-quenched collagen that emits fluorescence 
upon degradation). We found that collagen uptake in CAFs under BCAA-deprivation 
increased significantly compared to the BCAA-replete condition, and this increase was 
pronounced in the presence of TGF-β (Figure 6.1b). To further substantiate this, we 
studied the uptake of collagen by both PDAC cells and CAFs and found significantly 
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higher collagen uptake in CAFs (Figure 6.1c) compared to PDAC cells. 
 
Figure 6.1 Uptake of collagen under BCAA deprivation.  a. Relative proliferation 
rates of Mia Paca-2 cells co-cultured with CAFs and Collagen or 10mM Gabapentin 
under BCAA deprivation. n = 6 biologically independent samples. b. Uptake of DQ-
Collagen by CAFs assessed using confocal imaging after 24 h. Experiments were 
repeated independently three times with similar results. c. Uptake of DQ-Collagen by 
PDAC cell lines and CAFs measured using confocal imaging after 24 h. Experiments 
were repeated independently three times with similar results.  
6.3 Collagen uptake regulated by uPARP in CAFs 
 
Since fibroblasts internalize ECM proteins through (uPARAP/Endo 180, which is 
encoded by the MRC2 gene), we measured the expression of uPARAP/Endo180 in 
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PDAC and CAFs. In concurrence with our previous results, uPARAP/Endo180 
expression is much higher in CAFs compared to cancer cells (Figure 6.2ab). Moreover, 
inhibiting the expression of uPARP in CAFs significantly impacted the uptake of 
collagen (Figure 6.2c). These results cumulatively indicate that ECM internalization is 
indeed high in CAFs, and undetectable in PDAC cells. These ECM internalization results 
were confirmed by measuring intracellular BCAA levels and 13C enrichment in CAFs 
cultured with 13C-BCAAs for 12 hours before deprivation (Figure 6.3a). Notably, 
intracellular BCAA levels increased gradually over 6, 12, 24, and 48 hours post-
deprivation (Figure 6.3b). Whereas, 13C enrichment of BCAAs gradually decreased in the 
same timeframe (Figure 6.3b), indicating the introduction of unlabeled BCAAs in 
BCAA-deprived CAFs from ECM proteins. 
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Figure 6.2 Collagen uptake regulated by uPARP in CAFs. a. Flow cytometry assay 
indicated the expression of MRC2 in PDAC cell lines. Experiments were repeated 
independently three times with similar results. b. Flow cytometry assay indicated the 
expression of MRC2 in CAFs. Experiments were repeated independently three times with 
similar results.   c. Uptake of DQ-Collagen by CAFs transfected with siControl or 
siuPARP measured using confocal imaging after 24 h. Experiments were repeated 





Figure 6.3 Intracellular BCAA levels in CAFs under BCAA deprivation.  a. CAFs 
are cultured with labeled with 13C-BCAAs for 12 hours before inducing BCAA 
deprivation. Spent media and cells are collected after 6, 12, 24 and 48 hours under 
deprivation. Media samples are analyzed for secreted BCKAs using LC-QTOF, and 
intracellular samples are analyzed for BCAAs using GC-MS.   b. Intracellular BCAA 
levels were measured after 6, 12, 24 and 48 hours under BCAA deprivation. Mole 
percent enrichment of intracellular BCAAs was measured after 6, 12, 24, and 48 hours 
under BCAA deprivation. n = 3 biologically independent samples.   
6.4 CAFs utilize collagen through the proteasome 
 
To understand the underlying mechanism behind the degradation of ECM proteins 
in CAFs, we hypothesized that proteasomal proteolysis plays a major role in the 
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degradation of these internalized ECM proteins under nutrient-deprived conditions. 
Consistent with this notion, both BCAA-deprivation and TGF-β increased the 
chymotrypsin-like proteasome activity in CAFs, but not trypsin-like and caspase-like 
protease activities (Figure 6.4a). To further investigate the role of the proteasome in 
collagen degradation, cells were incubated with FITC-collagen I for 48h and then stained 
with an antibody for the proteasome α and β subunits (Figure 6.4b). It was evident that 
collagen is localized with proteasomes in the CAFs, thereby suggesting that proteasomes 
indeed degrade ECM proteins. We further tested our hypothesis by measuring BCKA 
secretion from CAFs and PDAC cell growth rates in coculture under BCAA-deprived 
conditions. We found that Delanzomib, the chymotrypsin-like proteasome activity 
inhibitor, attenuated ECM protein-mediated rescue of cancer cell growth by CAFs 
(Figure 6.4c). These results confirm that collagen is indeed degraded by proteasomal 
proteolytic activity in CAFs. Further, MG-132, a potent proteasomal inhibitor, also 
suppressed the rescue of cancer cell growth by CAFs (Figure 6.4d). To further expand 
our findings, we measured CAF-secreted BCKAs in the presence of Delanzomib and 




Figure 6.4 CAFs utilize collagen through the proteasome.  a. Proteasome activity in 
CAFs treated with TGF-beta and under BCAA deprivation. n = 6 biologically 
independent samples.  b. Colocalization of collagen and proteasome analyzed by 
immunofluorescence against proteasome 20s and FITC-collagen. Experiments were 
repeated independently three times with similar results.  c. Relative proliferation rates of 
Mia Paca-2 pancreatic cancer cells cocultured with CAFs in combination with Collagen 
or Delanzomib under BCAA deprivation. n = 6 biologically independent samples. d. 
Relative growth rates of Mia Paca-2 and Panc-1 cells cocultured with CAFs treated with 
MG-132 under BCAA deprivation conditions. n = 8 biologically independent samples.  e. 




6.5 CAF derived ECM labeling and tracing 
 
To establish whether internalized ECM proteins are a carbon source for CAF-
secreted BCKAs, we cultured CAFs on decellularized 13C-BCAA-labeled ECM proteins 
(Figure 6.5a). Decellularized 13C-BCAA-labeled ECM was obtained by culturing CAFs 
with 13C-labeled leucine, isoleucine, and valine for eight days so that CAFs could 
incorporate labeled BCAAs into ECM protein. To confirm the ECM structure, we used 
scanning electron microscopy to observe the matrix and found that the CAF-derived 3-D 
matrix is free of cellular debris and remained attached to the culture surface (Figure 
6.5b). Secreted ECM proteins were acid hydrolyzed, and their constituent BCAAs were 
found to be enriched by 40-50% 13C-labeled BCAAs (Figure 6.5c-e). We then cultured 
CAFs with 13C-BCAA labeled ECM under BCAA-deprived conditions and analyzed the 
spent media obtained after 48 hours of culture. BCKAs secreted by the CAFs were 
analyzed using LC-MS and found to be enriched with 13C derived from the proteolyzed 
ECM (Figure 6.5f). This indicated that when CAFs were cultured with this labeled ECM, 
they internalized and proteolyzed it to maintain intracellular BCAA pools and produce 
and secrete BCKAs. Collectively, these results provide evidence that the ECM in the 






Figure 6.5 CAF derived ECM labeling and tracing.  a. Schematic of the protocol used 
to synthesize ECM labeled with 13C-BCAAs and secretion of 13C-BCKAs after 
culturing BCAA-deprived CAFs in ECM labeled with 13C-BCAAs.  b. Scanning 
electron microscopy image of CAF-derived 3-D matrices. Experiments were repeated 
independently two times with similar results.  c. Fractional enrichment of BCAAs after 
acid hydrolysis of decellularized ECM proteins produced by CAFs cultured with 13C-
BCAAs. n = 3 biologically independent samples. d. Mass isotopomer distribution of 
BCAAs after acid hydrolysis of decellularized ECM proteins produced by CAFs cultured 
with 13C-BCAAs. n = 3 biologically independent samples.  e. Fractional enrichment of 
amino acids after acid hydrolysis of decellularized ECM proteins produced by CAFs 
cultured with 13C-BCAAs. n = 3 biologically independent samples. f. Fractional 
enrichment of BCKAs secreted by CAFs at the end of 48h of being cultured under BCAA 







In this chapter, we characterized the BCAA source for CAFs under BCAA 
deprivation. CAFs have been shown to secrete a vast array of ECM proteins, such as 
collagen, enzymes, and glycoproteins [277]. Therefore, we surmised that under the 
nutrient-scarce conditions of the pancreatic TME, the ECM proteins in the milieu could 
be a source of amino acids for CAFs. To illustrate that CAFs utilize ECM proteins, which 
in turn influence CAF-mediated rescue of PDAC cells under BCAA deprivation 
conditions, we showed collagen I or collagen IV could further support PDAC cells in 
cocultures. To characterize internalization, confirm uptake and cleavage of ECM proteins 
by CAFs using DQ collagen. We showed that collagen uptake in CAFs under BCAA-
deprivation increased significantly compared to the BCAA-replete condition or in the 
presence of TGF-β.  
It is well-established that stromal cells, including fibroblasts, internalize ECM 
proteins through (uPARAP/Endo 180, which is encoded by the MRC2 gene) [294, 295], 
and the expression of uPARAP/Endo180 is maximal in fibroblasts. We first showed that 
uPARAP/Endo180 expression is much higher in CAFs compared to cancer cells. 
Furthermore, inhibition of uPARP in CAFs significantly reduced the uptake of collagen. 
We also tested the proteasomal proteolysis role in the degradation of these internalized 
ECM proteins under nutrient-deprived conditions. WE also proved that proteasomes 
indeed degrade ECM proteins since the collagen is co-localized with proteasomes in the 
CAFs. We found that proteasome inhibitor Delanzomib reduced ECM protein-mediated 
rescue of cancer cell growth by CAFs.  To establish whether internalized ECM proteins 
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are a carbon source for CAF-secreted BCKAs, we cultured CAFs on decellularized 13C-
BCAA-labeled ECM proteins. BCKAs secreted by the CAFs were found to be enriched 
with 13C derived from the proteolyzed ECM. This indicated that when CAFs were 
cultured with this labeled ECM, they internalized and proteolyzed it to maintain 
intracellular BCAA pools and produce and secrete BCKAs. Collectively, we showed that 
the ECM in the pancreatic milieu could serve as a storage pool of BCAAs for the CAFs 
under nutrient-stressed conditions, and proteasome can also be a potential target in PDAC 
tumors.
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Transforming growth factor β (TGF-β) is a newly discovered group of TGF-β 
superfamily that can regulate cell growth and differentiation. In recent years, it has been 
found that TGF-β has important adjustment effects on cell growth, differentiation and 
immune function, such as inhibiting the growth of epithelial cells and endothelial cells, 
suppressing the differentiation of lymphocytes and suppressing the proliferation of 
immune cells. These biological functions have an inhibitory effect on the occurrence and 
development of tumor cells. However, studies have shown that TGF-β1 can promote the 
infiltration and migration of tumor cells when regulating the immune system of cells and 
the microenvironment of tumors [296, 297].  
7.1.1 Molecular biological feature of TGF-β  
The TGF-β superfamily consists of more than 40 proteins, including TGF-β, 
activin (A, AB, B, C, E), inhibin (A, B), bone morphogenetic proteins (BMPs) and 
growth and differentiation factors (GDFs). The human TGF-β cDNA sequence shows 
that the monomeric TGF-β is a polypeptide containing 112 amino acid residues, and the 
gene is located in the chromosome 19q13, human TGF-β has three subtypes of TGF-β1, 
TGF-β2, and TGF-β3. There are also two subtypes of TGF-β4 and TGF-β5 in birds and 
amphibians. The role of TGF-β1 is multi-directional, and almost all types of tissues in the 
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human body can synthesize and secrete. It plays an important role in regulating the 
growth of cells, the formation of the extracellular matrix, immune regulation, 
neovascularization, cell death and tumor development [298]. 
TGF-β1 needs to be activated with its receptor before it can exert its biological 
effects. Common receptors are TβRI (53 kDa), TβRIII (75 kDa) and TβRIII (280 kDa). 
TβR TβRII and I belong to transmembrane proteins, and they also have serine protein 
kinase activity in cells. TβRII is first activated by binding to a ligand, and then recruited 
and combined with TβRI. They jointly determine the identification characteristics of 
TGF-β. Activated TβRII can make the sequence of TβRII amino acid fragments 
phosphorylated by TTSGSGSG, which further activates the receptor's serine protein 
kinase activity, which triggers a cascade of cell signal transduction reactions. TβRI can 
promote the phosphorylation of Smad2 and Smad3 proteins and connect with the 
“pocket” structure of the SMD4 protein Mh2 region to form R-Smad-SMAD4 oligomers 
into the nucleus and further regulate target gene transcription [299]. The Smads protein is 
the central nucleus of the TGF-β1 signal that enters the nucleus from the cytoplasm. The 
Smad pathway is the classic pathway for the transduction of TGF-β signals. Besides, the 
activity of TGF-β signal transduction is also regulated by the negative feedback loop of I-
Smads (suppressive Smads: Smad6, Smad7) [300]. Moreover, TGF-β can also conduct 
signal transduction through non-classical SMAD-independent pathways. So far, SMAD-
independent pathways mainly include RhoA-Rock1, RAS, ShcA, ERK1/2, and p38 
MAPK pathways [301]. 
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7.1.2 The role of TGF-β1 in the development of tumors 
Under physiological conditions, TGF-β1 can effectively inhibit the growth of 
many types of cells, including tumor cells. The mechanism by which TGF-β1 suppresses 
normal cell growth is to regulate the genes so that the cell proliferation period is at rest. 
In the early stage of the tumor, it inhibits the proliferation of cancer cells by resisting 
mitosis. TGF-β1 controls cell proliferation mainly by blocking cell cycle progression and 
inducing or activating cyclin-dependent kinase (CDK) inhibitors such as p27Kip1 [302]. 
However, when the tumor develops to an uncontrollable stage, TGF-β1 loses this 
inhibitory effect on most tumor cells. At this time, the tumor cells began to secrete TGF-
β1. TGF-β1 can promote vascularization by up-regulating the expression of microRNA, 
increasing the ability of cancer cells to bind to adherent molecules of cells, thereby 
enhancing the invasion of cancer cells and promoting the growth of micro-circulation and 
metastasis of tumors [303]. At this time, TGF-β1 can induce normal cell death around the 
cancer cells, thereby eliminating their inhibitory effect on tumor growth. 
In the later stage of the tumor, TGF-β1 becomes a tumor-promoting factor, which 
plays an important role in the transition of the tumor. In PDAC, TGF-β1 can convert 
human acinar cells to duct-like cells in a SMAD-dependent pathway [304]. Furthermore, 
TGF-β1 regulates miR-100 and miR-125b through SMAD2/3 to promote PDAC 
progression [305]. 
7.1.3 TGF-β1 and EMT 
EMT is the transformation of epithelial cells into cells with an interstitial 
phenotype. The biological process is not only a basic process of body development but 
also a feature of tumor occurrence. Through EMT, epithelial cells have lost cell polarity, 
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epithelial phenotypes, such as connection to the basement membrane. At the same time, 
they have obtained higher migration and invasion, resistance to decay, and the ability to 
decompose the extracellular matrix [98]. TGF-β1 is an important regulatory factor in the 
process of EMT. Extracorporeal studies have shown that TGF-β recognition is the main 
inducer of EMT. The regulators of EMT can be adjusted through the Smad pathways, 
mainly including Snail, Slug, Twist, Cripto-1, FoxC2 and Six1 [306]. Activating the 
Smd2/3 in the epithelial cells can induce the expression of the nuclear HMGA2, and it 
can stimulate Snail1, Snail2, Slug, Twist by transcription [307]. TGF-β1-mediated 
formation of the Snail Smad3/4 complex can inhibit the expression of E-cadherin in 
epithelial cells, and E-cadherin will be lost during the EMT process and in the post-tumor 
period [308]. TGF-β1 inhibitors are being used reversal epithelial-mesenchymal 
transition as metastasis inhibitors in clinical trials [309].  
7.2 PDAC cell condition media activate BCAT1 
 
To unravel the mechanism underlying the regulation of BCAT1 expression in 
CAFs, we postulated that cancer cells reprogram fibroblasts to upregulate their BCAT1 
expression to meet the cancer cells’ demand for BCKAs under BCAA deprivation. It is 
well-established that resident quiescent fibroblasts and bone marrow-derived 
mesenchymal stem cells (MSCs) serve as precursors of activated CAFs, and factors 
secreted by cancer cells modulate this transformation [310]. We first transformed NOFs 
and MSCs into CAFs by culturing them in PDAC cell-conditioned medium (CM) for four 
weeks and measured the expression of genes involved in BCAA metabolism. This 
revealed that the basal expression of BCAT1 in NOFs and primary MSCs is low, 
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however, increased activation of NOFs and primary MSCs using cancer cell CM 
progressively increased BCAT1 expression and expression of activated CAF markers α-
smooth muscle actin, (αSMA), podoplanin (PDPN), and fibroblast specific protein 
(FSP1) (Figure 7.1). Consistent with previous results, there was no change in BCAT2 
gene expression in MSCs and NOFs cultured in PDAC cell CM (Figure 7.2). These 
results were further corroborated when CAFs were exposed to PDAC CM for three 
weeks, and similar upregulation of BCAT1 was found with no significant changes in 
BCAT2, BCKDHA, and BCKDHB (Figure 7.3). Next, we asked if these activated NOFs 
could acquire PDAC-supporting characteristics of CAFs. Notably, we found that, like 
CAFs, activated NOFs completely rescue PDAC cell growth under BCAA-deprivation 
conditions (Figure 7.4).  
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Figure 7.1 Panc-1 CM activates BCAT1 in NOFs. a. Effect of pancreatic cancer cell-
conditioned media (CM) on BCAT1 expression in NOFs over four weeks. n = 8 
biologically independent samples.  b.  BCAT2 expression in NOFs treated with 
pancreatic cancer cell-conditioned media (CM). n = 8 biologically independent samples.   
c.  α-smooth muscle actin, (α-SMA) expression in NOFs cultured with pancreatic cancer 
cell-CM over four weeks. n = 8 biologically independent samples.  d.  fibroblast specific 
protein (FSP1) expression in NOFs cultured with pancreatic cancer cell-CM over four 
weeks. n = 8 biologically independent samples.  e.  podoplanin (PDPN) expression in 
NOFs cultured with pancreatic cancer cell-CM over four weeks. n = 8 biologically 




Figure 7.2 Panc-1 CM activate BCAT1 in MSCs. a. Effect of pancreatic cancer cell 
CM on BCAT1 expression in primary MSCs over four weeks. n = 6 biologically 
independent samples.   b. Effect of pancreatic cancer cell CM on BCAT2expression in 
primary MSCs over four weeks. n = 6 biologically independent samples.    c. Effect of 
pancreatic cancer cell CM on αSMA expression in primary MSCs over four weeks. n = 6 
biologically independent samples.   d. Effect of pancreatic cancer cell CM on FSP-1 
expression in primary MSCs over four weeks. n = 6 biologically independent samples.   e. 
Effect of pancreatic cancer cell CM on PDPN expression in primary MSCs over four 




Figure 7.3 Panc-1 CM activates BCAT1 in CAFs. a. Effect of pancreatic cancer cell 
CM on BCAT1 expression in various CAFs. n = 6 biologically independent samples.  b. 
Effect of pancreatic cancer cell CM on BCAT2 expression in various CAFs. n = 6 
biologically independent samples. c. Effect of pancreatic cancer cell CM on BCKDHA 
expression in various CAFs. n = 6 biologically independent samples. d. Effect of 
pancreatic cancer cell CM on BCKDHB expression in various CAFs. n = 6 biologically 
independent samples.    
 
 
Figure 7.4 Activated CAF rescue cancer cell growth under BCAA deprivation. The 
growth rate of pancreatic cancer cells cultured with activated NOFs under BCAA 
deprivation. n = 6 biologically independent samples. 
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7.3 TGF-β regulated stromal BCAT1 
 
Having established that fibroblast activation specifically upregulates BCAT1 
expression in CAFs, we sought to elucidate the congruence between NOF activation 
pathways and BCAT1 expression. Although the signaling pathways that activate 
fibroblasts are still being studied, many pathways converge towards TGF-β-based 
activation [311]. We assessed if TGF-β could regulate BCAT1 expression in CAFs and 
surprisingly found that induction of BCAT1 expression by TGF-β is pronounced in CAFs 
(Figure 7.5a). By contrast, TGF-β could neither influence BCAT2 expression in CAFs 
nor induce changes in BCAT1 expression in PDAC cells (Figure 7.5ab). Importantly, 
depletion of TGF-β with a neutralizing antibody abrogated upregulation of stromal 
BCAT1 and αSMA expression mediated by cancer cell-secreted TGF-β. In contrast, there 
was no change in BCAT2 gene expression (Figure 7.5c-e). These results were further 
confirmed using immunofluorescence (Figure 7.6a). We also employed a genetic 
approach using αvβ5-integrin KO CAFs, which becomes activated upon pre-activated (as 
opposed to immature/latent) TGF-β in a non-cell-autonomous way. The BCAT1 
expression of αvβ5-integrin KO CAFs failed to be activated by conditioned media 
obtained from cancer cells (Figure 7.6b). Additionally, we measured the secretion rate of 
TGF-β by cancer cells and CAFs (Figure 7.6c). We found that cancer cells secreted TGF-
β at several folds higher concentrations compared to CAFs, thereby corroborating our 
claim that cancer-cell secreted TGF-β regulates BCAT1 expression. 
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Figure 7.5 TGF-β regulated stromal BCAT1. a. BCAT1 and BCAT2 mRNA 
expression measured in CAFs after two days of treatment with TGF-β. n = 6 biologically 
independent samples. b. BCAT1 expression in cancer cells treated with TGF-β. n = 8 
biologically independent samples. c. BCAT1 expression in NOFs cultured with 
pancreatic cancer cell-CM in the presence of Anti-TGFB1 antibodies or isotype 
antibodies for three weeks. n = 8 biologically independent samples.  d. BCAT2 
expression in NOFs cultured with pancreatic cancer cell-CM in the presence of Anti-
TGFB1 antibodies or isotype antibodies for three weeks. n = 8 biologically independent 
samples.  e. αSMA expression in NOFs cultured with pancreatic cancer cell-CM in the 
presence of Anti-TGFB1 antibodies or isotype antibodies for three weeks. n = 8 




Figure 7.6 Cancer cell-derived TGF-β regulated stromal BCAT1.  a. Representative 
images from IF analysis of BCAT1 and αSMA expression in NOFs cultured with 
pancreatic cancer cell-CM in the presence of Anti-TGFB1 antibodies or isotype 
antibodies for three weeks. Experiments were repeated independently twice with similar 
results. b. BCAT1 and BCAT2 expression in control and Integrin αvβ5 KO CAFs 
cultured with pancreatic cancer cell-CM for three weeks. n = 4 biologically independent 
samples.  c. ELISA shows TGF-β secretion levels from CAFs and PDAC cell lines. n = 8 
biologically independent samples.  
 
7.4 TGF-β regulated stromal BCAT1 through SMAD5 
 
Previous studies have provided evidence that SMAD proteins are the effectors of 
TGF-β activation, and once activated, they regulate gene expression by translocating to 




Figure 7.7 Panc-1 CM regulates SMADs in NOFs.  a. Effect of pancreatic cancer cell 
CM on SMAD5 expression in NOFs over four weeks. n = 6 biologically independent 
samples. d. SMAD2 expression in NOFs treated with pancreatic cancer cell-CM. n = 8 
biologically independent samples.  e. SMAD3 expression in NOFs treated with 
pancreatic cancer cell-CM. n = 8 biologically independent samples.    f. SMAD4 
expression in NOFs treated with pancreatic cancer cell-CM. n = 8 biologically 
independent samples.      
To establish which SMAD directly regulated BCAT1 expression, we performed 
quantitative ChIP-PCR to elucidate the targets for the BCAT1 binding regions. Our 
analysis revealed the enrichment of SMAD5 for BCAT1 promoter binding regions 
compared to the control regions (Figure 7.8a). Furthermore, only SMAD5 binding to the 
BCAT1 promoter regions is increased upon TGF-β activation, while SMAD4 binding 
was not affected. To further decipher if TGF-β and SMAD5 activation increased the 
BCAT1 promoter activity, we performed a dual-luciferase reporter assay. We found that 
incubation with TGF-β strongly increased BCAT1 promoter activity in CAFs (Figure 
7.8b). Expectedly, the increase of TGF-β-mediated BCAT1 promoter activity is 
suppressed on treatments with either TGF-β pathway inhibitor, RepSox or via silencing 
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of SMAD5 expression (Figure 7.8b). Further, IHC staining confirmed that the stromal 
component had increased expression of SMAD5 compared to the epithelial compartment 
(Figure 7.8c). To conclusively elucidate the transcriptional regulation of BCAT1 by 
SMAD5, we measured mRNA levels of BCAT1 in CAFs when transfected with siRNAs 
targeting SMAD4 or SMAD5 (Figure 7.8d). SMAD5 inhibition significantly impacted 
the BCAT1 expression at mRNA and protein levels (Figure 7.8e). In contrast, SMAD4 
silencing did not induce any changes in BCAT1 expression.  These results provide strong 
evidence that cancer cell-secreted TGF-β upregulates stromal BCAT1 activity through 







Figure 7.8 TGF-β regulated stromal BCAT1 through SMAD5.  a. ChIP assays 
performed with control IgG and anti-SMAD5 or anti-SMAD4 antibodies in CAFs treated 
with PBS control or TGF-β. n = 4 biologically independent samples. b. Transient 
transfection assays in CAFs with the reporter plasmid containing BCAT1 promoter. n = 8 
biologically independent samples. c. Representative IHC staining image comparing 
SMAD5 expression between stromal and tumor compartments. Experiments were 
repeated independently three times with similar results. d. mRNA expression of BCAT1 
in CAFs treated with siRNAs targeting SMAD4 or SMAD5. n = 6 biologically 
independent samples.     e. Immunoblots showing BCAT1 protein expression in CAFs 
treated with control siRNA and SMAD5 siRNA. Experiments were repeated 
independently three times with similar results. f. TGF-β secreted by cancer cells regulates 






TGF-β1 in the tumor microenvironment has a significant effect on the antitumor 
activity of T cells. In the presence of exogenous IL-2 and IL-4, TGF-β1 can regulate the 
growth of T cells and usually promotes proliferation [312]. TGF-β1 can cause the 
resident macrophage to become an inhibitor of CD4+ T cell proliferation [313]. TGF-β1 
can inhibit the differentiation of cytotoxic T cells and the lysis of cancer cells mediated 
by cytotoxic T cells. Also, TGF-β1 can block the expression of granzyme A, granzyme B 
and perforin, while the expression of granzyme B is directly linked to the Smad 
transcription factor [314]. TGF-β1 also has the function of suppressing the effect of NK 
cells and neutrophils, which leads to the deterioration of tumors [315]. The enhancement 
of TGF-β1 and IL-6 levels has the effect of promoting the progress of inflammation and 
gastric cancer. TGF-β1 also showed suppression of the expression of the cell populations 
MHC I and MHC II. The decrease of tumor cell MHC I expression will reduce the 
dissolution effect of tumor cells of NK cells, thereby accelerating the growth and 
migration of tumors. 
In this chapter, we showed that TGF-β could regulate BCAT1 expression in CAFs 
and induction of BCAT1 expression by TGF-β is pronounced in CAFs. Furthermore, 
depletion of TGF-β with a neutralizing antibody abrogated upregulation of stromal 
BCAT1 and αSMA expression mediated by cancer cell-secreted TGF-β.  Moreover, we 
identified SMAD5 as the regulator of BCAT1 through quantitative ChIP-PCR and dual-
luciferase reporter assay. In summary, we showed that cancer cell-secreted TGF-β 
upregulates stromal BCAT1 activity through SMAD5 activation in stromal cells. 
 128 
Chapter 8 Patient-derived Circulating Tumor Cells Have Upregulated BCKDH 




The number of CTCs that can be collected in clinical blood samples is very limited, 
except for cell counting and gene sequencing, it is usually not sufficient for routine drug 
sensitivity testing or cell phenotype analysis. Therefore, stable culture expansion of CTCs 
is a downstream function of CTCs. At the same time, in the case of a small number of 
cells, the lack of paracrine signals between cells will increase the difficulty of cell culture 
expansion. Yu et al. collected CTCs from estrogen receptor-positive breast cancer 
patients using CTC-ichip, and cultured in RPMI-1640 medium with epidermal growth 
factor (EGF), basic fibroblast growth factor (bFGF), B27 Supplement, with ultra-low 
attachment plates and hypoxia (4% O2) conditions [316]. Then 17.14% (6/35) sample 
CTCs proliferated successfully with doubling times of 3 days to 3 weeks. At the same 
time, it was also reported that adhesion would induce CTCs to age. Cayrefourcq et al.  
used the CELLSEARCH system to collect the CTCs suspension culture of patients with 
metastatic colorectal malignant adenocarcinoma, and the culture was first placed in 
DMEM/F12 medium with FBS,  insulin, L-glutamine, EGF, FGF-2, N2 Supplement, and 
cultured under hypoxic (2% O2) condition [317]. After a few weeks, the cultures then 
transferred to RPMI-1640 medium with EGF, FGF-2, Insulin-Transferrin-Selenium (ITS) 
under normal oxygen conditions to obtain a cell line capable of long-term survival [317]. 
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Gao et al. centrifuged the CTCs from patients with metastatic prostate cancer using the 
Ficoll Paque system, dispersed in Matrigel as organoids, and soaked in DMEM/F12 
medium with A83-01, B27 Supplement, Dihydrotestosterone (DHT), EGF, FGF2, 
FGF10, Glutamax Supplement, HEPES, N-Acetyl-L-cysteine (NAC), Nicotinamide, 
Noggin, R-spondin 1, SB202190 and Y-27632. Then, 5.88% (1/17) of the samples were 
successfully amplified with a doubling time of 1 week [318]. The mutation and pathology 
were similar to those of tumor cells and tissues in situ. Zhang et al. used CTC-chip to 
collect CTCs in the peripheral blood from patients with early-stage lung cancer [319]. 
First, fibroblasts, collagen and Matrigel were added to the chip, soaked in RPMI-1640 
medium supplemented with FBS. After 3D co-culture for one week, the number of tumor 
cells increased to an average of 8 times; after the cells were released from the chip and 
transferred to a multi-well plate for one week, the number of tumor cells increased to an 
average of 54 times, with a total culture success rate of 73.68% (14/19) [319]. In a recent 
study, Rivera-Báez et al. used high-throughput, label-free Labyrinth isolated CTCs based 
on cell sizes, CTCs were isolated from 10 locally advanced, then cultured in a simple, 2D 
monoculture approach with RPMI1640, CTCs from 3 individual patients successfully 
grew into cell lines [320]. The generally low success rate of CTCs cultivation is the 
academic problem facing us. At present, there is no "gold standard" applicable to the 
cultivation of tumor cells from all different sources, but the successful cultivation of 





8.2 BCAA related enzymes expression in CTCs 
 
To replicate tumor-stroma interactions in humans in the context of PDAC cell 
BCAA metabolism, and overcome inconsistencies observed in animal models, we have 
relied on human CTCs derived models. CTCs shed by the primary tumor are the seeds of 
metastasis[321] and established as a potential biomarker of disease progression[322]. 
CTCs mediate metastasis of many solid tumors, including PDACs, even after the 
resection of the primary tumor[323]. These cells can extravasate from the primary tumor 
site into the bloodstream and invade distant sites, resulting in the formation of metastases. 
CTCs freshly obtained from PDAC patient blood using the Labyrinth, a label-free size 
based inertial microfluidic CTC isolation device [324], allowed us to compare their 
transcriptional profile with the cells obtained from a healthy subject and CAF cell lines 
(Figure 8.1ab).  Healthy control samples are the PBMCs that were not depleted during 
our Labyrinth processing. Therefore, the data represents the background signal for gene 
expression in PBMCs and deviations from that are due to the presence of the CTCs in the 
patient samples. It showed that the gene expression of BCKDHA and DBT are higher in 
Day 0 CTCs compared to healthy controls and CAFs (Figure 8.1c).  In contrast, BCAT1 
expression is much higher in CAFs compared to CTCs (Figure 8.1c).  These data indicate 
the clinical relevance and corroborative evidence of our observations in the in vitro 
model. We then used patient-derived expanded CTC lines for downstream experiments 
[320]. Similar to PDAC cell lines, CTC lines showed lower expression of BCAT1 
compared to CAFs, and higher expression of DBT compared to CAFs at the mRNA level 
(Figure 8.1d).  Consistent with our findings in PDAC cell lines, CTC lines also had 
higher expression of BCAT2 and lowered BCAT1 at the protein level (Figure 8.1e).  
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Further, BCKAs could rescue the impeded proliferation of CTC lines under BCAA 
deprivation, thereby demonstrating that similar to their cancer cell line counterparts, CTC 
lines are also BCKA-dependent in stromal rich conditions (Figure 8.1f).  
 
Figure 8.1 BCAA related enzyme expression in CTCs.  a. CTCs are isolated from the 
blood of PDAC patients using the microfluidics-based LabyrinthTM Chip. Isolated CTCs 
are purified to generate CTC cell-lines used for downstream analyses. b. Representative 
images of CTCs separated by Labyrinth. Cells are stained with DAPI (blue), cytokeratin 
(red), CD45 (green) and Vimentin (pink). Experiments were repeated independently three 
times with similar results. c. Heatmap of gene expression of BCAT1, BCAT2, BCKDHA 
and DBT measured by qRT-PCR from Day 0 CTCs isolated from PDAC patients, CAF1 
cells, and cells isolated from a healthy subject. n = 7 biologically independent samples. d. 
Relative BCAT1, BCAT2, BCKDHA, BCKDHB and DBT mRNA expression 
determined by qRT–PCR in CAFs and Patient-derived CTCs. n = 4 biologically 
independent samples.  e. Immunoblots of BCAT1 and BCAT2 expression in CAFs and 
Patient-derived CTCs. HSP90 is used as loading control. Experiments were repeated 
independently three times with similar results. f. The influence of BCAAs and BCKAs on 
the growth of CTCs. n = 8 biologically independent samples.    
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8.3 BCAA metabolism in CTCs 
 
Most interestingly, there is a marked increase in the secretion of BCKAs by CAFs 
when they are cocultured with CTC lines as measured from the extracellular BCKA 
concentrations after 6, 12, 24, 36 and 48 hours of coculture (Figure 8.2ab). We did not 
find any secretion of ketoacids from cancer cells alone (Figure 8.2c). We next assessed if 
TCA cycle substrates other than BCKA could also rescue the loss of growth rate of 
PDAC cells- and CTC lines under BCAA deprivation. This could also reveal the role of 
BCKAs as opposed to other TCA cycle substrates in the oxidative TCA cycle. 
Anaplerotic TCA substrates only partially rescued the reduction in growth rate; however, 
BCKAs could completely rescue the growth of PDAC cells and CTC lines under BCAA 
deprivation (Figure 8.2d). 
 
Figure 8.2 BCAA metabolism in CTCs.  a. KIC concentration in spent media from 
CAFs in monoculture or cocultured with CTC line. n = 3 biologically independent 
samples.  *,p=0.0001,**,p=0.0008,***,p=0.0093. b. Extracellular concentration of 
BCKAs secreted by CAFs in monoculture and cocultured with CTCs over 6,12, 24 and 
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48 hours. n = 3 biologically independent samples.    c. Extracellular concentration of 
BCKAs secreted by CAFs in monoculture or cocultured with CTCs, and CTCs in 
monoculture for 48 hours. n = 4 biologically independent samples.   d. The relative 
growth rate of PDAC cell lines and CTC lines under BCAA deprivation but 
supplemented with α-KG, malate, succinate, acetate, citrate, NEAA mixture or the 
combination in the BCAA-deprived media. n = 8 biologically independent samples.    
8.4 BCAA metabolism in CTC organoid model 
 
We further corroborated our main hypothesis that stromal BCAT1 maintains the 
BCAA metabolism in a CTC-organoid model (Figure 8.3a-c). To generate the CTC 
derived organoid, CAF was first seeded on CAF-derived 3D ECMs one day before. Then 
the fresh isolated CTC was seeded on the cultures. CTC derived Organoid was cultured 
as previously described without TGF-β modulators (360). Importantly, the targeting of 
stromal BCAT1 reduced proliferation and de novo protein synthesis in cytokeratin+ 
cancer cells of CTC-organoids (Figure 8.3d). Our results substantiate that CAFs maintain 
their ability to fuel high BCKA demand observed in CTCs, a system that can capture the 
tumor heterogeneity more closely.  
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Figure 8.3 BCAA metabolism in the CTC organoid model.  a. Schematic of the 
protocol used to generate CTC derived organoid with CAF secreted ECM.  b. 
Representative images from CTC derived organoids. Cytokeratin is shown in green, and 
the nuclei stained with DAPI are shown in blue. Experiments were repeated 
independently three times with similar results. c. Representative FACS data of Pan-
Cytokeratin positive tumor cells in CTC derived organoid. Experiments were repeated 
independently three times with similar results. d. EdU staining and SUnSET assay on Pan 
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Cytokeratin+ tumor cells in the CTC derived organoid cultured with Cancer associated 
fibroblasts treated with vehicle or 10mM Gabapentin. n = 6 biologically independent 
samples.    
8.5 Discussion 
 
To replicate tumor-stroma interactions in humans PDAC, we used human CTCs 
derived models to confirm the BCAA metabolism. We isolated CTCs freshly obtained 
from PDAC patient blood using the Labyrinth.  We found that the expression of 
BCKDHA and DBT is higher in Day 0 CTCs compared to healthy controls and CAFs. In 
contrast, BCAT1 expression is much higher in CAFs compared to CTCs.  We then used 
patient-derived expanded CTC lines for downstream experiments. Similar to PDAC cell 
lines, CTC lines showed lower expression of BCAT1 compared to CAFs, and higher 
expression of DBT compared to CAFs.  Moreover, the same with our findings in PDAC 
cell lines, CTC lines also had higher expression of BCAT2 and lowered BCAT1 at the 
protein level. 
Organoids are miniature models of tissues grown in a 3D semi-solid extracellular 
matrix supplemented with specific growth factors. A single epithelial cell can form 
organoids within 7-10 days. These can dissociate into individual cells to restart organoid 
formation. In 2015, it was first reported the utility of organoid models to better 
understand the development of pancreatic ductal adenocarcinoma [325]. After 
transplantation, organoids derived from murine and human PDAC produced lesions 
reminiscent of pancreatic intraepithelial neoplasia and then developed into invasive 
PDAC [325]. Organoids derived from CTC may be very useful for simulating metastatic 
processes and drug-induced screening [326]. 
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We further corroborated our main hypothesis that stromal BCAT1 maintains the 
BCAA metabolism in a CTC-organoid model. To generate the CTC derived organoid, 
CAF was first seeded on CAF-derived 3D ECMs one day before. Then the fresh isolated 
CTC was seeded on the cultures. CTC derived Organoid was cultured as previously 
described without TGF-β modulators. Importantly, the targeting of stromal BCAT1 
reduced proliferation and de novo protein synthesis in cytokeratin+ cancer cells of CTC-
organoids.
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Ex vivo cultures of tumor tissue slices derived from different organs have been 
previously established [327]. Tissue slice culture has recently been shown to resemble the 
architecture of the original organ or tumor closely. It has been used in drug toxicity 
studies, drug testing mechanisms of resistance and gene therapy assays in pancreatic 
cancer [328, 329]. Because tissue slices in ex vivo culture retain most components of the 
tumor microenvironment, they are believed to more likely mirror in vivo tumor models 
then monoculture [327]. Cultured slices maintain their baseline morphology, surface area, 
and microenvironment for at least six days in culture, which provides enough time to test 
drugs or perform gene therapy assays. The tissue slices can also be tested using stable 
isotope tracer methods, which allows for metabolic analysis [330]. By using the tumor 
and the tissue surrounding the tumor, you more accurately model the effect of cancer 
treatments by avoiding genetic, physiologic and environmental complications that could 
be produced in a monoculture. Also, the tissue slice culture provides the ability to 




Studies have demonstrated that tissue slice culture resembles the architecture of the 
original organ or tumor and can be utilized to study better drug toxicity, resistance 
mechanisms and gene therapy testing in pancreatic cancer [328, 329]. Since tissue slices 
in ex vivo culture retain most components of the tumor microenvironment, they are 
believed to recapitulate in vivo tumor models [327]. To test our hypothesis, we will 
address the contribution of BCAA catabolism from the tumor microenvironment using 
tissue slice cultures.  
9.2 PDAC Tissue slice model 
 
We then illustrated that CAF-derived BCKAs support BCKA-dependence in CTC 
cell lines we wanted to validate these findings in a setting that mimics the in vivo TME. 
Previous studies have demonstrated that tissue slice culture resembles the architecture of 
the original organ or tumor and can be utilized to study better drug toxicity, resistance 
mechanisms, and gene therapy in pancreatic cancer [329]. Since tissue slices in ex vivo 
culture retain most of the components of the TME, they are believed to recapitulate better 
stromal-rich tumors than other in vivo tumor models [327]. We obtained fresh PDAC 
patient tissue slices, as shown here and validated their viability for fourteen days in 
culture (Figure 9.1).  
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Figure 9.1 PDAC Tissue slice model.  a. Schematic of human PDAC tissue slice 
culture. The freshly biopsied tumor is embedded in agarose and sliced into 200 µm thick 
slices using a vibrating microtome. Slices are cultured for downstream metabolic and 
functional analyses. b. Representative Live Dead assay of tissue slice at Day 0 and Day 
14. Live cells fluoresce bright green, whereas dead cells fluoresce red. Positive controls 




9.3 Targeting BCAA metabolism in tissue slice by siRNAs 
 
Based on our extensively developed mechanistic crosstalk, we examined whether 
simultaneously targeting the stromal-BCAT1 and cancer cell-DBT could result in an 
enhanced therapeutic effect. We used BCAT1 and DBT siRNAs to inhibit BCAA 
metabolism. Remarkably, knocking down either BCAT1 or DBT significantly reduced 
PDAC cell viability (Figure 9.2). Both PCNA and Ki67 positive cell populations 
significantly reduced in cytokeratin positive cells when either knocking down DBT or 
BCAT1 alone or combinations. Further, a reduction in expression of both DBT and 
BCAT1 validated our siRNA-DBT and siRNA-BCAT1 silencing (Figure 9.3a). 
Moreover, there were no changes in other BCAA-related genes. Next, we asked if 
BCKAs were indeed consumed by PDAC cells in our tissue slice model. Tissue slices 
were cultured in media containing 13C labeled BCKAs, and after 48 hours, the slices were 
homogenized in a cryo-cooled homogenizer to extract intracellular metabolites as well as 
intercellular protein. Intracellular BCKAs were found to be enriched between 10% and 
40%. Subsequently, 13C-BCKA-derived BCAAs were utilized for de novo protein 
synthesis. This is corroborated by the BCAAs obtained by hydrolyzing the intercellular 




Figure 9.2 Targeting BCAA metabolism in tissue slice by siRNAs.  a. Representative 
images from IF analysis of PDAC tissue treated with BCAT1 and DBT siRNAs. 
Cytokeratin is shown in green, PCNA staining is shown in red, Ki-67 staining in pink, 
and the nuclei stained with DAPI are shown in blue. Experiments were repeated 
independently twice with similar results. b. Percentage of PCNA-positive and Ki67-




Figure 9.3 Validation of BCAA metabolism in tissue slice.  a. The efficiency of 
BCAT1 and DBT siRNAs in the human PDAC tissue slices. Expression of BCAT1, 
BCAT2, DBT, BCKDHA and BCKDHB in the human PDAC tissue slices treated with 
BCAT1 and DBT siRNAs. n = 6 biologically independent samples. b. Fractional 
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enrichment of BCAAs of human PDAC tissue slices cultured with 13C-BCKAs. n = 5 
individual tissue samples from distinct patients. Violin plot represents the entire range of 
values, lines at the median, 10-90 percentiles. 
9.4 Gabapentin inhibits protein synthesis in the tissue slice 
 
We next tested if suppressing stromal BCAT1 could reduce BCKA-mediated de 
novo protein synthesis in cancer cells inside tissue slices using SUnSET IF. To 
specifically analyze cancer cells, we used areas of colocalization of puromycin with 
cytokeratin, a cancer cell-specific marker. Notably, cancer cell-specific de novo protein 
synthesis was pronouncedly reduced in slices cultured with Gabapentin (Figure 9.4). 
Overall, our results highlight that stromal-BCAT1 not only supports PDAC cell BCKA 
demand but also exposes the synthetic lethal vulnerabilities in stromal-rich PDAC by co-
targeting stromal BCAT1 and the cancer BCKDH complex (specifically DBT) as a 
clinically relevant therapy. 
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Figure 9.4 Gabapentin inhibits protein synthesis in tissue slice.  a. Representative 
images from SUnSET IF analysis of PDAC tissue treated with vehicle or 10mM 
Gabapentin. n = 3 biologically independent samples. b. Representative images from 
SUnSET IF analysis of PDAC tissue treated with vehicle or 10mM Gabapentin. 
Cytokeratin is shown in green, and Puromycin staining is shown in red. Experiments 







In the development of effective targeting therapy for pancreatic cancer, it is 
essential to have a powerful platform to accurately and reproducibly study the interaction 
of CAFs with PDAC cells in the tumor microenvironment. In this chapter, we have 
shown that the tissue slice culture of fresh human PDAC can survive for at least two 
weeks. There is much evidence to support our view that slice culture can accurately 
short-term model the tumor microenvironment. The literature is scarce, but it is growing 
recently, describing the precise section culture of different normal and tumor tissues. In 
this chapter, we using PDAC tissue slices to study tumor microenvironment metabolism 
demonstrated for the first time, and we also studied cancer cells and CAFs crosstalk in 
tissue slice. In order to further enhance our ability to understand the interactions between 
cells in tissue slices, we used multiple fluorescent antibodies to stain cancer cells and 
CAFs in tissue slices. 
In this chapter, we inhibited BCAA metabolism using BCAT1 and DBT siRNAs. 
Remarkably, knocking down either BCAT1 or DBT significantly reduced PDAC cell 
viability. Next, we checked BCKAs consumption in the tissue slice model. Intracellular 
BCKAs were found to be enriched between 10% and 40%, and 13C-BCKA-derived 
BCAAs were utilized for de novo protein synthesis, which was enriched by 2-15%. 
Furthermore, inhibiting stromal BCAT1 could reduce BCKA-mediated de novo protein 
synthesis in cancer cells inside tissue slices using SUnSET IF.  
Since the main goal of our work is to develop biopsy culture as a platform for 
evaluating the effects of immunotherapy, with particular emphasis on the development of 
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personalized cancer care, we have developed a technology to inspect biopsy culture 
directly. Using fluorescent-conjugated antibodies to stain viable sections of cancer cells 
allows us to obtain three-dimensional images through confocal microscopes. We hope to 
study further the endogenous 3D or subcellular interactions of cancer cells and CAFs in 
patient samples.  
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Chapter 10 Conclusions and Future Directions 
 
10.1 Summary of research 
 
Several recent reports conclude that the stromal cells’-secretory pathways play a 
major role in mitigating avid nutrient deficiency and increasing prototypic pro-survival 
pathways in PDAC cells. Pancreatic CAFs have been shown to secrete alanine and 
lysophosphatidylcholines, supporting the metabolic needs of PDAC cells in the nutrient-
deprived tumor milieu [242, 331]. Like macrophages, CAFs also secrete pyrimidines that 
induce gemcitabine resistance [332, 333]. Furthermore, while our study was in progress, 
it was recently shown that BCAAs contribute around 20% of the carbon in the TCA cycle 
of the pancreas [334]. However, the stromal role in PDAC BCAA metabolism, if any, is 
still unclear. 
In contrast to the current studies in BCAA metabolism, we investigated how 
stromal CAFs regulate BCAA metabolism in PDAC cells and whether there exists a 
mutualistic relationship vis a vis BCAA metabolism between CAFs and PDAC cells. We 
found an increase of BCAA catabolic fluxes and the associated BCAA catabolic enzyme, 
BCAT1, gene and protein expression in stromal CAFs compared to PDAC cells. 
Conversely, the BCAA oxidative enzyme complex, BCKDH, along with mitochondrially 
expressed BCAT2, was increased in cancer cells. We found that BCKAs play a 
significant role in maintaining metabolic activity in the nutrient-starved pancreatic 
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milieu. Unconventionally, BCKAs was used as a substrate for de novo synthesis of 
BCAAs by the reversible action of BCAT2, and these newly synthesized BCAAs 
maintained de novo protein synthesis in cancer cells in BCAA deprived conditions. Our 
results provide strong evidence for dependency on the BCKDH complex and suggest its 
synergistic involvement with BCAT2 in regulating BCAA metabolism in PDAC cells. To 
our knowledge, this is the first report that uncovers heavy reliance on BCKAs in stromal-
rich tumors and reveals DBT as a vulnerable target to exploit this dependency. Recent 
studies investigated BCAT2’s role in PDAC development and found BCAT2 is elevated 
in both mouse and human PDAC models [235, 247], which was responsible for 
enhancing BCAA uptake to sustain BCAA catabolism, mitochondrial respiration, and 
fatty-acid biosynthesis [247]. Our work develops a systematic understanding of BCAA 
metabolism in the PDAC tumor microenvironment, especially in the context of the 
pancreatic cancer-cell centric observations of previous studies. 
In contrast, we found that BCAT2 regulates BCKA-mediated de novo protein 
synthesis in PDAC cells and elucidate the central role of the BCKDH complex in 
regulating PDAC bioenergetics. On the other hand, DBT knockdown, which reduces 
BCKDH complex levels, is detrimental to both BCAA-driven and BCKA-driven 
knockdown. Together, this shows that BCKA-driven oxidation is only dependent on 
BCKDH expression and not on BCAT2 expression. Our results are also in line with 
Neinast et al. [334], where they show that BCKDK inhibitors do not affect BCKDH-
mediated oxidation in the pancreas, alluding to a high basal BCKDH activity in the 
pancreas. Several CAF subpopulations have been identified recently, which may explain 
the heterogeneity or plasticity seen in CAFs.  
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Further, the effect of varying concentrations of the BCAT1 inhibitor, Gabapentin 
on LAT transporters, is poorly studied in CAFs and must be assessed in future studies. 
Within the scope of this study, we have worked extensively to develop clinically relevant 
human PDAC-derived ex vivo models to corroborate and highlight the impact of the 
metabolic crosstalk discovered in vitro. Due to the dynamic interplay of metabolism in 
distinct compartments of the tumor, this study was focused on in vitro and clinical ex vivo 
studies, where these metabolic mechanisms can be observed, characterized and quantified 
readily. Unfortunately, validating these observations in popular in vivo models such as 
KPC and KP mouse models becomes extremely challenging. One major divergence of 
mouse models from human PDAC tumors is the limitation of studying the interaction 
between human PDAC cancer cells with mouse CAFs. The second major challenge is the 
technological limitations of assessing compartmentalized metabolism in vivo. In the 
future, improvement in mass spectrometry imaging and increasing sensitivity of 
chromatography-coupled MS will allow spatial resolution of not only static metabolite 
abundances but also the flux of metabolites across cell-types and tissue compartments.  
We discovered that ECM proteins could be a source of amino acids for BCKA 
synthesis in CAFS under certain nutrient-starved conditions. Interestingly, TGF-β 
upregulated ECM-protein internalization and BCAT1 expression in CAFs are essential 
for BCKA synthesis in CAFs. Recently, PDAC cells were shown to use ECM proteins for 
maintaining amino acid levels [335]. However, our findings that CAFs uptake ECM 
under nutrient limiting conditions are in congruence with previous studies underscoring 
that ECM uptake through the uPARAP receptor is upregulated in fibroblasts [336]. 
Before our results, CAFs were shown to secrete ECM and induce a fibrotic environment 
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in tumors. By contrast, our results stress that this process is reversed under nutrient-
deprived conditions. 
Moreover, we showed that internalized ECM is degraded through proteasomal 
proteolysis, specifically through the chymotrypsin-like proteasome activity. Using 
decellularized 13C-BCAA-labeled ECM proteins, we observed that BCKAs secreted by 
CAFs were enriched with 13C derived from the proteolyzed ECM, thereby confirming 
that ECM in the pancreatic milieu could serve as a source for CAF-secreted BCKAs 
under nutrient-stressed conditions. We reveal a mechanistic basis behind TGF-β mediated 
BCAT1 regulation in CAFs, showing that the TGF-β/SMAD5 axis directly targets 
BCAT1 in CAFs. Thus, cancer-secreted TGF-β regulates the internalization of ECM 
from the TME to supply amino acid precursors for BCKA secretion by CAFs. Our in 
vitro findings were further corroborated in two different patient-derived models: CTCs 
and PDAC tumor slices. These lines of evidence expand our findings to systems that 
recapitulate tumor heterogeneity and mimic the in vivo cancer microenvironment. Our 
results indicate that BCAT1 in CAFs supports the high BCKA demand in PDAC cells.  
We reveal the synthetically lethal BCAA metabolism vulnerabilities in PDAC. Our 
efforts in co-targeting stromal BCAT1 and the cancer BCKDH complex -specifically 
DBT- bridge the gap between knowledge of BCAA metabolism in the stroma and BCAA 





10.2 Future directions 
 
10.2.1 CAF heterogeneity in BCAA metabolism 
There are also several CAF subpopulations identified recently, and this may prove 
the heterogeneity or plasticity of CAF. Moreover, different CAFs may have different 
metabolic profiles and coupling with cancer cells. The first population was also identified 
as the population we used. It is a population that expressed markers of myofibroblasts, 
such as αSMA, and was therefore named myofibroblastic CAFs, which is known to bed 
regulated by TGF-β/SMAD pathways [337]. Furthermore, there is a population that 
expressed inflammatory markers such as IL6 and leukemia inhibitory factor (LIF) and 
was therefore named inflammatory CAFs, which is regulated by IL-1/JAK pathways 
[337, 338]. IL1 induces LIF expression and downstream JAK/STAT activation to 
generate inflammatory CAFs and demonstrate that TGFβ antagonizes this process by 
downregulating IL1R1 expression and promoting differentiation into myofibroblasts.  
Our initial result showed that IL-1 does not influence BCAT1 or SMAD5 (Figure 10.1). 
Nevertheless, there are still other CAF populations. 
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Figure 10.1 IL-1 does not influence BCAA related genes.  a. BCAT1 mRNA 
expression measured in CAFs after two days of treatment with IL-1α. n = 4 biologically 
independent samples. b. αSMA mRNA expression measured in CAFs after two days of 
treatment with IL-1α. n = 4 biologically independent samples.  c. SMAD4 mRNA 
expression measured in CAFs after two days of treatment with IL-1α. n = 4 biologically 
independent samples.   d. SMAD5 mRNA expression measured in CAFs after two days 
of treatment with IL-1α. n = 4 biologically independent samples. 
 
Recently, there is a new CAF subtype that expresses MHC class II (MHCII)–
related genes and induces T-cell receptor (TCR) ligation in CD4+ T cells in an antigen-
dependent manner named these cells antigen-presenting CAFs[339]. Antigen-presenting 
CAFs can convert into myofibroblasts upon suitable culture conditions, suggesting that 
pancreatic CAF subpopulations represent dynamic and interconvertible. Moreover, the 
MHCII expressed by antigen-presenting CAFs acts as a decoy receptor to deactivate 
CD4+ T cells by inducing either anergy or differentiation into Tregs. In this case, antigen-
presenting CAFs are expected to decrease the CD8+ to the Treg ratio and contribute to 
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immune suppression in the PDAC microenvironment. Future studies are warranted to 
assess the role of the heterogeneous population of CAFs in BCAA metabolism. 
10.2.2 Deactivation of pancreatic CAFs through sodium butyrate and GW3965 
Previously, we showed that sodium butyrate (NaB) and GW3965 (GW) could 
deactivate CAFs [340]. NaB is a 4-carbon short-chain fatty acid, which is naturally 
derived from the fermentation of dietary fiber through the gut microbiota [341]. NaB has 
been shown as an HDAC inhibitor and a regulator of cell proliferation, apoptosis and 
differentiation [342]. In cancer, overexpression of HDAC usually inhibits tumor 
suppressor genes, cell cycle inhibitors, epithelial differentiation factors and apoptosis-
inducing factors. HDAC inhibitor can induce cell differentiation, apoptosis and inhibit 
HIF1-α and VEGF [343]. 
Liver X receptor (LXR) agonists have also been used to inhibit tumor cell growth. 
LXR is a member of the nuclear receptor superfamily of ligand-dependent transcription 
factors. They perform important cellular functions, including regulating cholesterol 
homeostasis, lipid and glucose metabolism, and regulating inflammation [344]. LXR 
agonist has been shown to disrupt proliferation, the cell-cycle progression of PDAC cells 
[345].  At the molecular level, LXR is the controlling factor of several cell cycle genes. 
LXR can also inhibit inflammation-related genes such as IL-6 [346].  LXRs are also 
effective regulators of adipogenesis through SREBP1c and its down-regulated genes 
FAS, ACC and SCD-1 [347]. LXR-induced SREBP stimulates the transcription of many 
genes involved in the synthesis and uptake of cholesterol and fatty acids. GW3965 is a 
synthetic LXR agonist that has been shown to alter the distribution of adipose tissue in 
mice and inhibit the production of inflammatory cytokines [348]. 
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We examined that treatment of PDAC tissue slices with NaB and GW would 
restore CAFs’ quiescent state. We show that the treated tissue slices show reduced 
expression of CAF activation markers (Figure 10.2) and up-regulated expression of 
quiescent markers (Figure 10.3). 
 
Figure 10.2 Expression of CAF activation markers in PDAC tissue slices.  a. Relative 
αSMA mRNA expression in PDAC tissue slices. n = 4 biologically independent samples. 
b. Relative COL1 mRNA expression in PDAC tissue slices. n = 4 biologically 
independent samples. c. Relative FAP mRNA expression in PDAC tissue slices. n = 4 
biologically independent samples. d. Relative MMP2 mRNA expression in PDAC tissue 
slices. n = 4 biologically independent samples. e. Relative TIMP1 mRNA expression in 
PDAC tissue slices. n = 4 biologically independent samples. 
 155 
 
Figure 10.3 Expression of quiescent markers in PDAC tissue slices.  a. Relative 
GFAP mRNA expression in PDAC tissue slices. n = 4 biologically independent samples. 
b. Relative FASN mRNA expression in PDAC tissue slices. n = 4 biologically 
independent samples. c. Relative SREBP1c mRNA expression in PDAC tissue slices. 
n = 4 biologically independent samples.  
Besides, we show that NaB and GW treatment can also influence the properties of 
ECM. As shown in the figure, if we treated the CAFs from the beginning, the CAFs 
stopped to produce ECM; if treated in the middle, the CAF ECM would be deactivated to 
normal ECM (Figure 10.4a-c).  For the adhesion assay, we further showed that the 
deactivated ECM is harder for PDAC cells to attach (Figure 10.4d-e). The properties of 
this ECM still need to be further examined. We could further examine whether the 
stromal cell-induced quiescence caused by NaB and GW treatment would lead to a 
decrease in tumor growth and metastasis. 
 156 
 
Figure 10.4 Deactivation of ECM by NaB + GW.  a-c. Scanning electron microscopy 
image of CAF-derived 3-D matrices treated by vehicles (a), NaB + GW for eight days (b) 
or four days (c). Experiments were repeated independently two times with similar results.  
d. Fluorescence microscopy images comparing the adhesion of GFP-labeled Mia Paca-2 
and Patu 8988t cells with ECM treated by vehicles and NaB + GW. Experiments were 
repeated independently two times with similar results. e. Relative adhesion percentage of 
Mia Paca-2 and Patu 8988t pancreatic cancer cells with ECM treated by vehicles and 
NaB + GW. n = 3 biologically independent samples.    
 
10.2.3 CAFs secrete NAD+ precursors to support PDAC cells. 
The Nicotinamide adenine dinucleotide (NAD) and its phosphorylated form 
(NADP) contained in nicotinamide play an important role in the metabolism of all 
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organisms.  Like many phosphorylation products, NAD is synthesized de novo by some 
smaller units, such as tryptophan (Trp), nicotinamide (Nam), nicotinic acid (NA), 
nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). Trp becomes 
NAD+ through the de novo biosynthetic pathway in the liver [349]. Once converted to 
other molecules, it merges with the Preiss-Handler pathway, which is the same pathway 
used by NA to reach NAD+. Although tryptophan does produce NAD+, its efficiency is 
60 times lower than other precursors [350]. 
Nam is a common form of vitamin B3, sometimes called niacinamide. Nam will 
go through the same remedial approach as NR, but it must be stopped by bypassing the 
rate-limiting step before NR becomes NAD+. Nam also participated in the salvage part of 
the approach. When enzymes that consume NAD+ (such as sirtuins (a family of proteins 
that regulate cell health)) use NAD+, they divide it into the necessary parts and then send 
them back as needed to create more NAD+ [351]. NA is another form of vitamin B3, also 
known as niacin, and is sometimes used as a general term for all vitamin B3. Nicotinic 
acid was discovered by chemists who study nicotine, and its name was changed to niacin 
to distinguish it from tobacco. As we all know, NA causes flushing. Since the 1940s, NA 
has been used to fortify flour and rice all over the world due to its advantages. NA enters 
NAD+ through the Preiss-Handler pathway, which also integrates chemically converted 
tryptophan (amino acid NAD+ precursor) into NAD+ [352]. 
Nicotinamide Mononucleotide (NMN) is an intermediate compound between NR 
and NAD+, which means that NR must first become NMM before it can become NAD+ 
[353]. NMN is a new member of NAD+ precursor products. We know it is a beneficial 
precursor, but only recent studies have begun to clarify its ability to enter cells intact. 
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NMN and NR have never been intensively studied in clinical studies to see if one NAD+ 
produces less NAD+ energy than the other. NR is a form of vitamin B3 and is generally 
considered to be a highly effective precursor, which means that it consumes the least 
energy when taken orally and becomes NAD+. This is because NR bypasses a step in the 
NAD+ biosynthetic pathway, which is also the niacinamide pathway [354]. NR is 
increasingly used for NAD+ supplementation because it is well known that NR can 
increase the level of NAD+. In animal studies, this increase leads to specific benefits such 
as mitochondrial health, but so far, there is no evidence that these animal studies can be 
inferred to humans. NaR (nicotinic acid riboside) is a newly discovered eukaryotic NAD+ 
precursor. NaR is converted to NAD+ in three steps, first by nicotinamide riboside kinase 
(NMRK)-dependent [355].  
 In the initial siRNA screening, we identified the CAF-mediated rescue of PDAC 
cell growth rate under NAD+ precursors deprivation. Furthermore, this effect is further 
enhanced when NAPRT is knockdown. This suggested that CAF is secreting NaR 
(Figure 10.5ab). Colony formation assay suggested NaR is an effective NAD+ precursor 
(Figure 10.5c). Further, gemcitabine is a pyrimidine anti-nucleoside, has long served as a 
core component of chemotherapy treatments for PDAC. Gemcitabine resistance has been 
shown to be easily developed in PDAC, although the mechanism behind this link remains 
unclear. Since NaR is also a nucleoside analog, it probably completes the transporters 
with gemcitabine, and this could cause gemcitabine resistance. Our results indicated that 
NaR could cause gemcitabine resistance at low concentrations (Figure 10.6). Thus, NaR 
released by CAFs may directly confer gemcitabine resistance to PDAC cells. 
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Figure 10.5 CAFs secrete NaR to support PDAC cells.  a. Effect of NAMPT or 
NAPRT knockdown in CAFs on the CAF-mediated rescue of the Panc-1 cell growth rate 
under NAD+ precursors deprivation. n = 4 biologically independent samples. b. Effect of 
NAMPT or NAPRT knockdown in CAFs on the CAF-mediated rescue of Patu8988t cell 
growth rate under NAD+ precursors deprivation. n = 4 biologically independent samples. 




Figure 10.6 NaR Confer Gemcitabine Resistance to PDAC Cells.  a. Relative viability 
and IC50 of Capan1 cells treated with Gem in the presence of NaR. n = 4 biologically 
independent samples. b. Relative viability and IC50 of Panc-1 cells treated with Gem in 
the presence of NaR. n = 4 biologically independent samples. c. Relative viability and 
IC50 of Patu8988t cells treated with Gem in the presence of NaR. n = 4 biologically 
independent samples.  
 
Previous studies showed that members of the SLC29 family (ENT, equilibrative 
nucleoside transporters) and/or SLC28 family (CNT, concentrative nucleoside 
transporters) family could mediate the transport of NaR and NR. We performed RT-PCR 
to identify which CNT or ENT isoform mRNA is most abundant in CAFs (Figure 
10.7ab). We found that SLC28A2 and SLC28A3 are highly expressed in CAFs, while 
cancer cells have high expression of ENTs. Also, the CAF-mediated rescue of PDAC cell 
growth rate under NAD+ precursors deprivation is reduced when SLC28A2 is 
knockdown (Figure 10.7c). Furthermore, this effect is further enhanced when NAPRT is 
knockdown. To check the effect of CAF on PDAC cell NAD+ metabolism, we treated 
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PDAC cells with CAF CM or NaR. CAF CM and NaR have a similar effect in PDAC 
cells, up-regulated NMRK1 and down-regulate NAMPT or NAPRT (Figure 10.8a). This 
suggests that CAF shifts PDAC cells to more NaR dependent, and reduced dependence of 




Figure 10.7 CAF secrete NaR through SLC28A2.  a. Expression of SLC28 family 
(CNT) in CAFs and pancreatic cancer cell lines. n = 4 biologically independent samples. 
b. Expression of SLC29 family (ENT) in CAFs and pancreatic cancer cell lines. n = 4 
biologically independent samples. c. Effect of SLC28A2 or SLC28A3 knockdown in 





Figure 10.8 CAF secreted NaR up-regulated NMRK1 and down-regulate NAMPT 
or NAPRT.  a. Expression of NMRK1, NAMPT and NAPRT in PDAC cells treated with 
CAF CM or NaR. n = 4 biologically independent samples. b. OCR measurements in 
PDAC cells with NaR. n = 6 biologically independent samples. c. Fatty acid oxidation 
OCR measurements in PDAC cells with NaR. n = 6 biologically independent samples. 
 
10.2.4 Identifying BCKA Transporters 
Unlike BCAAs, BCKA transport is not governed by a single amino acid 
transporter. However, it is instead mediated by monocarboxylate transporters (MCTs), 
which also control the transport of lactate, pyruvate, and ketone bodies through the 
plasma membrane. There are at least 7 MCTs that are active in different tissue types. In 
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order to identify the MCT in the pancreatic tumor stroma, we performed RT-PCR to 
identify which MCT isoform mRNA is most abundant in CAFs (Figure 10.9). We found 
that MCT1 is highly expressed in PDAC cells, while MCT2 is highly expressed in CAFs. 
Nevertheless, because MCTs are shared with lactate, pyruvate and other α-keto acids, we 
cannot identify the specific transporters based on the expression. 
 
Figure 10.9 Expression of monocarboxylate transporters in CAF and PDAC cell 
lines.  a. Relative MCT1 mRNA expression in CAFs and pancreatic cancer cell lines. 
Expression normalized to gene expression in CAF1. n = 6 biologically independent 
samples. b. Relative MCT2 mRNA expression in CAFs and pancreatic cancer cell lines. 
Expression normalized to gene expression in CAF1. n = 6 biologically independent 
samples. c. Relative MCT4 mRNA expression in CAFs and pancreatic cancer cell lines. 
Expression normalized to gene expression in CAF1. n = 6 biologically independent 
samples. 
For the future study, we will perform CRISPR screening to identify the BCKA 
related transporters. A previous study indicated BCAT2 is a bifunctional protein 
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catalyzing branched chain amino acid transamination and branched chain alpha-keto acid 
transport [356]. The transport properties of BCAT2 suggest that this protein may be the 
branched-chain alpha-keto acid transporter [356]. So, in order to implement such a 
screening strategy, we will use the BCAT2 knockout cell lines we generated. We will 
transduce the BCAT2 knockout cells with a lentiviral single guide RNA (sgRNA) library 
that targets ~3000 metabolic enzymes, small-molecule transporters, and metabolism-
related transcription factors (~10 sgRNAs per gene) and also contains 499 control 
sgRNAs [357]. The transduced cells were cultured in DMEM media with or without 
BCKAs. For each gene, we generated a gene score by calculating the mean log2 fold-
change in abundance from the beginning to the end of the culture period of all the 
sgRNAs targeting the gene (Figure 10.10).  
 
Figure 10.10 Screening strategy of BCKA transporters.  a. Schematic of BCAT2 
knockout cells. b. Screening strategy of BCKA transporters.  
 
10.2.5 Nuclear BCAT2 regulate lipid metabolism 
PPARs are members of the superfamily of transcription factors expressed by the 
target gene [358]. PPARs include three subtypes: PPARα, PPARβ, and PPARγ, and 
PPARs of different subtypes that regulate different target genes. PPARs are known as 
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fatty acid receptors, mainly involved in fatty acid metabolism [359]. PPARα is mainly 
expressed in liver tissues, by regulating the expression of genes related to fatty acid 
oxidation in the liver, it can differentiate liver fat cells, fat storage, transportation and 
fatty acid oxidation. The PPARα gene mainly regulates the mitochondrial and 
peroxisomal β oxidation system and microsomal ω oxidation system [359]; PPARα can 
also regulate the peroxisomal β oxidation pathway through the expression of some key 
enzymes (such as acetyl coenzyme A oxidase, ACSL1 and dehydrogenase 
multifunctional enzyme, ketone acetyl coenzyme A thiolase, etc.) [360]. Also, some 
studies have shown that activated PPARα can also mediate the expression of 
apolipoprotein apoA I; promote lipoprotein lipase synthesis, catalyze lipolysis of 
triglycerides (TG) in lipoproteins into free fatty acids (FFA) [358]. 
PPARγ can be divided into four subtypes: γ1, γ2, γ3, and γ4 [361]. PPARγ is 
mainly involved in the fat tissue differentiation and lipid metabolism process, including 
regulating lipid metabolism, fat cell terminal differentiation, and glycometabolism; 
besides, PPARγ is used in the development of liver fibrosis development process. 
Previous studies have shown that PPARγ is highly expressed in adipocytes and can 
induce liver cells to express apolipoproteins, fatty acid oxidase systems and lipoprotein 
lipases, etc., thereby promoting the oxidative metabolism of lipids, which can also 
enhance fatty acid transport proteins and fatty acid transfer enzymes Gene expression of 
fatty acid storage such as FAT/CD36, aP2, phosphoenolpyruvate carboxykinase 
(PEPKK), ACSL1, etc., and inhibits β3-adrenergic receptors, leptin and tumor necrosis 
factor-alpha (TNFα) expression and fatty acid release [360]. Also, PPARγ plays an 
important role in the transformation of HSC from static phenotype to active phenotype. 
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PPARγ regulates liver fibrosis signal channels such as TGFβ/Smad signal channel, Ras-
MAPK signal channel, NF-κB signal channel, etc., to slow down the process of fibrosis 
[361]. 
When we were first staining the BCAT2 in human PDAC tissue, we found 
BCAT2 is also located in the nucleus. Since BCAT2 is a transaminase, BCAT2 can also 
transport lipid to the nucleus to bind with PPARs as other transaminases. The co-
localization is also confirmed in the PDAC cell lines (Figure 10.11).  
 
Figure 10.11 Expression of BCAT2 in PDAC tissue and cell lines.    a. Representative 
IHC staining image of BCAT2 expression in human PDAC tissue. Experiments were 
repeated independently three times with similar results. b. Colocalization of BCAT2, 
mitochondria and nucleus analyzed by immunofluorescence against BCAT2, Mitotracker 
and DAPI. Experiments were repeated independently three times with similar results.  
 
To further check the interference between BCAT2 and PPARs. We used the 
BCAT2 knockdown cells treated with PPAR inhibitors, and we found that GW9662, 
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which inhibits PPARα/γ, is more effective in BCAT2 knockdown cells (Figure 10.12). 
Moreover, we also checked the expression of PPAR in the BCAT2 knockdown cells, 
similar to the GW99662 result, and we found that BCAT2 knockdown cells have a high 
expression of PPARA and lower expression of PPARG. These data indicate that BCAT2 
may be linked to PPARα/γ functions.
 
Figure 10.12 BCAT2 and PPAR.  a. Representative IHC staining image of BCAT2 
expression in human PDAC tissue. Experiments were repeated independently three times 
with similar results. b. Colocalization of BCAT2, mitochondria and nucleus analyzed by 
immunofluorescence against BCAT2, Mitotracker and DAPI. Experiments were repeated 
independently three times with similar results.  
 
Since PPAR regulates lipid metabolism, we check the lipid oxidation in BCAT2 
knockdown cells. We found the lipid oxidation is up-regulated in the BCAT2 knockdown 
cells (Figure 10.13a). Furthermore, a recent study has shown that ferroptosis is linked to 
lipid oxidation [362]. So we check the use of Erastin, which is a small molecule capable 
of initiating ferroptotic cell death in the BCAT2 knockdown cells (Figure 10.13b). We 
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found that Erastin is more effective when BCAT2 is knocking down. This further proves 
the BCAT2 may be linked to lipid metabolism. 
 
Figure 10.13 BCAT2 and lipid oxidation.  a. Representative IHC staining image of 
BCAT2 expression in human PDAC tissue. Experiments were repeated independently 
three times with similar results. b. Colocalization of BCAT2, mitochondria and nucleus 
analyzed by immunofluorescence against BCAT2, Mitotracker and DAPI. Experiments 
were repeated independently three times with similar results.  
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Chapter 11 Materials and Methods 
 
11.1 Cell Culture  
11.1.1 PDAC Cell lines 
All the cell lines used in this study were purchased from ATCC, used below 
passage 25 and continuously cultured in 100 U/ml penicillin and 100 U/ml streptomycin. 
The Mia Paca-2, Panc-1 and Patu 8988t cell lines were routinely cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) with 10% fetal bovine serum (FBS) (Atlanta 
Biologicals, S11150). AsPc1 and BxPC3 cell lines were routinely cultured in Roswell 
Park Memorial Institute (RPMI) 1640 (Invitrogen) with 10% FBS. All cell lines were 
mycoplasma free based on PCR-based assays run every month in the lab.  
For metabolic and metabolomics assays, 10% dialyzed FBS (Sigma-Aldrich, F0392) was 
used. For the rescue experiments, the DMEM medium without BCAAs was used (United 
States Biological). 
11.1.2 Fibroblast Cell Culture  
Patient-derived fibroblast cells were kindly provided by Drs. Edna Cukierman, 
Anirban Maitra and Mara Sherman and internal STR profiling were maintained and 
checked annually. CAFs were cultured at 37˚C under 5% CO2 using DMEM 
supplemented with 10% FBS and 100 u/ml-mg/ml penicillin-streptomycin. Normal 
fibroblast cell lines IMR-90 and MRC-5 were purchased from ATCC and cultured at 
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37˚C under 5% CO2 using DMEM supplemented with 10% FBS and 100 u/ml-mg/ml 
penicillin-streptomycin. MSCs were provided by Dr. Michael Andreeff and cultured in α-
MEM containing 10% FBS, 4% pooled human platelet lysate and 1% penicillin-
streptomycin. Only third or fourth passage cells were used for experiments. 
11.1.3 CTC Cell Culture 
Cells were maintained at 37°C, 5% CO2 under normoxic conditions. PDAC CTC-
derived cell lines were grown in RPMI-1640 supplemented with 10% FBS and 1% 
antibiotic-antimycotic (Gibco).  
11.1.4 Tissue slice culture 
Fresh pancreatic cancer tissue samples were procured immediately after surgical 
resection from the University of Michigan Hospital. Informed consent was obtained from 
all patients. The remaining connective, fibrotic or adipose tissue was removed with razor 
blades. Tumor specimens were embedded in 3% low melting point agarose/PBS before 
cutting in the Leica VT1200 tissue slicer. The slice thickness ranged between 100–200 
µm. Slices were then cultured in DMEM with penicillin (100 U/mL), streptomycin (100 
U/mL) and amphotericin (Fungizone 2.5 μg/mL). All experiments were performed in 
triplicate and were repeated at least three times.  
11.2 CTC isolation from patient blood and healthy controls 
The experimental protocol was approved by the University of Michigan Medicine 
Institutional Review Board, and all patients gave their informed consent to participate in 
the study. Patients were diagnosed with metastatic PDAC and were treatment naïve at the 
time of the first sample collection. Blood was collected in EDTA tubes and processed 
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within two hours of sample collection. Red blood cells (RBCs) were depleted from the 
sample using RBC aggregation via HetaSepTM (STEMCELL Technologies) following the 
manufacturer’s protocol. Briefly, blood was divided into 3 mL aliquots and mixed with 
600μL HetaSepTM, and centrifuged at 90xg for 1 minute, at room temperature, with the 
centrifuge brake off. The sample was then further incubated for an additional 10 minutes 
at room temperature to improve RBC depletion. The nucleated cell fraction was collected 
and diluted to 3x the original blood volume with phosphate-buffered saline (PBS) (Gibco). 
The resultant sample was processed through the Labyrinth at a flowrate of 2500 μL/min. 
The flow was stabilized for 1 mL of flow volume, before the CTC outlet, outlet 2, was 
collected, termed the CTC-enriched labyrinth product. This sample was divided into CTC 
enumeration (800 μL) and RNA analysis (≈3-4 mL). 
11.3 Immunofluorescent staining and CTC enumeration 
The CTC-enriched labyrinth product was divided across 4 Polysine microscope 
slides (Thermo Scientific), 200μL each, using Thermo ScientificTM Cytospin 4 (Thermo 
Scientific). The slides were placed into an EZ Cytofunnel (Thermo scientific) and spun at 
800rpm for 10 minutes. To fix the cells, 200μL of 4% paraformaldehyde (PFA) was added 
to the Cytofunnel and spun a second time under the same conditions. Slides were stored at 
4°C coated in PBS until used for immunofluorescent staining.  
Slides were permeabilized with 0.2% Triton X-100 for 3 minutes, washed 3x with 
PBS, and blocked using 10% goat serum (Life Technologies) for 30 minutes at room 
temperature. The slides were then incubated overnight at 4°C with primary antibodies 
diluted in 10% goat serum - mouse anti-human Pan-Cytokeratin (CK) (Bio-Rad, 
MCA1907), mouse anti-human CD45 (Bio-Rad, MCA87GA), and rabbit anti-human 
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Vimentin (Vim) (CST, 5741). The next day the slides were washed 3x with 5 minutes 
incubation PBS washes. Slides were then incubated in the dark for 45 minutes at room 
temperature with secondary antibodies - (Alexa Fluor 488, 546, and 647). The slides were 
washed 3x with 5minute incubation PBS washes and mounted using Prolong Gold Antifade 
Mountant with DAPI (Invitrogen). The slides were scanned using a Nikon TI microscope 
at 20x magnification. The tiled images were individually analyzed, and CTC was identified 
based on their fluorescent signature in each channel.  
Cells were considered CTCs when they were DAPI+/CD45 (AF488)-/CK (AF546) +. 
CTC phenotype was determined based on vimentin expression. Cells were considered 
epithelial if DAPI+/CD45(AF488)-/CK(AF546) +/Vim (AF647)-, and epithelial to 
mesenchymal transition (EMT) if DAPI+/CD45(AF488)-/CK(AF546) +/Vim (AF647) +.  
11.4 Proliferation assay 
Cells were cultured on 96-well plates in the indicated conditions. For cancer cells, 
cell growth was measured after that as fluorescence intensity using a plate reader 
(SpectraMax M5, Molecular Devices). For CAFs, the CyQUANT® direct cell 
proliferation assay was performed according to the manufacturer’s instructions. 
11.5 Coculture assay with fibroblasts 
Direct coculture in which two cell types were grown in physical contact was 
performed. In brief, CAFs or NOFs were seeded first, and after the attachment, GFP 
labeled pancreatic cancer cells were seeded overnight. The medium was changed to 
BCAA deprivation or with different drugs after 24 hours. Fluorescence value as 
proliferation rates was measured at 485/515 nm, or flow cytometry assay was performed. 
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11.6 Conditioned media (CM) preparation  
PANC-1 cells were grown in DMEM + 10% FBS medium, and conditioned 
medium was harvested after 16 h and centrifuged at 3,000 rpm for 5 min, and the 
supernatant was passed through the 0.45-µm filter. NOFs or MSCs were exposed to fresh 
CM repeatedly for four weeks. 
11.7 Colony formation assay 
Cell growth of shRNA-treated cell lines was assayed through crystal violet 
staining. 500 cells were seeded in 6-well plates. At the indicated time point (usually two 
weeks), cells were fixed with 80% methanol and stained with crystal violet solution 
overnight. All experiments were performed in triplicate. 
11.8 Protein assay 
Protein assays are used to do normalization in our experiment and are done 
according to Bicinchoninic Acid (BCA) Protein Assay protocol (Thermo Fisher). In brief, 
200 µl reagent mixture was added to a 96-well assay plate and mixed with samples or 
standard, and then incubated at 37°C for 30 min. The absorbance was read on a 
spectrophotometer at 562 nm, and a standard curve was generated to determine sample 
protein concentration. 
11.9 SiRNA, shRNA and CRISPR knockdown 
Cells were transfected with siBCAT1 (Sigma, EHU072291), siDBT (Sigma, 
EHU035851), siSMAD4 (Sigma, EHU149321), siSMAD5 (Sigma, EHU104241), 
siMRC2(Sigma, EHU003351) and respective negative controls (Sigma, SIC001) using 
Lipofectamine RNAiMAX Reagent (Thermo Fisher Scientific) and Opti-MEM 
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accordingly to manufacturer’s instructions and analysis was performed three days after 
transfection. 
shRNA vectors were purchased from Sigma-Aldrich (St. Louis, USA). The clone 
IDs for each shRNA are as follows: shBCAT1-1: TRCN0000005907; shBCAT1-2: 
TRCN0000010976; shBCAT2-1: TRCN0000035115; shBCAT2-2: TRCN0000286266; 
shDBT-1: TRCN0000025837; shDBT-2: TRCN0000025838; A non-targeting shRNA 
(shCTRL) was used as a control. Knockdown was confirmed by qRT–PCR or 
immunoblotting.  
For CRISPR knockdown of BCAT2, sgRNA oligonucleotide pairs (Pair1, 
CACCGCACGGATCATATGCTGACGG, AAACCCGTCAGCATATGATCCGTGC, 
Pair2, CACCGGTTCACGGATCATATGCTGA, 
AAACTCAGCATATGATCCGTGAACC were phosphorylated, annealed, and cloned as 
previously described into the BbsI-linearized pSpCas9(BB)-2A-Puro (PX459) V2.0 
(PX459) plasmid (Addgene, #62988). 
11.10  Quantitative RT-PCR 
Total RNA was isolated using Trizol (Life Technologies) according to the 
manufacturer’s instructions. RNA concentration was determined using a purified RNA by 
NanoDrop Lite Spectrophotometer (Thermo Fisher Scientific) and 1µg of cDNA 
synthesized using the iScript cDNA synthesis kit (BioRad). Quantitative-RT PCR was 
performed using a QuantStudio 3 Real-Time PCR System (Applied Biosystems, Foster 
City, CA) with the Power SYBR™ Green PCR Master Mix (Invitrogen, Carlsbad, CA) as 
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per the manufacturer’s instructions. The primer sequences used for qRT–PCR are shown 
in Table 11.1. 
Table 11.1 Primer sequences for qRT-PCR. 
Gene Forward Reverse 
BCAT1  GCCTTGGTGTGTGACAATGG CCATCACCCCCTGATGTCTG 
BCAT2  AAATGGGCCTGAGCTGATCC GAGTCATTGGTAGGGAGGCG 
BCKDH











SMAD3  AGCTGACACGGAGACACATC GTTGCATCCTGGTGGGATCT 
SMAD4  GAGACATACAGCACCCCAGC TGTGGAAGCCACAGGAATGT 
SMAD5  ACAACACAGCCTTCTGGTTCA CGTGGCATTTTGTGGCATGT 
For the CTCs, the remainder of the CTC-enriched labyrinth product was centrifuged 
at 300xg for 10 minutes to pellet the cells. The cell pellet was resuspended in 700μL TRIzol 
to lyse the cells and incubated at room temperature for 5 minutes and frozen at -20°C until 
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ready for RNA purification. RNA was purified using a modified lysis protocol and the 
Total RNA Purification kit (Norgen Biotek Corp.). Once thawed, 140μL of chloroform was 
added to the TRIzol sample and centrifuged at 12,000xg for 15 minutes. The RNA layer 
was collected and mixed with an equal volume 70% ethanol and loaded onto the spin 
column and washed 3x using the provided wash solution and eluted into 30μL volume. 
cDNA was prepared using SuperScript IV VILO with ezDNaseTM Enzyme (Invitrogen) 
following the manufacturer’s protocol. Real-time PCR was performed using TaqManTM 
Fast Advanced Master Mix (Applied Biosystems) with following probes 18s: 
Hs99999901_s1, BCAT1:Hs00398962_m1, BCAT2:Hs01553550_m1, BCKDHA: 
Hs00958109_m1, BCKDHB: Hs00609053_m1, DBT: Hs01066445_m1 following the 
manufacturer’s protocol and run on the QuantStuido 3. Detection thresholds were 
determined using the QuantStuidoTM Design & Analysis Software.  
11.11  Immunoblotting 
Cells were washed twice in ice-cold phosphate-buffered saline (PBS), scraped and 
collected as pellets after centrifugation at 4,000 r.p.m. for 5 min. The pelleted cells were 
incubated in RIPA buffer with proteinase and phosphatase inhibitors for 15 min. Lysates 
were then collected and centrifuged at 14,000 r.p.m. for 15 min at 4 °C. Protein 
concentrations were measured using the BCA Assay. SDS–PAGE and immunoblotting 
were performed in pre-cast Bis-Tris 4–20% gradient gels (Bio-Rad). Blots were imaged 
using a ChemiDoc (Bio-Rad ChemiDoc™ MP System). The following antibodies were 
used: BCAT1 (Novus Biologicals, NBP2-01826), BCAT2 (Cell Signaling Technologies 
(CST), 9432S), DBT (Abcam, ab151991), HSP90 (CST, 4877) and Vinculin (Santa Cruz 
Biotechnology, sc-25336).   
 177 
11.12  ChIP-PCR 
CAFs were treated with vehicle or 5 ng/ml TGF-β1, then cross-linked, fixed and 
processed with Simple ChIP Enzymatic Chromatin IP Kit (Magnetic Beads) (CST, 9003) 
according to the manufacturer’s instructions. Cell lysates were Immuno-precipitated with 
anti-SMAD4 antibody (CST. 38454), SMAD5 antibody (CST, 12534) and rabbit IgG 
ChIP grade (CST, 2729). Region of BCAT1 promoter or non-promoter region were 
amplified by Power SYBR™ Green PCR Master Mix (Invitrogen, Carlsbad, CA) as per 
the manufacturer’s instructions. 
11.13  Dual-luciferase reporter assay 
BCAT1 promoter regions were conjugated to the translation start site of the 
NanoLuc gene in the pNL2.1 vector (Promega). CAFs were plated in 96-well plates 12 h 
before transfection. The NanoLuc reporter vectors were co-transfected with promoter 
firefly luciferase reporter vector using Lipofectamine 3000 Reagent (Thermo) according 
to the manufacturer’s protocol. After 48 h of the transfection, the luminescence was 
quantified and normalized using Nano-Glo Dual-Luciferase Reporter Assay (Promega). 
11.14  Puromycin incorporation assay 
Surface sensing of translation (SUnSET) assay was performed as previously 
described[363]. Briefly, cells were incubated with 10µg/mL puromycin (Thermo Fisher) 
for 10 min, followed by washing with ice-cold PBS and lysing with RIPA buffer. Cell 
lysates were loaded onto SDS–PAGE, and western blotting was performed with a mouse 
anti-puromycin monoclonal antibody (Millipore), and normalized against Ponceau S 
staining (Sigma). 
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11.15  Mitochondrial NADH/NAD+ measurement  
Mitochondrial NADH/NAD+ sensor, RexMito, was prepared as previously 
described[364]. Mia Paca-2 cells were transfected using Lipofectamine 2000 Reagent 
(Thermo) according to the manufacturer’s protocol. Then the cell medium was replaced 
by a complete medium, BCAA deprived medium, or BCAA deprived medium with 
BCKA. We used a Nikon A1Si Laser Scanning Confocal Microscope to visualize the 
fluorescence of transfected cells 24–48 h after transfection. Fluorescence detection was 
carried out using the 488 laser line for RexYFP and 561 laser line for HyPerRed-C199S. 
Imaging intensity was measured, and Ratio imaging was generated by Nikon NIS-
Elements AR. 
11.16  Flow cytometry 
In the mixed coculture, cancer-associated fibroblasts were seeded in a 6-well plate 
for 24 hours. For the SUnSET assay, then GFP labeled cells were added and cocultured 
for three days in the indicated medium. Puromycin intensity was analyzed by FACS in 
tumor cells with GFP gating. For the NADH/NAD+ measurement, PKH26 labeled cells 
were added and cocultured for three days in the indicated medium. NADH/NAD+ ratio 
was analyzed by FACS in tumor cells with PKH26 gating. All data were acquired with 
the Bio-Rad ZE5 flow cytometry analyzer, and analysis was performed using FlowJo. 
11.17  Measurements of OCR 
Mitochondrial OCR was measured by XF96 Analyzer (Seahorse Biosciences). 
Cells were seeded in 96-well seahorse plates and incubated at 37 °C with 5% CO2 
overnight. The medium was replaced with 100 μL medium free of serum and sodium 
bicarbonate. Plates were then incubated in a CO2-free incubator for one h before placing 
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them in the analyzer. The OCRs were measured with the procedure of 3-min mixing, 2-
min waiting, and 3-min measuring. Oligomycin, FCCP and Rotenone/Antimycin A were 
injected through port A, B and C, respectively, to calculate mitochondrial function under 
different stress. All data were normalized to total cell protein as measured by the BCA 
assay. 
11.18  Substrate specific OCR 
OCR was measured in MAS medium supplemented with 0.2% (w/v) BSA, four 
mM ADP, 1 nM XF Plasma Membrane Permeabilizer (Seahorse Bioscience), 500 nM 
Coenzyme B12 and biotin and sequentially offered Oligomycin, FCCP and antimycin. 
Permeabilized pancreatic cancer cells were offered 5 mM branched-chain ketoacids. 
Substrate specific respiration was calculated as the maximum respiration, and the data 
were normalized to total cell protein. 
11.19  Immunohistochemistry (IHC) and immunofluorescence (IF) staining 
Tissues were fixed in 10% formalin overnight and embedded in paraffin. PDAC 
sections were deparaffinized in xylene, rehydrated through sequential ethanol, and rinsed 
in PBS. Non-specific signals were blocked using 10% goat serum in 0.1% Triton X-100. 
Tumor samples were stained with the following primary antibodies: αSMA(Sigma, 
A5228, 1:500), BCAT1 (Sigma, HPA048592, 1:200), SMAD5 (Sigma, HPA058931, 
1:200), Ki-67(Santa Cruz Biotechnology,sc-23900,1:500), PCNA(Santa Cruz 
Biotechnology, sc-56,1:500). After overnight incubation, the slides were washed and 
incubated with biotinylated secondary antibody (Vector Laboratories) for 30min at room 
temperature. All slides were then incubated with avidin-biotin-peroxidase complex for 30 
min, and the signals were visualized by using DAB Substrate Kit (Vector Laboratories). 
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The tissue sections were counterstained with VECTOR Hematoxylin QS and mounted 
with VectaMount after dehydration. IF staining was performed on tissue slices or 
chamber slide cultures (Thermo Fisher Scientific). The primary antibody was Anti-
Proteasome 20S alpha + beta (Abcam, ab22673). Samples were mounted on microscope 
slides with Prolong Antifade with DAPI and imaged using a Nikon A1Si Laser Scanning 
Confocal Microscope.  
11.20  BCAT activity assay 
The enzymatic activity assay is performed as previously described[365]. CAFs 
were homogenized in the buffer consisting of 20 mM EDTA, 20 mM EGTA, 0.4% (w/v) 
CHAPSO, 5 mM DTT, protease inhibitor cocktail, and 25 mM Hepes. The tissue 
homogenates were then frozen in a -80 °C freezer for one h and then thawed at room 
temperature. The cellular debris was removed by centrifugation at 15,000g for 10 min at 
4 °C. The supernatant is then mixed with reaction buffer containing 10 mM L-leucine, 2 
mM NAD+, and 100 mM sodium carbonate/bicarbonate buffer. The disappearance of 
absorbance at 340 nm due to NADH oxidation is measured continuously. BCAT activity 
is quantified by comparing the rate of loss of absorbance at 340 nm in the 
spectrophotometric assay mixture with or without bacterial leucine dehydrogenase or 
lacking bacterial leucine dehydrogenase. 
11.21  Collagen Uptake 
For the collagen uptake assays, cells were cultured with 25 µg/ml Collagen for 
indicated periods in different media. Subsequently, cells were washed three times with 
ice‐cold PBS and fixed with 4% formaldehyde in PBS for 15 min. After fixation, cells 
were washed in PBS and mounted using Prolong Antifade + DAPI. 
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11.22  Proteasome activity assay 
Proteasome activity was assessed by using the Cell-Based Proteasome-Glo Assay 
(Promega, G1180). Cells were trypsinized and plated according to the manufacturer’s 
recommended instructions. Then cell medium was replaced by complete medium, 
BCAA-deprived medium or medium with 5 ng/ml TGF-β. Luminescence was detected 
using SpectraMax M5 Microplate Reader (Molecular Devices) after two days. 
11.23  Preparation of CAF-derived 3D ECMs 
The cell-derived ECMs were generated as previously described[277]. Briefly, 
confluent CAF cultures were maintained for eight days in the presence of daily added and 
freshly prepared ascorbic acid and 13C-labeled leucine, isoleucine and valine. Matrices 
were fixed or decellularized seven days after plating. Cells were extracted from the 
matrices using 0.5% Triton X-100 (Sigma-Aldrich) and 20 mM NH4OH. The matrices 
were washed in PBS three times and then treated with 10 U/ml DNAse (Sigma-Aldrich) 
in DPBS for 30 minutes at 37°C. Labeled ECM was washed with PBS before plating 
CAFs; after 48 hours, the media was extracted for LC-MS. 
11.24  CTC derived organoid culture 
To generate the CTC derived organoid, CAF was first seeded on CAF-derived 3D 
ECMs one day before. Then the fresh isolated CTC was seeded on the cultures. CTC 
derived Organoid was cultured as previously described without TGF-β modulators[325], 
it uses Advanced DMEM/F12 (Gibco) containing 1X antibiotic-antimycotic (Gibco) as 
the base. Supplements include the following: N-acetyl-L-cysteine (NAC; Sigma-Aldrich), 
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Gastrin I(Sigma-Aldrich), Nicotinamide (Sigma-Aldrich), R-spondin 1 (Peprotech), 
EGF(Peprotech) and FGF-10(Peprotech). 
11.25  Scanning electron microscopy (SEM)  
ECM was fixed in 2.5% glutaraldehyde in PBS at room temperature for one hour 
and then rinsed with PBS, followed by sequential dehydration with ethanol at 
concentrations of 50%, 70%, 90%, 95%, and 100% for 10 min each. The specimen was 
then immersed for 10 min in a solution of 1:1 ethanol: hexamethyldisilazane (HMDS) 
and then transferred to 100% HMDS, followed by overnight air dry in the hood.  The 
dehydrated specimen attached to double-sided carbon tape is mounted on a SEM stub and 
coated with gold by sputtering.  The ECM was examined by FEI Nova 200 Nanolab 
Dual-beam FIB scanning electron microscope under low beam energies (2.0-5.0 kV) at 
the Michigan Center for Materials Characterization (MC2) at the University of Michigan. 
11.26  Metabolic flux analysis 
11.26.1 Metabolite extraction for in vitro studies 
Cells cultured in 6-well plates were quenched with 800 µL of ice-cold 
methanol/water (1:1) solution containing 1 µg of Norvaline. Cells were scraped while 
keeping the plate on ice, followed by the addition of 800 µL of chloroform. The cell 
extracts were transferred to microcentrifuge tubes and vortexed for 30 minutes at 4 °C.  
11.26.2 Metabolite extraction from tissue slices  
Frozen tissue slices were transferred to Preceyllys CKMix Lysing tubes (Bertin 
Corp., 03961-1-009) and kept on dry ice. 200 µL of ice-cold methanol/water (1:1) 
solution containing 1 µg of Norvaline was added to the tubes to submerge the beads and 
 183 
tissue barely. The samples were homogenized using a Precellys Evolution Homogenizer 
with the Cryolys attachment to maintain the temperature below 4 °C in the 
homogenization chamber. Homogenization was achieved using two 30 second cycles at 
6000 rpm with a pause of 60 seconds. Additional homogenization cycles were performed 
only when samples were not homogenized. Following homogenization, an additional 600 
µL of ice-cold methanol/water (1:1) solution was added to the tubes, as well as 800 µL of 
chloroform. The homogenized extracts were transferred to microcentrifuge tubes and 
vortexed for 30 minutes at 4 °C. 
11.26.3 Sample processing for polar metabolites, the amino acid composition of 
proteins, and lipids 
Metabolite extracts were centrifuged at 14,000g for 10 mins to separate the polar 
phase, protein interphase and chloroform phase. The water/methanol phase containing 
polar metabolites were transferred to fresh microcentrifuge tubes and dried in a SpeedVac 
and stored at -80 °C until GC-MS analysis. The chloroform phase containing lipids were 
transferred to microcentrifuge tubes and dried under nitrogen and stored at -80 °C. The 
protein layer was rinsed gently with chloroform, then PBS, and the liquid was discarded. 
The rinsed protein fractions were transferred to glass tubes with sealable caps and 
subjected to acid hydrolysis with 6M hydrochloric acid at 100 °C for 18-24 hours to 
obtain constituent amino acids. Hydrolyzed samples were dried under nitrogen and stored 
at -80 °C until GC-MS analysis. 
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11.26.4 GC-MS analysis for intracellular polar metabolites and amino acids from 
hydrolyzed protein 
 30 µL of methoxyamine hydrochloride (MOX, Thermo Scientific) was added to 
dried samples and incubated at 30 °C for 2 hours with intermittent vortexing. 45 µL of 
MBTSTFA+1% TBDMCS was added to the samples and incubated at 55 °C for 1 hour. 
Derivatized samples were transferred to GC vials with glass inserts and added to the GC-
MS autosampler queue.  GC-MS analysis was performed using an Agilent 7890 GC 
equipped with a 30-m HP-5MSUI capillary column connected to an Agilent 5977B MS. 
For polar metabolites, the following heating cycle was used for the GC oven: 100 °C for 
three minutes, followed by a ramp of 5 °C/min to 300 °C and held at 300 °C for a total 
run time of 48 min. Data were acquired in scan mode. The relative abundance of 
metabolites was calculated from the integrated signal of all potentially labeled ions for 
each metabolite fragment. Mass Isotopologue Distributions (MID) were corrected for 
natural abundance using IsoCor before analysis with the model. Metabolite levels were 
normalized to internal standard Norvaline’s signal and quantified using 6-point 
calibration with external standards for 19 polar metabolites. 
11.26.5 LC-MS analysis to quantify BCKA secretion in media samples 
Spent culture media samples were collected from culture plates, and 200 µL was 
transferred to fresh microcentrifuge tubes for metabolic analysis. 800 µL of pre-chilled 
methanol was added to media samples and kept at -20 °C for 2 hours to deproteinize the 
samples. The samples were centrifuged at 14,000g for 10 minutes at 4 °C, following 
which the supernatant was transferred to fresh tubes and dried in the SpeedVac. Media 
samples were derivatized with 500 µL of 12.5 mM OPD (o-phenylenediamine) solution 
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in 2M hydrochloric acid. Samples were incubated at 80 °C for 20 minutes and transferred 
to an ice-bath to terminate the derivatization reaction. The derivatized solution was 
transferred to microcentrifuge tubes containing 0.08g of sodium sulfate. 500 µL of ethyl 
acetate was added to the samples, followed by vigorous vortexing and centrifuging at 
1000g for 10 minutes. The ethyl acetate phase containing the derivatized ketoacids was 
transferred to fresh tubes and dried under nitrogen. The dried samples were reconstituted 
in 200 µL of 200 mM ammonium acetate solution and transferred to LC vials with glass 
inserts. The samples were analyzed with an Agilent Infinity LC stack using an Agilent 
Eclipse Plus C18 column (2.1 mm x 100 mm x 1.8 µm) connected to an Agilent 6520 
QTOF. The following parameters were used for analysis, 5 mM ammonium acetate as 
Solvent A, methanol as solvent B, 380 µL/min flow rate, 5-10 µL injection volume, 55% 
B for 4.2 minutes, ramp B to 95% for 0.9 minutes, retain 95% B for 1.5 minutes, return to 
initial conditions and equilibrate for 2.5 minutes. The analysis was performed in full-scan 
mode with the MS in positive ion mode. 
11.26.6 Mole Percent Enrichment (MPE) 
MPE represents the fractional contribution of 13C from a substrate to intermediate 
metabolite. It is calculated as follows, where NC is the number of carbons that can be 
labeled as 13C, and xi is the fraction of (M+i)th isotopologue: 





11.26.7 Newly synthesized BCKA flux 
To estimate de novo synthesized branched-chain ketoacid flux from 13-carbon 
labeled BCAA, we measure 13-carbon enrichment in respective branched-chain ketoacid 
much before cells reach isotopic steady-state: 
BCAA catabolic flux =  
[(13C mean enrichment)t=T − (13C mean enrichment)t=0] ∗ (Intracellular abundance of BCKA)
(Total cell protein) ∗ (Time to achieve 13C enrichment, T)
 
11.27  Statistics and Reproducibility 
Data are presented as mean ± s.d. All experiments were repeated twice with similar 
results unless otherwise stated. Graphpad Prism software V8.4 was used to conduct the 
statistical analysis of all data.  A comparison of the data sets obtained from the different 
experimental conditions was performed with the two-tailed Student t-test. Comparisons 
between multiple groups were made using one-way analysis of variance (ANOVA) with 
Tukey’s post hoc comparison, and two-way ANOVA with Dunnett’s post-testing for 
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